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Abstract 
Despite strikingly high global prevalence of VVC, affecting up to 75% of women 
during their child-bearing years and resulting in up to 140 million episodes of RVVC, 
treatment options for women with azole-resistant isolates remain limited. Many 
women experience failed clinical treatment resulting in use of prolonged 
maintenance therapies for an excess of 6 months, which are often unsuccessful. 
Further, there is a clear lack of understanding in the literature pertaining to disease 
onset and potential mechanisms of treatment failure. Gaining a deeper knowledge 
of VVC is obstructed by controversy surrounding the presence of Candida biofilm 
on vaginal mucosa. As a result, there are currently no FDA-approved treatments for 
biofilm-related episodes. Additionally, a better understanding of the antagonistic 
interactions between Candida and vaginal Lactobacillus species could lead to the 
development of alternative probiotic therapies for the treatment of recurrent azole 
resistant VVC. 
 
This PhD study aimed to assess a panel of clinical samples from healthy woman 
and those with RVVC to investigate the influence of Candida, the vaginal 
microbiome, and how microbial interactions influence disease pathology. A 
bibliometric analysis of literature pertaining to Candida and Lactobacillus biofilm 
research was carried out to assess caveats in current understanding. Clinical 
samples were assessed for Candida load and presence of biofilms using a range of 
microbiological techniques. Candida clinical isolates were screened for biofilm 
formation and antifungal susceptibility to frontline azole-treatments. 16S rRNA 
sequencing was used to characterise both the healthy and RVVC vaginal 
microbiome and to correlate patient metadata to microbial populations. Finally, RNA 
sequencing technology was utilised to identify potential mechanisms of antagonism 
between C. albicans and L. crispatus in an in vitro co-culture biofilm model. 
 
The results of this study identified elevated Candida levels in RVVC and evidence 
of Candida biofilm formation in clinical samples of RVVC including presence of C. 
albicans hyphae and aggregation and detection of biofilm-related gene expression. 
Further, Candida clinical isolates were capable of heterogeneous biofilm formation 
and displayed increased antifungal tolerance. Analysis of microbial populations 
present in health and RVVC identified a partial replacement of health-associated 
Lactobacillus species including L. crispatus and L. jensenii by L. iners during RVVC. 
ii 
Additionally, women with RVVC using hormonal contraceptives were found to have 
a more similar bacterial profile to healthy women, compared with women using other 
contraceptives. C. albicans biofilm reduction by Lactobacillus species was observed 
in an in vitro co-culture model. Further, RNA sequencing revealed an α-amino acid 
biosynthesis/breakdown pathway by which L. crispatus may out-compete C. 
albicans during VVC to re-establish vaginal health. Finally, bi-daily addition of L. 
crispatus was shown to reduce C. albicans composition within a complex biofilm 
model. 
 
This study highlights the potential impact of Candida biofilm formation in RVVC and 
the importance of the consideration of biofilms for diagnosis and treatment. 
Additionally, it contributes to our current understanding of the vaginal microbiome 
during RVVC and antagonistic interactions between Candida and Lactobacillus. 
This work provides a foundation for future studies to further elucidate triggers for the 
development and recurrence of VVC/RVVC and the pathogenesis of the microbes 
involved. This and similar work will hopefully lead to the development of novel, more 
appropriate prevention and treatment options for persistent, azole resistant VVC. 
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Fungal infections are becoming increasingly recognised as a substantial health 
burden on the global population. Over 1 billion people are estimated to suffer from 
fungal infections each year, resulting in over 1.5 million deaths (Bongomin et al., 
2017). These infections are commonly associated with mucosal sites such as the 
vagina and oral cavity, and though not life threatening, are associated with high 
rates of morbidity. It is estimated that most women will suffer from at least one 
episode of vaginitis in their lifetime, making it the most common complaint from 
women attending General Practitioner (GP) clinics (Sobel, 1997). An estimated 75% 
of women will suffer from vulvovaginal candidiasis (VVC) in their childbearing years 
with up to 8% developing recurrent VVC (RVVC), defined as four or more cases 
within one year (Sobel, 1992, Sobel et al., 1998). These recurrent cases are 
debilitating, impact quality of life and can result in significant mental health 
implications. VVC has been linked to use of antibiotics and contraceptives as well 
as new sexual partners, however it is not considered a sexually transmitted disease 
and no distinguishable cause has been identified. 
 
The biofilm-forming yeast Candida albicans is reported as the predominant 
pathogen responsible for up to 90% of VVC cases (Sobel et al., 1998). Candida 
species, predominantly C. albicans, form thick biofilms that dramatically increase 
fungal tolerance to drugs commonly used in the treatment of VVC such as 
fluconazole, flucytosine and amphotericin B (AMB) (Baillie and Douglas, 2000). 
Despite the identification of Candida biofilms on vaginal mucosa, the predicted 
therapeutic challenge this presents in VVC is still disputed (Swidsinski et al., 2019). 
VVC is a significant burden both economically and for women’s health and its 
prevalence is poorly documented globally due to high levels of self-treatment. 
Identifying triggers for development and recurrence of VVC and the pathogenesis 
of the microbes involved could considerably improve prevention and treatment 
options for women with recurrent, azole-resistant cases.  
 
This chapter reviews literature surrounding current understanding of VVC and the 
vaginal environment during health and disease as well as investigating current 
treatment options and highlighting the clinical importance of biofilm-induced 
antifungal-resistance in Candida.  
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1.1 Vaginitis 
Vaginitis is a major cause of morbidity within the female population and is 
predominantly caused by bacterial vaginosis (BV) (40-45%), VVC (20-25%) and 
trichomoniasis (15-20%) (Paladine and Desai, 2018).  An imbalance of the vaginal 
microbiome resulting in overgrowth of pathogenic microbes is thought to contribute 
to onset of vaginitis. BV is associated with a decrease or absence of protective 
lactobacilli species in the vagina and overgrowth of the biofilm-forming anaerobic 
coccobacillus, Gardnerella vaginalis. G. vaginalis is frequently asymptomatically 
present in the vagina but can form dense biofilms, releasing lysogenic toxins which 
result in symptoms of disease (Patterson et al., 2007b). Treatment with 
metronidazole is recommended for BV, however, 20-40% of patients suffer from 
recurrent cases within one month of treatment (Danielsson et al., 2011). The reason 
for these recurrent episodes is often attributed to increased antimicrobial resistance 
attained as a result of bacterial biofilm formation. A common side-effect of BV 
antibiotic treatment is the onset of the fungal syndrome, VVC.  
 
VVC, commonly referred to as vaginal thrush, is a result of overgrowth of Candida 
in the vagina. Current understanding of VVC onset involves dysbiosis of the vaginal 
microbiome as well as atypical host immune responses to Candida, however this is 
poorly understood. 
 
1.1.1 Clinical significance 
Although not associated with mortality, out of the 75% of women affected by VVC, 
50% have at least one subsequent episode, with 5-8% developing RVVC (Sobel et 
al., 1998). The cause of recurrence of VVC is largely unknown and has been related 
to considerable morbidities including pelvic inflammatory disease, infertility and 
menstrual disorders. In addition to associated morbidities, the global market is also 
significantly impacted by VVC with an estimated annual cost of US $600 million in 
2013 for products such as Canesten (clotrimazole, Bayer, Leverkusen, Germany), 
fluconazole and itraconazole (Denning et al., 2018b). A novel drug, ibrexafungerp, 
has shown efficacy for the treatment of resistant episodes of RVVC which could 
greatly reduce the burden of VVC/RVVC in the future (Azie et al., 2020). 
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RVVC impacts patients’ daily lives, with many women reporting loss of confidence, 
relationship difficulties and lower quality of life (Irving et al., 1998). One cross-
sectional study of 44 women comparing the mental health of women with RVVC and 
those with no history of RVVC, reported significantly higher levels of clinical 
depression and poorer satisfaction with life in women with RVVC (Irving et al., 1998). 
Due to the nature of the disease, it is more likely that women would participate in 
online surveys as opposed to presenting at gynaecological clinics to partake in 
clinical studies. One such online survey was conducted to investigate the health of 
620 women with RVVC in the USA, UK, France, Germany, Italy and Spain (Aballea 
et al., 2013). Results from this study found a 35% increase in the proportion of 
women with anxiety/depression in the RVVC cohort compared to the general 
population. Due to the nature of this study however, self-reported diagnoses could 
not be verified and therefore the findings could be exaggerated. Nonetheless, these 
studies highlight the multifactorial impact of RVVC on the global female population 
and the importance of effective management and treatment of RVVC. 
 
While not fully characterised, onset of VVC is associated with overgrowth of Candida 
species in the vagina and risk factors include the use of antibiotics, pregnancy, 
immunosuppression, new sexual partners and hormone replacement therapy (HRT) 
(Denning et al., 2018b). Due to commensal carriage, isolation of Candida from the 
vagina in the absence of symptoms is not indicative of VVC. For this reason, 
diagnosis requires the presence of VVC-associated symptoms such as burning, 
itching, vulvar pruritis and cottage-cheese discharge. Symptoms can vary by case 
and as such, diagnosis relying on patient health, risk factors and clinical examination 
alone is problematic. Microscopy to identify yeast cells is often performed, however, 
positive identification of yeast cells or hyphae is only achieved in around 50% of 
cases (Mendling et al., 2012). Comparison of the accuracy of clinical diagnosis 
against DNA probing to diagnose VVC found sensitivity and specificity of detection 
to be 83.8% and 84.8%, respectively (Lowe et al., 2009). Diagnosis therefore 
requires the presence of clinical symptoms and positive microbiological culture or 
Gram stain of yeast cells and/or hyphae from vaginal or vulvar swabs (Gonçalves 
et al., 2016). 
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Failure of clinical treatment to effectively eradicate VVC, results in the development 
of RVVC, defined as four or more episodes of VVC within 12 months. The estimated 
incidence of RVVC is 138 million cases annually with many cases being considered 
chronic conditions requiring extended suppressive therapies to alleviate symptoms. 
Despite this high prevalence, the causes of failed treatment and subsequent 
recurrence remain largely speculative and includes factors such as use of 
antibiotics, levels of oestrogen and use of contraceptives (Pirotta and Garland, 
2006, Nwokolo and Boag, 2000, Spinillo et al., 1993). Biofilms formed by Candida 
species have been suggested to be an underappreciated reservoir for failed clinical 
treatment in VVC due to their inherent resistance to azoles used in VVC treatment 
(Muzny and Schwebke, 2015, Sherry et al., 2017, Rodriguez-Cerdeira et al., 2019, 
Wu et al., 2019, Harriott et al., 2010b). However, some authors dispute the presence 
of Candida biofilms in the vagina despite biofilms being a key aspect of vaginitis in 
BV (Swidsinski et al., 2019, Sobel, 2015b, Hardy et al., 2017). Factors other than 
antifungal resistance have been suggested to be important including the role of 
polymicrobial interactions, tissue invasion, germ tube formation and immunological 
defects in the host (Talaei et al., 2017, Swidsinski et al., 2019). Nonetheless, the 
mechanisms by which Candida switches from asymptomatic commensal to 
pathogen remain undefined. 
 
1.1.2 Epidemiology 
VVC is not a reportable disease and is often self-treated using over-the-counter 
antifungal agents, so the exact prevalence and distribution of disease is impossible 
to determine. Additionally, many studies rely on self-diagnosis of VVC, symptoms 
of which can often be misdiagnosed with symptoms of BV. RVVC affects women 
worldwide and a recent study has estimated its global prevalence based on 
demographics of women in their childbearing years (Figure 1) (Denning et al., 
2018a). 
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Figure 1.1 Global prevalence of RVVC per 100,000 women. Taken from (Denning et 
al., 2018b).  
 
A study by Denning et. al. estimated the annual prevalence of RVVC to be >130 
million cases, increasing to >150 million cases by 2030 (Denning et al., 2018a). The 
global incidence of RVVC is expected to increase due to the ageing female 
population and increase in the use of HRT in older women. This increase of RVVC 
cases is likely to be exacerbated in developing countries due to localised population 
growth and lack of accessible antifungal treatments. It is therefore critical that 
appropriate treatment and prevention methods are established to avoid increasing 
the burden of RVVC on healthcare facilities and the global market. Despite attempts 
to enumerate cases of VVC and RVVC, at present without sufficiently specific and 
sensitive diagnostic tools and with the availability of over-the-counter treatments, it 
remains impossible to determine an accurate prevalence for the disease worldwide.  
 
Recent classification of the vaginal microbiome to unique community state types 
(CST) has provided a significant advance in vaginal research, allowing a 
standardised method of analysis across studies. The first article to identify these five 
classifications was a clinical study assessing the pH and microbiome of 394 pre-
menopausal women from four ethnic groups (Asian, white, black and Hispanic) 
(Ravel et al., 2011a). CST are based on the most prevalent bacteria in each 
community and are defined as follows: I – Lactobacillus crispatus, II – Lactobacillus 
gasseri, III – Lactobacillus iners and V – Lactobacillus jensenii, summarised in Table 
1.1. The fourth group is defined as a diverse group with no clear dominant species 
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and comprising various anaerobes including Prevotella, Dialister, Atopobium, 
Gardnerella, Megasphaera, Peptoniphilus, Sneathia, Eggerthella, Aerococcus, 
Finegoldia and Mobiluncus. Notably, this may not be indicative of higher diversity 
than other communities and may be attributed to the lack of a dominant species. 
These communities were used to determine interracial differences in vaginal 
microbiome; additionally, pH levels were observed among ethnic groups (Ravel et 
al., 2011a). 
 
Table 1.1: pH of vaginal community groups in women of different ethnicities. Adapted 
from (Ravel et al., 2011a). 
 
 
The most common CST amongst the women involved in the study was CST III, 
which accounted for 34% of the total sample pool. The production of lactic acid was 
unanimous in all CST groups maintaining vaginal pH ~4.5, with a notably higher pH 
in CST IV, associated with lower levels of lactic-acid bacteria (LAB). This low vaginal 
pH is thought to be associated with maintenance of vaginal health through inhibition 
of non-LAB. Higher proportions of black and Hispanic women were characterised to 
the diverse CST (40.3% and 38.1%, respectively), suggesting a potential 
predisposition of these women to vaginal dysbiosis due to reduction in LAB. 
Conversely, it could be hypothesised that women of white and Asian decent may 
possess some level of protection against vaginitis due to vaginal colonisation with 
primarily Lactobacillus species. 
 
Ethnic Groups
Community groups Asian White Black Hispanic All ethnic groups
I (L. crispatus ) Subjects 24 44 23 14 105
pH 4.4 ± 0.52 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
II (L. gasseri ) Subjects 5 8 5 7 25
pH 4.4 ± 0.44 4.7 ± 0.44 5.0 ± 0.0 4.7 ± 0.22 5.0 ± 0.7
III (L. iners ) Subjects 41 26 33 35 135
pH 4.0 ± 0.0 4.3 ± 0.30 4.0 ± 0.0 4.4 ± 0.59 4.4 ± 0.6
IV (Diversity Group) Subjects 19 10 42 37 108
pH 5.5 ± 0.44 5.5 ± 0.74 5.3 ± 0.44 5.3 ± 0.44 5.3 ± 0.6
V (L. jensenii ) Subjects 7 9 1 4 21
pH 5.0 ± 0.89 4.85 ± 0.22 4.7 ± 0.44 5.0 ± 0.59 4.7 ± 0.4
All groups Subjects 96 97 104 97 394
pH 4.4 ± 0.59 4.2 ± 0.30 4.7 ± 1.04 5.0 ± 0.74 4.4 ± 0.7
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1.1.3 Vaginal microbiome during health and VVC 
The vaginal microbiome was first investigated by Döderlein in 1892 and was found 
to consist exclusively of Gram-positive bacilli, which are now known to be 
Lactobacillus species. Next-generation sequencing technologies have allowed 
greater depth of analysis into the microbial world to elucidate how immune tolerance 
and defence against potential pathogenic microorganisms is established. The 
vaginal microbiome is somewhat unique in that a low microbial diversity is 
associated with health. Vaginal dysbiosis, or onset on vaginitis, is therefore 
characterised by an increase in species diversity. It has become clear through 
microbiome analysis that there is no definitive health-associated vaginal 
microbiome. Instead, the five identified CSTs all represent a homeostatic 
environment with the functional capacity to prevent disease. In general, the vaginal 
microbiome of healthy premenopausal women is primarily comprised of lactobacilli 
species, namely L. iners, L. crispatus, L. gasseri and L. jensenii (Ravel et al., 2011b). 
Conversely, the microbiome during BV is well characterised showing a significant 
increase in microbial diversity compared with the low diversity found in healthy 
women (Liu et al., 2013b). This increase in diversity is coupled with a notable 
reduction in Lactobacillus and replacement with G. vaginalis resulting in biofilm 
formation, virulence and symptomatic BV (Vitali et al., 2015). 
 
Studies have reported varied results when comparing the vaginal microbiome of 
women with VVC with healthy women. Some studies suggest that there is no 
evidence that the healthy microbiome protects against onset of disease (Zhou et al., 
2009b). However, recent literature reports that disease is likely associated with a 
greater microbial diversity and loss of specific, protective lactobacilli species 
accompanied by predominance of BV-associated bacteria such as G. vaginalis and 
other anaerobes (Liu et al., 2013a, Jian et al., 2015). Where a clear shift towards 
dysbiosis of the microbiome is observed in BV and Chlamydia trachomatis 
infections, VVC research has identified subtle differences in bacterial diversity that 
suggests VVC as an intermediate state between health and disease (Ceccarani et 
al., 2019). Further, studies assessing bacterial abundances in VVC have not seen 
significant reductions in levels of Lactobacillus (Liu et al., 2013b, Sobel and Chaim, 
1996). Instead, it is becoming increasingly recognised that the functional capacity 
of specific Lactobacillus species present in health is more important in protection 
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against VVC. A common factor in microbiome studies of VVC at species-level is the 
reduction of species including L. crispatus, L. jensenii and L. gasseri and increase 
in L. iners (Ceccarani et al., 2019, Fredricks et al., 2005, Wertz et al., 2008). This 
suggests a protective role of these specific species during health which is 
subsequently lost in in disease. 
 
1.1.4 Immunopathology of VVC  
Our understanding of the role of the immune response in VVC has changed 
drastically over recent decades. Candidiasis at mucosal sites such as 
oropharyngeal and gastrointestinal infections are known to be more common in 
patients with impaired T-cell immune responses (Clift, 1984, Samaranayake, 1992). 
As such, early VVC research in the 1990’s assumed that protection against vaginal 
candidiasis was due to T helper-1 (Th-1) and Th-2 cell-mediated immunity (CMI). 
However, various in vitro and animal studies investigating the role of CMI through 
T-cell infiltration have failed to identify any role for Th-1 or Th-2 cytokines in VVC 
(Taylor et al., 2000). Further, no evidence of increased Candida-specific antibodies 
in vaginal secretions has been found to suggest protection via humoral immunity 
(Wozniak et al., 2002). This resulted in the conclusion that, unlike Candida infections 
in other body sites such as the oral cavity, patients with compromised immune 
systems do not show increased susceptibility to VVC (Leigh et al., 2001). 
 
More recently, an important study involving human participants that were 
intravaginally infected with live Candida observed a non-inflammatory immune 
response, with elevated levels of polymorphonuclear neutrophils (PMNs) in women 
with an increased fungal load (Fidel et al., 2004). As such it was hypothesised that 
VVC results from a lack of PMN-mediated killing of Candida cells in the vaginal 
mucosa. Further studies have strengthened this hypothesis showing activation of 
the NLRP3 inflammasome causing release of inflammatory mediators such as 
alarmins and IL-1β from vaginal epithelial cells, leading to PMN recruitment (Yano 
et al., 2012, Bruno et al., 2015). This results in further recruitment of these 
inflammatory mediators, ultimately leading to the hyperinflammation seen during 
VVC (Yano et al., 2018). A summary of the current proposed host immune response 
to VVC by (Rosati et al., 2020) can be observed in Figure 1.2.  
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Figure 1.2: Immune response in RVVC. RVVC is a result of an exaggerated host immune 
response to environmental and immunological stimuli. Taken from (Rosati et al., 2020). 
 
Therefore, it is currently hypothesised that VVC is not a result of an impaired 
adaptive immune response but is in fact due to an exaggerated innate response by 
PMNs. However, with evolving next-generation transcriptomic sequencing 
becoming increasingly available, it may be possible to further elucidate the immune 
mechanisms behind VVC pathogenesis. 
 
 
1.2 Lactobacillus 
Lactobacillus were first identified as the only bacteria present in the vaginal 
environment in 1892. Although it is now known that Lactobacillus species account 
for around 70% of the microbiome, their importance has been recognised 
throughout the 1900’s and our understanding of these microbes continues to 
develop at present. The vaginal environment becomes colonised within 24 hours of 
birth and Lactobacillus become the predominant organism during puberty (Davis 
and Dobbing, 1974, Schwebke, 2001). This is due to increased glycogen levels of 
the vaginal epithelium as a result of increased oestrogen. Lactobacilli thrive in the 
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vaginal environment by metabolising glucose and maltose from glycogen 
breakdown via α-amylase and producing lactic acid, resulting in a protective acidic 
pH. Further, during menopause, a reduction in oestrogen levels reduces glycogen 
which lowers lactic acid production causing a rise in pH levels (Hickey et al., 2012). 
This ultimately reduces Lactobacillus levels in the vagina and has been shown to 
increase risk of infection (Burton and Reid, 2002). This highlights the importance of 
Lactobacillus species in vaginal health and their protective role throughout women’s 
lives. 
 
1.2.1 Role of Lactobacillus in vaginal health 
In healthy women, LAB, predominantly lactobacilli, are thought to be responsible for 
maintaining a homeostatic microbiome by inhibiting growth and adhesion of other 
microbes via the production of secreted metabolites such as lactic acid, 
biosurfactants, bacteriocins and hydrogen peroxide (H2O2) (Morales and Hogan, 
2010). However, the mechanisms behind the influence these metabolites have on 
Candida remains largely unknown. 
 
Figure 1.3: Commensal vaginal Lactobacillus inhibit adhesion of Candida to the 
vaginal epithelium via secreted metabolites. Lactobacillus inhibits Candida colonisation 
of vaginal mucosa through occupation of the niche and the production of biosurfactants. 
Additionally, Lactobacillus species lower the pH of the environment and produce H2O2 and 
bacteriocins which are inhibitory to Candida. Adapted from (Morales and Hogan, 2010). 
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The role of lactobacilli in vaginitis is uncertain; generally, they are thought to have a 
protective role and have been shown to prevent C. albicans adhesion to HeLa cells 
as well as enhancing recruitment of phagocytes and aiding in pro-inflammatory 
cytokine release (Matsuda et al., 2018b) (Rocha-Ramírez et al., 2017). A healthy 
vaginal flora, although not defined, is thought to consist mainly of H2O2-producing 
Lactobacillus species, maintaining a low, antimicrobial pH of <4.5. Infection is 
therefore a result of dysbiosis of this Lactobacillus-dominated environment, leading 
to loss of protective organisms and allowing overgrowth of disease-associated 
species. During BV, a notable reduction in Lactobacillus is observed with increased 
levels of G. vaginalis, Mycoplasma hominis, Prevotella spp., Peptostreptococcus 
spp., Mobiluncus spp., Bacteroides spp., A. vaginae and Megasphera spp. (Cribby 
et al., 2008, Falagas et al., 2007). This observation is consistent and has resulted 
in an over-interpretation of the significance of reduced vaginal Lactobacillus. The 
Nugent criteria used to diagnose BV, assesses disease by the levels of 
Lactobacillus morphotypes present in vaginal fluid (Hickey et al., 2012). This 
observation does not account for the biological function of these species, and it may 
therefore be more appropriate to observe vaginal communities present to determine 
disease status. 
 
Unlike BV, the dysbiotic event in VVC onset is largely unknown as studies have 
observed minimal reductions in Lactobacillus levels of women with VVC. Although 
it is hypothesised that VVC is due to a loss of Lactobacillus, the lowered pH of the 
Lactobacillus-dominated environment could result in Candida stress responses 
being triggered leading to hyphae formation and release of virulence factors causing 
dysbiosis of the microbiome. This was shown by Beyer and colleagues (Beyer et 
al., 2018b) where the MAP kinase CgHog1 of Candida glabrata was up-regulated in 
response to clinically relevant concentrations of lactic acid. CgHog1 increases the 
ability of C. glabrata to persist within the body, suggesting this could contribute to 
severity of VVC. However, the mechanistic trigger for VVC onset and failed 
treatment is likely multifactorial and remains undefined. 
 
1.2.2 pH 
The pH of the human body varies widely at different body sites from the highly acidic 
stomach pH of ~2, to the mildly acidic sites such as the skin and vagina, to neutral 
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and even alkaline in the saliva and colon, respectively. The pH of vaginal fluid can 
vary from around 6.6 to 4.2 depending on the presence of menstrual blood, 
however, it is typically sustained between 4 to 4.5 (Eschenbach et al., 2000). This 
acidic pH is thought to be maintained by the presence of LAB, namely Lactobacillus 
species. It is important to note that, although microorganisms are the primary 
source, vaginal epithelial cells also contribute to maintaining the acidic pH through 
the secretion of organic acids (Charlier et al., 2009, Boskey et al., 2001). During 
puberty, until menopause, increased levels of oestrogen results in high levels of 
glycogen deposits in the vagina (Paavonen, 1983). Glycogen is then broken down 
by α-amylase to glucose and maltose which is then anaerobically metabolised by 
commensals of the vaginal to produce acetic and lactic acid, lowering the pH and 
favouring LAB growth (Boskey et al., 1999). It is therefore during child-bearing years 
that the vagina is most acidic, and subsequently most inhibitory to pathogenic 
microbes. 
 
The acidic pH of the vagina is associated with a decreased risk of chlamydia, 
trichomoniasis and has been shown to inhibit bacteria and inactivate viruses such 
as Herpes Simplex virus (Tuyama et al., 2006, Hanna et al., 1985). However, 
microorganisms such as Candida, found in many body sites, possess the ability to 
adapt to the external stimulus of environmental pH allowing for colonisation of the 
vagina. C. albicans can neutralise acidic and alkaline environments and has been 
shown to alter the pH by 3 units in 12 hours (Vylkova et al., 2011). This promotes 
fungal survival within the niche as well as allowing for hyphal morphogenesis and 
the production of virulence factors. Further, studies have reported an absence of 
lactic acid toxicity against C. albicans at acidic pH as low as 3 (Kasper et al., 2015a). 
C. albicans can also metabolise lactic acid in the presence of glucose (Lourenco et 
al., 2018). Therefore, evidence of Candida inhibition by Lactobacillus supernatants 
must be a result of other secreted metabolites present. However, although not 
directly inhibitory, concentrations of lactic acid present in the vagina (80mM) have 
been shown to increase susceptibility of C. albicans and C. glabrata to azole 
treatment (Lourenco et al., 2018). 
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1.2.3 D- and L- lactic acid 
The presence of organic acids such as acetic and lactic acid, produced by LAB and 
vaginal epithelium when oestrogen is present, are hallmarks of vaginal health and 
are important for inhibition of pathogens and prevention of infection. Lactobacillus 
species are the main source of both D- and L-lactic acid production with the vaginal 
epithelium responsible for <15% of L-lactic acid production (Boskey et al., 2001). 
The D-lactic acid isomer provides greater protection against vaginal infection than 
the L-isomer (Witkin et al., 2013). L. iners is only capable of L-lactic acid production, 
unlike the other three commonly isolated Lactobacillus species outlined previously, 
which produce both isomers. The protective D-lactic acid isomer is most abundant 
in communities with high concentrations of L. crispatus and lowest when there are 
high levels of L. iners, G. vaginalis or Streptococcus (Witkin et al., 2013). The 
bactericidal properties of D-lactic acid have been widely studied showing it to 
enhance the protective properties of H2O2 and bacteriocins as well as inhibiting 
vaginal pathogens such as G. vaginalis, Neisseria gonorrhoea and Trichomonas 
vaginalis (Cadieux et al., 2009, Breshears et al., 2015). Further, lactic acid creates 
an anti-inflammatory environment by stimulating production of the anti-inflammatory 
cytokine IL-1RA in vaginal epithelium as well as suppressing the production of pro-
inflammatory cytokines including IL-6 and TNFα (Hearps et al., 2017).  
 
1.2.4 Hydrogen peroxide 
H2O2 is another microbicidal secreted metabolite produced by many vaginal 
Lactobacillus spp. which is thought to contribute to the maintenance of vaginal 
health. H2O2 is an oxidising agent, toxic to catalase-negative bacteria, including 
anaerobes such as G. vaginalis, N. gonohorreae and C. albicans (Klebanoff et al., 
1991, St Amant et al., 2002, Fitzsimmons and Berry, 1994). Studies have shown 
H2O2 production in the range of 1.01–15.50 μg/mL in up to 95% of vaginal 
Lactobacillus strains capable of H2O2 production (L. crispatus, L. acidophilus, L. 
fermentum and L. jensenii) (Aslim and Kilic, 2006, Aroutcheva et al., 2001). Given 
its high production levels in the vagina and potent toxicity to vaginal pathogens, the 
use of H2O2 as a potential treatment for BV has been investigated. Two studies 
found vaginal irrigation with 3% H2O2 to sufficiently cure BV and aid in restoration of 
the healthy vaginal microbiome, proving efficacy of this potential treatment 
(Winceslaus and Calver, 1996, Cardone et al., 2003). Given that microbiome studies 
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of BV consistently find significant reductions in levels of H2O2-producing 
Lactobacillus species during disease (Ceccarani et al., 2019, Vitali et al., 2015), the 
effect of replacing the H2O2 produced by these key species appears to treat 
infection. One study investigating the effect of H2O2 concluded that it may protect 
against BV, but not VVC (Mijac et al., 2006). This conclusion was based on similar 
levels of H2O2 production in health and VVC. With development of sophisticated 16S 
rRNA and transcriptomic sequencing, it may now be more appropriate to consider 
the function capacity of the Lactobacillus species present during health and VVC. 
Further, potential interactions between Candida and Lactobacillus species which 
may affect H2O2 production should be considered.  
 
The antimicrobial properties of H2O2 in the vaginal environment have been 
questioned due to evidence of inactivation of H2O2 by vaginal secretions and semen. 
The addition of either cervicovaginal fluid or semen to H2O2 in vitro were found to 
inactivate antimicrobial properties of H2O2 against Herpes Simplex Virus, N. 
gonorrhoeae, or any of six BV-associated bacteria (O'Hanlon et al., 2010). Further, 
a condemning review of the potential antimicrobial properties of H2O2 was published 
concluding that it is implausible that H2O2 has any antimicrobial effect in the vaginal 
environment (Tachedjian et al., 2018). However, it is important to note that none of 
these studies have considered the potential antifungal effect of H2O2 during VVC 
and, for this reason, it is still of clinical importance to consider the presence of H2O2-
producing Lactobacillus species in VVC. 
 
1.2.5 Bacteriocins 
Bacteriocins are antimicrobial peptides produced by almost all LAB that provide 
these organisms with an ecological advantage for colonising body niches. 
Bacteriocins’ mode of action involves pore formation and permeabilization of the cell 
membrane of competing organisms leading to amino acid and ion efflux, resulting 
in cell death (Gillor et al., 2005). These secreted metabolites have been extensively 
studied in the development of Lactobacillus probiotics. One bacteriocin, Nisin, 
produced by Lactococcus lactis subsp. lactis has been FDA-approved for use as a 
food preservative (Cleveland et al., 2001). Although suggested as a potential 
contraceptive due to its spermicidal activity, it cannot be considered for vaginal 
treatment as it is strongly bactericidal to healthy vaginal Lactobacillus (Dover et al., 
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2008, Aranha et al., 2004). Several bacteriocins from vaginally isolated 
Lactobacillus have been shown to possess antimicrobial activity against vaginal 
pathogens including N. gonorrhoeae, G. vaginalis and C. albicans (Table 1.2). 
 
Table 1.2: Bacteriocins produced by vaginally isolated bacteria.  
Taken from (Dover et al., 2008).
 
 
Many investigations into the importance of bacteriocins in the vaginal environment 
focus on the impact they may have in BV (Kelly et al., 2003, Dezwaan et al., 2007). 
Therefore, natural growth inhibition of Gram-positive vaginal commensals, including 
Streptococcus and Lactobacillus, in response to vaginally produced bacteriocins, 
SPECIES BACTERIOCIN ACTIVITY AGAINST REFERENCE
Lactobacillus 
rhamnosus  160
Lactocin 160 Gardnerella vaginalis Li et al., 2005 and Aroutcheva 
et al., 2001c
Prevotella bivia
Peptostreptococcus 
anaerobius
Peptostreptococcus 
assacharoliticus
Micrococcus luteus
Listeria monocytogenes
Lactococcus lactis 
subsp. lactis HV219
Bacteriocin 
HV219
Enterococcus faecalis Todorov et al., 2006
Escherichia coli
Lactobacillus casei
Listeria innocua
Proteus vulgaris
Pseudomonas 
aeruginosa
Lactobacillus 
salivarius CRL1328
Enterococcus faecalis Ocana et al., 1999
Enterococcus faecium
Neisseria gonorrhoeae
Lactobacillus 
pentosus  TV35b
Pentocin TV35b Clostridium sporogenes Okkers et al., 1999
Closridium tyrobutyricum
Lactobacillus curvatus
Lactobacillus fermentum
Lactobacillus sake
Listeria innocua
Propionibacterium 
acidipropionici
Candida albicans
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has been hypothesised as a potential cause of vaginal dysbiosis leading to BV 
onset. It is important to note, however, that this interaction is also relevant to VVC 
as reduced Lactobacillus levels allow for Candida overgrowth and symptomatic 
VVC. 
 
 
1.3 Candida 
As discussed in previous sections, C. albicans is the most prevalent causative 
organism identified in VVC (Sobel et al., 1998). C. albicans is also commonly 
isolated from the vagina as an asymptomatic commensal with a carriage rate of up 
to 33% in women of reproductive age (Achkar and Fries, 2010b). C. albicans is an 
opportunistic pathogen capable of causing systemic bloodstream mycoses in 
immunocompromised patients with associated mortality rates of up to 70% (Moran 
et al., 2009). Other non-albicans Candida (NAC) species account for 10-20% of VVC 
cases and are associated with complicated VVC with less severe symptoms but 
higher recurrence rates (Fidel et al., 1999). The most common NAC isolated in 
European studies is C. glabrata (14%) followed by other species such as Candida 
parapsilosis, Candida tropicalis and Candida krusei (Corsello et al., 2003b). Recent 
studies have shown a change in epidemiology with C. glabrata and other NAC 
species being isolated in greater than 50% of cases and more in RVVC (Ahmad et 
al., 2009). This increase in prevalence of innately fluconazole-resistant C. krusei is 
particularly concerning for future treatment options.  
 
Candida is capable of survival in many different environment and host niches 
including the oral cavity, gastrointestinal tract, and vagina. It can exist as both a 
commensal and pathogenic yeast through its ability to undergo morphological 
changes and form hyphae. This yeast form allows Candida to colonise the vagina 
asymptomatically, without detection by the immune response. However, 
environmental stressors such as pH and bacterial competition cause a dimorphic 
switch in Candida to form hyphae (Noble et al., 2017). Hyphal morphogenesis allows 
Candida to form thick biofilms adhered to vaginal epithelium which penetrate vaginal 
tissues of women with VVC, causing associated local inflammation (Ramage et al., 
2001b, Harriott et al., 2010b). Candida biofilm formation in the vagina, although 
disputed, has been shown previously along with deep hyphal penetration of vaginal 
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epithelium in both in vivo and ex vivo (Figure 1.4) (Wu et al., 2020, Harriott et al., 
2010b, Cassone, 2015). 
 
1.3.1 Biofilms 
The mechanism by which VVC occurs in the host is undefined and controversial. 
There is suggestion the microbiome plays a role whereby Candida overgrows, 
competing with commensals and transitioning from saprophytic yeast cells to 
pathogenic biofilms. The National Institutes of Health has estimated that biofilms are 
responsible for up to 80% of all human infections, highlighting the importance of 
understanding and preventing biofilm formation. Candida species, predominantly C. 
albicans, form thick biofilms which dramatically increase fungal tolerance to drugs 
commonly used in the treatment of VVC such as fluconazole, flucytosine and AMB 
(Taff et al., 2013). Sessile cells have been shown to tolerate antifungal 
concentrations 1000-fold greater than their planktonic counterparts (Ramage et al., 
2012b).  
 
Of biofilm-forming Candida species, the formation of C. albicans biofilms are most 
well studied and have been shown to form in four distinct stages: adhesion, 
proliferation (or initiation), maturation, and dispersion (Figure 1.4). The first stage, 
adhesion, involves round yeast cells adhering to a biotic or abiotic surface. This 
adhesion is mediated through recognition of ligands on the surface such as 
fibrinogen and fibronectin, quorum sensing, and expression of EAP1 and the ALS-
family of genes (ALS1-ALS4) (Parsek and Greenberg, 2005, Dranginis et al., 2007). 
Deletion of ALS1, ALS2 or ALS3 has been shown to eliminate C. albicans ability to 
adhere to surfaces, highlighting the importance of these genes in early biofilm 
development (Zhao et al., 2005, Oh et al., 2005). After formation of this basal layer 
of yeast cells during the adhesion stage, C. albicans cells begin to proliferate, 
remaining attached to the surface. In this stage, pseudohyphae and hyphae begin 
to form from these budding yeast cells and continue to form and elongate throughout 
biofilm development. C. albicans biofilms are generally considered to be mature 
after 24 hours of development and are characterised by a thick, complex 3-
dimensional structure comprised of yeast cells and hyphal cells encapsulated in 
extracellular matrix (ECM) composed of carbohydrates, glycoproteins, lipids, and 
nucleic acids (Zarnowski et al., 2014). The final stage of dispersion results in the 
Chapter 1 – Introduction 
19 
 
observation and positive yeast culture from vaginal discharge of women with active 
VVC. 
 
 
Figure 1.4: Stages of C. albicans biofilm development. Adapted from (Lohse et al., 
2018).  
 
C. albicans biofilms on vaginal mucosa have been observed previously by 
identification of significant fungal load, biofilm architecture and extra-cellular matrix 
using confocal and electron microscopy using a murine model (Figure 1.5) (Harriott 
et al., 2010a). Biofilms are a potential contributing factor to increased virulence and 
failed clinical treatment resulting in persistence of symptoms and recurrence of VVC. 
Despite the identification of Candida biofilms on vaginal mucosa, the predicted 
therapeutic challenge this presents in VVC is still disputed. Other studies deny the 
presence of vaginal biofilms, and instead suggest other factors such as germ tube 
formation and polymicrobial tissue invasion as a more critical feature of VVC 
(Swidsinski et al., 2018, Sobel, 2015a).  
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Figure 1.5: C. albicans biofilm formation on vaginal mucosa. C. albicans biofilm 
formation on murine vaginal mucosa in both an in vivo model (VVC induced in mice then 
vaginal tissue excised) and and ex vivo model (Mouse vaginal tissue excised before 
introduction of C. albicans). Taken from (Harriott et al., 2010b). 
 
Through extensive research and clinical studies, it is well accepted that BV results 
from a loss of protective vaginal lactobacilli with a concomitant increase in BV-
associated bacteria such as G. vaginalis and A. vaginae (Machado et al., 2015). 
These bacteria then form a thick G. vaginalis-dominated biofilm adhered to vaginal 
epithelium, dissemination of which results in diagnostic “clue cell” isolation in vaginal 
secretions (Swidsinski et al., 2005). Currently, there are no large-scale studies 
visualising Candida biofilm formation on vaginal biopsies in women with either VVC 
or RVVC, such as those which were carried out to investigate G. vaginalis biofilm 
formation in BV. Additionally, there are currently no defined VVC or RVVC biofilm 
models to study the impact of Candida biofilm formation in the disease. Such studies 
could provide key knowledge of RVVC pathogenesis and resistance which could 
greatly improve how clinical treatment is provided. 
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1.3.2 Resistance 
The frontline treatment for VVC is orally administered fungistatic fluconazole. 
Although this is often effective in alleviating symptoms, antifungal tolerance in 
Candida is reported and can cause failed treatment with the need for prolonged 
suppressive therapies (Sobel et al., 2004). Candida biofilm formation is closely 
linked to development of antifungal tolerance, particularly to the azole family of 
antifungals. One study observed a 5 to 8-fold higher tolerance to various azoles, 
AMB and flucytosine in 48h C. albicans biofilms compared to their planktonic 
counterparts (Hawser and Douglas, 1995). Azole tolerance is most common in long-
term suppressive treatment regimens, such as those used to treat RVVC. Various 
mechanisms of antifungal resistance in Candida to different therapeutics have been 
described and are graphically summarised in Figure 1.5.  
 
 
Figure 1.6: Candida colonisation of the vaginal mucosa and resistance mechanisms. 
Azole resistance is achieved through increased expression of efflux pumps eliminating 
intracellular drug accumulation. Altered ergosterol content is thought to contribute to 
polyene resistance in C. albicans. Taken from (Rodriguez-Cerdeira et al., 2019). 
 
Mechanisms of resistance to azoles in Candida include up-regulation of genes 
controlling efflux-pump activity such as Cerebellar Degeneration Related Protein 1 
(CDR1) and Multi-drug Resistance 1 (MDR1) as well as mutations in the ERG11 
target gene which reduce affinity and intracellular drug accumulation (Albertson et 
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al., 1996, White, 1997). Although acquired resistance is rare in Candida biofilms, 
intrinsic resistance to azole therapies is almost universal, making azoles completely 
ineffective for the treatment of biofilm-associated disease. This lack of efficacy 
against Candida biofilms is evident by the low cure rates of RVVC using suppressive 
azole therapies (Donders et al., 2008).  
 
Other treatment options for azole-resistant isolates include the use of the polyenes, 
AMB and nystatin. Although AMB is effective against most systemic fungi including 
Candida species, it is associated with considerable toxicity and is rarely used in the 
treatment of VVC/RVVC. Resistance to AMB has been reported since the 1980s, 
with some Candida species including C. lusitaniae and C. guillermondii displaying 
intrinsic resistance (Dick et al., 1980, Kovacicova et al., 2001). More concerning is 
the development of AMB resistance by C. albicans, C. glabrata and C. krusei during 
treatment (White et al., 1998). Although the mechanism of AMB resistance in 
Candida is not fully defined, a recent study showed altered ergosterol content and 
mitochondrial function in AMB-resistant members of the C. haemulonii complex 
(Silva et al., 2020). Nystatin can be used as an alternative maintenance therapy to 
boric acid. Although studied to a lesser extent, due to the two drugs belonging to 
the polyene’s family, resistance profiles to nystatin can be inferred from those to 
AMB. 
 
It is important to note the potential presence of ‘persister cells’ in VVC/RVVC may 
contribute to failed clinical treatment. These small sub-populations of biofilms or 
biofilm aggregates provide protection to the cells within the population, similar to 
that seen in biofilms, allowing them to survive in the presence of antifungal 
intervention (Keren et al., 2004). Persister cells are commonly reported in bacterial 
biofilms however their presence in C. albicans biofilms has been observed (LaFleur 
et al., 2006). The presence of these free-floating biofilm aggregates may provide an 
explanation for failed clinical treatment in women where no clear biofilm is observed. 
Although it is currently being fully evaluated, no resistance to the novel drug, 
ibrexafungerp, has been reported to date. 
 
Despite the well-accepted increased tolerance to antifungals as a result of biofilm 
formation, and the identification of Candida biofilms on vaginal mucosa, there are 
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currently no FDA-approved therapeutics specifically for women with biofilm-
associated VVC/RVVC. 
 
1.3.3 Clinical significance of non-albicans Candida species 
As mentioned previously, NAC species are becoming more prevalent causative 
organisms in VVC worldwide. Although more often associated with milder symptoms 
than C. albicans VVC, NAC species often cause complicated VVC, with higher rates 
of recurrence due to increased antifungal resistance amongst these species 
(Deorukhkar et al., 2014). It is impossible to determine the true rates of NAC VVC 
due to underreporting, over-the-counter antifungal use, and misidentification. Under 
current diagnostic guidelines, following morphological identification of Candida 
using Gram stain and wet mount, identification of fungal species is carried out by 
observing germ tube formation. Positive germ tube formation results in a C. albicans 
identification, however both Candida dubliniensis and Candida africana also form 
germ tubes (Borman et al., 2013, Vilela et al., 2002). Diagnosis could be improved 
using chromogenic agars and newer molecular techniques which are more sensitive 
and specific with considerably faster output times and are being implemented to 
identify pathogens in STIs, however it is not yet common practice in VVC diagnosis 
(Sobel and Akins, 2015). Although it is commonly the case in a clinical setting, it is 
evidently important not to rely on microscopy, culture methods or PCR alone to 
identify Candida to species-level. 
 
Risk factors associated with NAC-associated candidiasis include diabetes mellitus, 
older age (decreased oestrogen) and recent antifungal use. The pathogenesis of 
NAC VVC is more poorly understood than the more commonly studied C. albicans 
candidiasis. C. glabrata can employ an immune invasion strategy through survival 
within macrophage (Seider et al., 2014). Further, C. glabrata can suppress reactive 
oxygen species (ROS) production in the phagosome, preventing toxicity and 
suppressing proinflammatory responses (Kasper et al., 2015b). Although genetically 
similar to C. albicans, C. dubliniensis is considerably less pathogenic. This is likely 
in part due to the lack of genes encoding ALS3, SAP5 and SAP6 in C. dubliniensis, 
leading to reduced virulence and adhesion to vaginal epithelium (Moran et al., 
2012). 
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Clinically, NAC VVC is more difficult to treat due to the antifungal resistant profiles 
of NAC species. Of particular clinical concern is the widespread resistance to 
frontline azole-family antifungals throughout NAC species. One study evaluating 
resistance profiles of Candida clinical isolates found 38%, 41%, 35%, 37% and 33% 
of C. tropicalis, C. glabrata, C. krusei and C. dubliniensis, respectively, to be 
resistant to fluconazole, with similar profiles with itraconazole and ketoconazole 
(Deorukhkar et al., 2014). Further, MICs have been shown to increase by >4-fold 
following exposure to antifungals in vaginal NAC isolates (Richter et al., 2005). 
Notably, increased resistance to AMB and fluconazole has been observed in C. 
glabrata in low pH environments. Therefore, antifungal resistance could be 
exacerbated by the acidic vaginal environment during VVC (Danby et al., 2012). 
However, the effect of low environmental pH on the mode of action of azoles has 
not yet been investigated. This highlights the importance of careful consideration of 
the causative organism of VVC before clinical decisions for antifungal treatment can 
be made. 
 
 
1.4 Treatment of VVC 
VVC can be defined as either uncomplicated or complicated VVC. Uncomplicated 
VVC is defined as sporadic episodes of mild symptoms caused by C. albicans 
(Sobel et al., 1998). Whereas, complicated VVC is defined as severe infection, VVC 
caused by a NAC, C. albicans infection in an immunocompromised patient or 
development of RVVC (Sobel et al., 1998). Decisions for clinical treatment are 
determined by whether the patient has complicated or uncomplicated VVC (Pappas 
et al., 2009). For uncomplicated VVC the frontline therapeutic of choice for VVC is 
the azole-family of drugs given as either a topical cream or orally administered 
systemic treatment. A single dose of oral fluconazole is sufficient to treat sporadic 
C. albicans VVC in 80-90% of cases (Dovnik et al., 2015b).  
 
Treatments for RVVC and VVC caused by NAC species are more complicated, 
requiring prolonged azole treatment as suppressive therapies and are often 
unsuccessful. As described in detail above, fluconazole treatments are completely 
ineffective against C. albicans biofilms and are a likely cause of failed clinical 
treatment of VVC and development of RVVC. In cases of complicated VVC such as 
Chapter 1 – Introduction 
25 
 
C. glabrata azole resistant VVC, daily treatment with boric acid or nystatin 
suppositories is recommended for two weeks. Alternatively, a topical treatment with 
17% flucytosine can be administered alone or in combination with 3% AMB daily for 
two weeks. For treatment of RVVC, a 10–14 day maintenance therapy with topical 
or oral fluconazole is recommended followed by a weekly 150mg dose of 
fluconazole for 6 months. Despite known consequences of biofilm formation for 
therapeutic success, treatment options for women with azole-resistant isolates 
remain limited with the majority of recurrent cases required prolonged maintenance 
therapies which never fully cure symptoms of VVC/RVVC. 
 
1.4.1 Current treatment options  
Since their development in the 1980s, azole antifungals have been used to target 
ergosterol synthesis in the fungal cell wall. They target lanosterol 14α-demethylase, 
encoded by ERG11, which disrupts ergosterol synthesis, inhibiting Candida growth 
and increasing susceptibility to host defences (Figure 1.7). No particular azole is 
thought to be more effective than another, additionally, it is unclear whether choice 
of oral or topical agents impacts clinical outcome (Dharmik et al., 2013, Whaley et 
al., 2016). Fluconazole is the most popular azole treatment for VVC due to its high 
cure rates against VVC, safety and availability both by prescription and over the 
counter. Fluconazole is also often prescribed as a maintenance therapy to treat 
RVVC taken as a weekly dose of 200mg for 2 months, followed by 200 mg every 
two weeks for 4 months, and 200 mg monthly for 6 months, depending on the 
patient’s response to the treatment (Donders et al., 2008). Although this 
maintenance therapy is often sufficient to suppress recurrence of symptoms during 
treatment, it does not cure RVVC and is therefore often prescribed for years (Sobel 
et al., 2004). This long-term use and over the counter availability of fluconazole 
drives antifungal resistance and with no suitable FDA-approved alternatives leaves 
few options for the estimated 130 million women with RVVC each year. 
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Figure 1.7: Mechanism of azole and polyene antifungal treatments. Azoles 
inhibit ergosterol synthesis from lanosterol resulting in fungal growth arrest. 
Polyenes, including amphotericin B (AMB) and nystatin, bind to ergosterol in the cell 
wall inducing pore-formation leading to disruption of the membrane potential, 
intracellular ion leakage and ultimately cell death. Created with Biorender.com. 
 
Following confirmation of azole-resistance in VVC, daily treatment with 600mg of 
vaginally administered boric acid is routinely implemented for two weeks. However, 
boric acid has been shown to alleviate symptoms and fungal isolation in up to just 
70% of cases (Sobel et al., 2003a). Boric acid is predominantly fungistatic and not 
fungicidal, although the mode of action is not fully elucidated. It is thought that its 
inhibitory effect may be due to its weakly acidic properties, however this is yet to be 
studied in vitro. One study identified significant reduction of CDR1 expression in C. 
albicans treated with boric acid, suggesting the drug may decrease efflux pump 
activity in Candida rendering it more susceptible to treatment with azoles (De Seta 
et al., 2009). This study also observed evidence of fungal growth arrest of C. 
albicans, similar to findings in S. cerevisiae which showed defects in cell budding 
and cell wall formation following boric acid treatment (Schmidt et al., 2010). Notably, 
despite its use as an alternative to antifungal treatment and claims of antifungal 
efficacy, very little data is available regarding the mechanisms of boric acid 
inhibition. Further, boric acid toxicity in humans has been documented when orally 
ingested or absorbed in to the bloodstream, indicating potential safety concerns 
(Moseman, 1994). An alternative to boric acid is the use of 17% flucytosine topical 
cream. Flucytosine has previously been shown to be effective in up to 90% of cases 
that failed boric acid and azole therapy (Sobel et al., 2003a). However, this study 
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was carried out on a small sample set (30 women) and there are very few studies 
investigating the efficacy of flucytosine against RVVC. Additionally, flucytosine is not 
commercially available and potential of acquired resistance in Candida is high, 
therefore it is rarely prescribed and not recommended for suppressive therapies 
(Horowitz, 1986). 
 
The efficacy of therapeutics such as AMB and boric acid has been assessed for the 
treatment of RVVC. Both drugs when delivered intravaginally for 14-21 days were 
found to be effective in around 70% of patients (Phillips and gynecology, 2005) 
(Sobel et al., 2003b). Both drugs belong to the polyene family of antifungals and act 
by disruption of the fungal cell membrane through binding to ergosterol (Figure 1.7). 
This binding induces pore-formation resulting in intracellular ion leakage and 
disruption of the membrane potential leading to growth inhibition or cell death. AMB 
has also been shown to activate reactive oxygen species production inside the cell, 
increasing its fungicidal properties. The efficacy of oral fluconazole for the treatment 
of RVVC was directly compared with two-week treatments with another polyene, 
nystatin. Results demonstrated both drugs to be sufficient treatments for RVVC and 
concluded nystatin as a suitable alternative for the treatment of azole-resistant 
isolates (Fan et al., 2015). AMB is used in VVC therapy due to its wide antifungal 
spectrum and low resistance rates (Ci et al., 2018). Studies investigating the efficacy 
of AMB combination therapies against azole-resistant C. glabrata cases are 
promising with culture-negative results after up to 8 weeks of daily treatment with 
100mg AMB and 1000mg flucytosine (White et al., 2001). Additionally, 50mg of AMB 
administered vaginally for two weeks was found to be effective in up to 70% of cases 
(Phillips, 2005). 
 
1.4.2 Potential of pre/probiotic therapies 
Probiotics involve the use of live microorganisms, whereas prebiotics are defined as 
“non-viable substrates that serve as nutrients for beneficial microorganisms 
harboured by the host, including administered probiotic strains and indigenous 
microorganisms” (Gibson et al., 2017). Lactoferrin, a naturally secreted antimicrobial 
peptide present in various bodily secretions including vaginal secretions and breast 
milk, is the most well-studied prebiotic due to its potent antibacterial and antifungal 
properties (Bertuccini et al., 2018, Russo et al., 2018, Liao et al., 2019). Moreover, 
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this key component of the innate immune system has been shown to inhibit C. 
albicans both alone and in cooperation with fluconazole (Wakabayashi et al., 1996, 
Lupetti et al., 2003). Both bovine and human lactoferrin bind to the plasma 
membrane of C. albicans, inducing apoptosis and can therefore be fungicidal in 
azole-resistant isolates (Andres et al., 2008). A recent clinical study assessed the 
efficacy of bovine lactoferrin in combination with probiotic Lactobacillus species L. 
rhamnosus ATCC SD5675 and L. acidophilus LMG S29159 to prevent recurrence 
of RVVC (Russo et al., 2019). Results from this study were promising with only 
33.3% and 29.2% of treated women experiencing recurrence after 3 and 6 months, 
respectively compared with 91.7% and 100% of women in the placebo group at 3 
and 6 months, respectively. More clinical studies assessing the efficacy of this 
combination prebiotic/probiotic treatment are required and may lead to improved 
therapeutics for the prevention of recurrent vaginitis in the future. 
 
A recent extensive review of the potential of Lactobacillus probiotics for the 
treatment of VVC/RVVC concluded that despite promising studies, there remains 
insufficient evidence to support this therapeutic strategy at present (Falagas et al., 
2006). Studies investigating the effectiveness of probiotic therapies over the last two 
decades have shown clear beneficial results for patients in the short-term. However, 
few studies have assessed the ability of probiotic to augment vaginal flora over 
longer periods of time (Jeng et al., 2020). Given the overall safety of the use of 
Lactobacillus probiotics and their potential efficacy in re-establishing eubiosis in the 
vagina in vitro, their use as a potential therapy merits further investigation. This 
would require large-scale, high-quality clinical trials recruiting women with 
VVC/RVVC to understand the effect of Lactobacillus probiotic therapy in the 
pathophysiological human environment. 
 
The potential to treat RVVC through microbiome replacement therapy has been 
investigated, possibly through use of Lactobacillus probiotics. Probiotic therapy 
involves the administration of live microorganisms which directly result in a health 
benefit for the patient (Reid et al., 2003). Robust evidence exists showing L. 
rhamnosus GG successfully reduces disease duration of acute Rotavirus diarrhoea 
in children (Majamaa et al., 1995). Due to the diversity of the vaginal microbiome, it 
is difficult to determine which Lactobacillus species would be the most important to 
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replace with probiotic therapy. One study evaluated L. plantarum P17630 combined 
with the standard treatment of clotrimazole for 3 days and concluded a potential 
resolution of vaginal discomfort with the probiotic (De Seta et al., 2014). Additionally, 
the probiotic potential of L. casei var. rhamnosus (now named L. rhamnosus GR-1) 
has been assessed. One clinical case study cured symptomatic RVVC for >6 
months using L. rhamnosus GR-1 pessaries in a woman who had previously 
suffered 20 episodes of VVC in 30 months (Reid et al., 1994). Although not a vaginal 
commensal and only able to transiently colonise the vaginal tract, probiotic therapy 
with L. rhamnosus GR-1 may provide a scaffold for the re-colonisation of health-
associated commensal Lactobacillus species. 
 
Probiotic lactobacilli may also be used to augment treatment of vaginitis when used 
as an adjuvant therapy in addition to antifungal treatment. One study compared the 
treatment of VVC with 150mg oral fluconazole alone or 150mg oral fluconazole with 
bi-daily orally administered L. rhamnosus GR-1 and L. reuteri RC-14 in 55 Brazilian 
women (Martinez et al., 2009). This study observed a 28.2% reduction in C. albicans 
culture-positive patients with the probiotic adjuvant therapy compared with 
antifungal treatment alone. Similar observations were achieved when comparing 
fluconazole and fenticonazole treatments alone or combined with vaginally 
administered probiotic with L. acidophilus, L. rhamnosus, Streptococcus 
thermophilus, and L. delbrueckii subsp. bulgaricus (Kovachev and Vatcheva-
Dobrevska, 2015). Use of a probiotic-antifungal adjuvant therapy may be more 
favourable as vaginal dysbiosis due to antifungal use can lead to onset of BV 
(Pawlaczyk et al., 2006), however this may be circumvented by maintenance of the 
microbiome by probiotic Lactobacillus. 
 
1.4.3 Future therapies 
A novel drug, approved for use to treat VVC in July 2021, Ibrexafungerp (previously 
SCY-078) may provide an alternative avenue for women experiencing failed 
treatment. Ibrexafungerp is the first of a novel “fungerp” class of triterpenoid glucan 
synthase inhibitor antifungals with distinct mode of action from echinocandins. 
Ibrexafungerp is administered orally and acts to destabilize the fungal cell wall 
through depletion of (1,3)-β-D-glucan polymers (Figure 1.8).  
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Figure 1.8: Mode of action of echinocandins and fungerp antifungals on the 
yeast cell wall. Taken from (Azie et al., 2020). 
 
Resistance to echinocandins has been documented in various Candida species 
through the acquisition of point mutations in FKS1 and FKS2 genes. While 
resistance to ibrexafungerp has been shown in C. glabrata to be mediated by FKS 
mutations within the glucan synthase gene, the binding site for the drug is distinct 
from echinocandins resulting in lower rates of resistance (Jimenez-Ortigosa et al., 
2017). Additionally, the activity of ibrexafungerp was shown to be minimally affected 
by the presence of echinocandin-resistance via introduction of FKS mutations in 
Candida species including C. albicans, C. glabrata, C. krusei and C. dubliniensis 
(Pfaller et al., 2017). Increasing rates of resistance to both azoles and 
echinocandins in C. glabrata is of clinical concern (Ghannoum et al., 2019), however 
consistent results showing greater activity of ibrexafungerp against 
azole/echinocandin-resistant Candida species is promising for future treatment 
alternatives (Pfaller et al., 2017). Further, the activity of fluconazole, micafungin and 
ibrexafungerp against C. albicans and C. glabrata were assessed at pH level of 7.0, 
5.7 and 4.5 (Larkin et al., 2019). Unlike the other antifungals assessed, 
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ibrexafungerp displayed the most potent antifungal activity at a pH of 4.5, relevant 
to the vaginal environment. 
 
Ibrexafungerp provides a novel class of antifungals with broad range of activity 
against Candida species and a distinct mode of action from azoles and 
echinocandins. Additionally, it has demonstrated good tolerability and low toxicity in 
recently completed phase 1 and phase 2 clinical trials (Akizawa et al., 2018). 
Ongoing phase 3 clinical trials will hopefully confirm the safety and efficacy of 
ibrexafungerp for the treatment of VVC. The approval of inbrexafungerp may provide 
an exciting alternative one-day treatment for women suffering from azole-resistant 
VVC/RVVC. 
 
 
1.5 Next Generation Sequencing 
Sequencing for long DNA reads using primer-extension and chain-termination 
methods, now commonly known as the Sanger sequencing method, was pioneered 
by the British biochemist, Frederick Sanger in 1977 (Sanger et al., 1977, Maxam 
and Gilbert, 1977). Following this valuable discovery, many landmarks in 
sequencing history were achieved including sequencing of the Epstein-Barr virus in 
1984, Applied Biosystems marketing the first automated sequencer in 1987, and 
sequencing the genome of the nematode Caenorhabditis elegans in 1998 (Baer et 
al., 1984, Consortium, 1998). These breakthroughs paved the way to the completion 
of the Human Genome project to successfully sequence the human genome, which 
concluded in 2003. Although Sanger sequencing was highly accurate and resulted 
in the successful sequencing of the human genome, this chain-termination method 
was time-consuming and costly. It was estimated that the human genome project 
cost $100 million in 2001. The introduction and development of Next Generation 
Sequencing (NGS) using pyrosequencing methods greatly reduced time and costs 
associated with genome sequencing to $10,000 per genome by 2011 and just 
$1,000 by 2015 (Pareek et al., 2011, Telenti et al., 2016). NGS sequencers include 
the Ion torrent, Roche 454, Illumina, and Nanopore platforms. Over the last 10 
years, Illumina platforms have dominated the field of DNA sequencing due to their 
highly accurate read identification and accessibility to smaller labs (Bharti and 
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Grimm, 2021). Work in this thesis was carried out using the Illumina MiSeq platform 
with paired-end reads and the Nanopore MinION platform. 
 
1.5.1 Illumina sequencing platforms 
Illumina sequencing platforms utilise the sequence by synthesis method, reading 
one base at a time through a process known as bridge amplification. In this process, 
short DNA strands (up to around 350bp) are ligated at each end with adaptor 
sequences. These adaptor sequences are complementary to oligonucleotide 
strands attached to a solid support (flow cell). Adaptor sequences bind DNA for 
amplification to the flow cell, allowing bridges to form between sequences, where it 
is then subject to rounds of amplification which results in the formation of clonal 
clusters each containing 1000s of copies of each amplified DNA fragment. Each 
flow cell contains multiple channels containing millions of oligonucleotide sequences 
running in parallel, which is why techniques utilising this method are referred to as 
massively parallel sequencing. Fluorescently labelled nucleotides are then added to 
the flow cell and bind to their complementary bases on the amplified DNA fragments 
resulting in specific fluorescent emission detectable using sequential imaging of the 
flow cell.  
 
Illumina sequencers have improved in throughput and accuracy with each 
generation, with Phred scores >40 (De Maio et al., 2019). Currently, the most widely 
used Illumina sequencer is the HiSeq platform. The MiSeq sequencer is more 
financially accessible for smaller labs with high accuracy, an output range of 540mb 
– 15gb, 1-25 million reads per run, and a maximum read length of 2x300 bp. The 
more powerful Illumina sequencers, NextSeq and NovaSeq are available for more 
extensive applications such as large whole-genome and whole-transcriptome 
sequencing. The 16S rRNA gene is around 1600bp long and is made up of 9 
hypervariable regions (V1-V9) (Wang and Qian, 2009). Sequencing the more 
conserved regions is often utilised to determine higher-ranking taxa such as phylum 
or family, however regions with higher levels of variability are used to identify 
bacteria to genus or species-level (Kim et al., 2011). As Illumina sequencers only 
amplify a subsection of the 16S rRNA gene, careful consideration of the region of 
interest is required during experimental design. Additionally, studies sequencing 
mock communities have identified the introduction of bias and disproportionate taxa 
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based on the chosen amplified region (Yu et al., 2008, Yang et al., 2016). Although, 
increasing read length could circumvent this limitation of Illumina sequencing, this 
can greatly increase error rates (Tan et al., 2019). 
 
1.5.2 Oxford Nanopore MinION platform 
Nanopore sequencing using Oxford Nanopore Technologies (ONT) MinION 
sequencer is the latest long-read, single-molecule sequencing platform to be 
developed. The proposed method of Nanopore sequencing in the late 1990s would 
push a single strand of long DNA through a protein nanopore, stabilised in a thin, 
electrically resistant polymer membrane (Kasianowicz et al., 1996). An electric 
current would then be passed across the membrane and the ion current changes 
introduced by the passing nucleotides are used to determine each base in real time. 
However, it would be over 15 years before a collaboration between Professor Hagan 
Bayley and Oxford Nanopore would lead to the first benchtop sequencer using this 
method, the MinION, being commercialised (Jain et al., 2016). Each MinION flow 
cell has 2,048 individual nanopores embedded in separate membranes, of which 
512 are selected for analysis. Despite its ultra-long reads, the MinION has lower 
accuracy than Illumina sequencers with Phred scores often <10 (Laver et al., 2015). 
According to the ONT, the average accuracy of the latest R10.3 flow cell is >99.9% 
with an output of up to 50Gb (Liu et al., 2021). Error rates are dictated by achieving 
the correct translocation speed of the DNA strand through the pore and have been 
shown to increase in longer sequencing runs (Meller et al., 2000). ONT has also 
introduced the GridION (100Gb output) and PromethION (6Tb output) sequencers 
which can run multiple flow-cells in tandem allowing for larger sequencing runs.  
 
The MinION is the most widely used of ONTs sequencing platforms, being used in 
many genomic and transcriptomic studies (Kerkhof et al., 2017, Benitez-Paez and 
Sanz, 2017, Sessegolo et al., 2019). The advantages of the MinION are its 
portability, high throughput library preparation and relatively low start-up costs. 
Additionally, the ultra-long read capacity allows for taxa identification by 
amplification of the whole 16S rRNA gene, eliminating the risk of bias introduced 
through region selection. Another advantage of the ONT platforms is the ability to 
analyse data from the beginning of the run and as sequencing progresses, allowing 
for considerably reduced analysis time compared with Illumina sequencers. Finally, 
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ONT research is largely community driven with the “Nanopore community” being 
developed to allow users to troubleshoot and access sequencing and analysis 
protocols. However, the biggest short fall is the MinION has a typical accuracy of 
95% compared with 99.9% of Illumina. 
 
Nanopore sequencing, although rapidly developing, is still in its infancy and one of 
the major pitfalls is the current lack of bioinformatic tools for analysis of sequencing 
data produced by this method (Santos et al., 2020). The most common and user-
friendly tool is the ONT developed data analysis web service, EPI2ME. This tool is 
available to ONT customers and provides workflows for analysis of nanopore 
sequencing data from barcoding to filtering reads and taxonomic assignment using 
BLAST to the NCBI database. However, the parameters for filtering reads, trimming 
and alignment are set by the web tool and are not adjustable, limiting the user’s 
analysis. The most prominent drawback encountered by ONT users is the lack of 
compatibility of the taxonomic assignment output with other bioinformatic analysis 
tools for downstream analysis. The most commonly used databases for taxonomic 
identification include Greengenes (McDonald et al., 2012), SILVA (Quast et al., 
2013), RDP (Cole et al., 2014) and NCBI (Federhen, 2012), however these were 
developed for compatibility with Illumina data outputs and are not compatible with 
Nanopore outputs. Although the MinION sequences the full 16S rRNA region, 
allowing for accurate microbial identification to species-level, it is important to note 
its analytical limitations (Santos et al., 2020). Significant improvements to the error 
rates have been made since the development of the MinION sequencer, however 
more sophisticated bioinformatic tools designed for compatibility with Nanopore 
sequencing outputs are required to fully exploit the capabilities of this novel 
technology. 
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1.6 Summary and Aims 
The literature reviewed in this introduction outlines our current understanding of 
VVC/RVVC onset, epidemiology, microbiological factors, and treatment. Despite 
exceptionally high annual case numbers globally, VVC/RVVC remains a significant 
health burden with debilitating recurrent cases severely impacting the mental health 
of affected women. This review highlights caveats in our knowledge of RVVC. 
Specifically, the importance and clinical consequence of Candida biofilm formation 
on vaginal mucosa and increased antifungal tolerance during RVVC remains largely 
understudied in the field of women’s health. Additionally, relatively little is known 
about the role of the microbial populations and potentially important bacterial 
interactions taking place during RVVC. Finally, despite high levels of recurrence and 
failed clinical treatment, alternative treatment options for women with azole-resistant 
isolates remains limited to prolonged suppressive therapies which are often 
unsuccessful in curing disease. A greater understanding of VVC/RVVC could greatly 
reduce annual cases and lead to the development of appropriate therapies for 
women with recurrent, azole-resistant isolates. 
 
It is hypothesised that clinical samples from patient with RVVC will display a biofilm 
phenotype with the propensity for antifungal resistance. Additionally, based on 
previous studies, the microbiome of RVVC is expected to be somewhat similar to 
healthy patients, however subtle differences could result in altered microbial 
interactions during RVVC. The aims of this study were therefore to: 
• Gain insights into the vaginal environment during health and RVVC by 
assessing a panel of RVVC clinical samples and observe potential sources 
of failed clinical treatment. 
• Investigate variations in microbial populations in health and RVVC with 
respect to patient treatments and behaviours. 
• Observe interkingdom interactions between Candida and health-associated 
Lactobacillus species which may influence disease.
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2.1 Introduction 
Antagonism between Candida and Lactobacillus species has been documented for 
decades, primarily in the study of oral and gastrointestinal candidiasis (Kohler et al., 
2012, Hasslof et al., 2010). Despite knowledge that Lactobacillus inhibits Candida 
adhesion and hyphal morphogenesis, Lactobacillus probiotics are not commonly 
used as therapeutics in antifungal-resistant vaginitis. Further, the potential formation 
of Candida biofilms at mucosal sites, and how this may impact interactions between 
Lactobacillus and the fungus, remains largely understudied, particularly in vaginal 
candidiasis. Within the scientific community, to assess understanding of a particular 
field of research and identify potential caveats in current knowledge, an extensive 
literature review of the subject area is carried out (Snyder, 2019) . However, as the 
number of publications in each field continues to expand and datasets become 
larger through increased use of omics technology, it has become increasingly 
difficult to evaluate entire fields of research in a meaningful way. Although originally 
introduced in 1987, bibliometric analysis to perform quantitative assessment of 
entire fields of scientific literature is only recently becoming more widely used 
(Broadus, 1987). The ability of this technology to manage and assess large volumes 
of publications may provide a solution for large-scale in silico analysis, which 
previously would not have been possible. 
 
Although bibliometric analysis provides a unique tool for managing the expanding 
pool of scientific literature, it requires an expertise in programming language 
software such as R or Python to perform. This is because bibliometric analysis 
requires various steps of analyses and mapping using this software (Guler et al., 
2016). Many researchers are not proficient in such software packages, the majority 
of which also require commercial licenses. The complexity of the process ultimately 
limits the potential of bibliometric analysis for most researchers simply due to a lack 
of programming knowledge and accessibility. However, a recent novel tool 
developed in R to carry out comprehensive bibliometric analysis through a web 
application has been developed (Aria and Cuccurullo, 2017). This open-source 
Biblioshiny® tool allows researchers to import files containing research items 
retrieved from databases such as Scopus and Web of Science. Researchers can 
then perform comprehensive bibliometric analyses using the web application. As it 
is programmed in R, Biblioshiny® can perform various graphical techniques and is 
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easily upgraded and modified to suit developing bibliometric analysis. The 
development of this resource has greatly increased the availability and potential of 
bibliometric analysis without the need for extensive knowledge of programming 
language software. 
 
 
Hypotheses and aims 
 
In the age of increasingly concerning widespread antimicrobial resistance and more 
research focussing on alternative treatment therapies, the potential of Lactobacillus 
species to treat biofilm-associated candidiasis infections may become more 
apparent. Due to controversary regarding the presence of Candida biofilms in the 
vagina, it is expected that few research items will be retrieved in this area of 
research. This chapter was written as a mitigation strategy during successive 
lockdowns and lab closures due to the COVID-19 pandemic. Therefore, this chapter 
aimed to: 
• Utilise bibliometric analysis using the Biblioshiny® web tool to observe the 
fields of scientific literature where interkingdom interactions between 
Candida and Lactobacillus are most widely recognised.  
• Investigate where in the literature the impact of Candida biofilm formation is 
appreciated.  
• Finally, this chapter aimed to investigate these themes with respect to 
vaginitis infection. It is expected that Candida and Lactobacillus research will 
primarily be focussed on oral health and the treatment of oral candidiasis.  
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2.2 Materials and Methods 
 
To produce data for this chapter, the online web application, Biblioshiny® was used 
(Aria and Cuccurullo, 2017). This relatively novel software provides an open-source 
tool allowing researchers to perform comprehensive science mapping analysis of 
specific fields of scientific literature without requiring an extensive knowledge of 
programming language software such as R. 
 
2.2.1 Data collection 
Data for this chapter was collected from the Clarivate Analytics Web of Science™ 
online database by utilising different search terms which are defined in Figure 2.1. 
The initial search for metadata relating to “Candida” and “Lactobacillus” retrieved 
2,330 articles from the Web of Science Core Collections™ database. An additional 
search using the search terms “Candida”, “Lactobacillus” and “Biofilm” was also 
carried out. This search retrieved 188 items. Finally, a search for metadata relating 
to “Candida”, “Lactobacillus”, “Biofilm” and “vaginitis” was carried out, however this 
only retrieved 8 items. Metadata relating to each search were then exported in 
batches of 500 before being merged in to one master file to be uploaded to the 
Biblioshiny® web application for analysis. 
 
2.2.2 Bibliometrics analysis 
To carry out bibliometrics analysis on the retrieved metadata, the Biblioshiny® web 
application available through the Bibliometrix® package (Version 3.0.0), loaded via 
R-Studio® (Version 1.2.5042) was utilised. Using the Biblioshiny® application, search 
results were refined to include only articles published between 1990-2020. Search 
results were also filtered to exclude corrections, editorials, letters, notes and 
reviews. This resulted in a total of 1,860 and 155 research items relating to the 
“Candida” and “Lactobacillus” search and the “Candida”, “Lactobacillus” and 
“Biofilm” search, respectively. The online web application was then used for data 
visualisation relating to annual scientific production, relevant sources, author 
contributions, common keywords, and collaborative links for each search. An 
illustration of the bibliometric analysis workflow can be seen in Figure 2.1. 
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Figure 2.1: Comprehensive science mapping workflow provided by the 
Biblioshiny® web application (Aria and Cuccurullo, 2017). Bibliometric data is 
collected, formatted, and exported from an online database. Data is then uploaded 
to a bibliometric software tool for analysis and normalisation before data can be 
visualised and interpreted. 
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2.3 Results 
 
Search terms were designed to investigate the relevance of interkingdom 
interactions between Candida and Lactobacillus and to determine which fields of 
research these interactions are currently being appreciated. Search terms used and 
the number of metadata retrieved from each can be found in Table 2.1. 
 
Table 2.1: Search terms used to obtain research articles from the Web of Science 
Core Collection™ database. 
 
 
Analysis of the annual growth rate of Candida and Lactobacillus research observed 
a steady increase in the number of research articles produced from 1990-2020 
(Figure 2.2). Annual production in the field was relatively low throughout the 1990s 
with an average of 22 research articles published each year, increasing towards the 
end of the decade. This average annual growth rate from 1990-2004 was 8.36%. A 
notable increase of interest in the field can be observed from 2004 onwards, with an 
average of 89 annual publications between 2004-2020. An average annual growth 
rate of 7.7% was observed for this period. A peak in annual publications is seen in 
2019 with 145 articles, however, given the increasing trend this will likely be 
surpassed in coming years. 
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Figure 2.2: Annual growth of scientific articles published in Candida and 
Lactobacillus research. Number of articles published in the field of Candida and 
Lactobacillus research between 1990-2020. 
 
To further assess levels of interest in Candida and Lactobacillus research, the total 
and average number of citations each year were observed (Table 2.2). Despite there 
being relatively few publications per year in the 1990s, total citations each year are 
relatively high with a peak of 52 citations in 1998. Total numbers of citations 
remained at this level until 2010, where a steep drop is noted with <20 total citations 
from 2015-2020. When average citations per article per year is observed, many of 
the articles published in the 1990s were receiving very few publications with an 
average of between 1-2 citations per article. Interestingly, despite there being fewer 
citations overall in later years, each article was receiving between 2-4 citations 
throughout the 2000s. This could suggest that fewer authors are publishing in the 
area as it becomes of less global interest. However, it may also reflect the sources 
of these articles becoming more stringent and some papers which may have been 
published in the past decade would not be accepted by present peer-review 
procedures. 
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Table 2.2: Annual scientific production and citations in the years between 1990-2020 
in Candida and Lactobacillus research. 
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To investigate the most relevant sources of Candida and Lactobacillus research, the 
top ten scientific journals publishing relevant research were plotted along with their 
dynamics between 1990-2020 (Figure 2.3). This data also allowed for an insight into 
which fields of literature Candida and Lactobacillus research are being published. 
The most published in scientific journal was the International Journal of Food 
Microbiology, the source of 24% of total publications (Figure 2.3A). Although there 
was a sharp rise in publications from this journal from 1998-2004, annual production 
has since continued to drop steadily. Despite Food Microbiology being the second 
most relevant source, dynamics show a significant decrease in publications from 
2012 (Figure 2.3B). Emerging sources such as PLOS One and LWT-Food science 
and Technology have increased rapidly since 2010 and will likely become the most 
relevant sources in the coming decade. It is clear from this data that the most 
relevant sources of Candida and Lactobacillus research publish in the field of 
microbiology with particular emphasis on the food industry.
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Figure 2.3: Most relevant sources of Candida and Lactobacillus research 
Top 10 most relevant sources of scientific literature and number of articles published in Candida and Lactobacillus research between 1990-2020 (A). Dynamics 
of the top 5 most relevant sources in the field between 1990-2020 (B). 
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To further investigate relevant scientific fields within Candida and Lactobacillus 
research, the top 10 most relevant authors publishing between 1990-2020 based on 
numbers of published articles and their collaborative links were observed (Figure 
2.4). A relatively small range between the most relevant authors was observed with 
between 10-13 published articles (Figure 2.4A). One of the top publishing authors, 
Jorge A. O. C., was found to have strong collaborative links with other relevant 
authors, Junqueira J. C. and Rossoni R.D. (Figure 2.4B). However, no collaborative 
links with other authors in the field were identified for the other most published 
author, Meurman J. H. Additionally, other identified relevant authors including Bellen 
G., Donders G. G. G. and Vitali B. were found to have close collaborative links.
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Figure 2.4: Relevant authors and collaborative links in Candida and Lactobacillus research 
Relevant authors based on number of published articles in the field between 1990-2020 (A). Network of collaborations between the most published authors 
(B). Node size is weighted by author contribution; Closed networks of one colour represent closely linked collaborative groups. Isolated nodes were removed.
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To investigate global contribution to the field of Candida and Lactobacillus research, 
scientific production was observed with respect to the corresponding author’s home 
country (Figure 2.5). Countries identified with a larger contribution to the field are 
indicated by dark blue colouration and primarily include countries in North America, 
Europe and eastern Asia. Countries with a lower contribution are shown in light blue 
and include countries in Africa, South America, and central Asia. Finally, countries 
with a grey colour were found to have no publications relative to Candida and 
Lactobacillus research. 
 
 
Figure 2.5: Scientific production by country of Candida and Lactobacillus research. 
Scientific contribution by country indicated by dark blue (large contribution), light blue (small 
contribution) and grey (no contribution) to Candida and Lactobacillus research between 
1990-2020. 
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Further to the previous analysis, relevance of each country by scientific contribution 
to the field was assessed. (Figure 2.6). The highest contributing countries were 
found to be China and the USA, closely followed by Italy with between 139-169 
publications (Figure 2.6A). All countries were found to primarily publish as single 
country publications (SCP). The USA had the most multiple country publications 
(MCP) with 19% of total publications involving collaboration with another country. 
Further, the relevance of these countries to the field was measured by the number 
of citations per article (Figure 2.6B). The USA and Italy had the most total citations 
with >5000 citations each. However, despite having the highest total contribution to 
the field, China had significantly fewer citations than the USA and Italy with 2999 
total citations and the lowest average citations per article at 18. Interestingly, 
countries with a much smaller total contribution such as Belgium, closely followed 
by Germany and Sweden were found to have the highest numbers of citations per 
article with an average of 44 citations per publication.
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Figure 2.6: Relevance of scientific contribution by country. 
Number of articles published by the corresponding author’s country (A). Split bars represent single country publications (SCP) and multiple country 
publications (MCP). Total and average number of citations from the highest published countries between 1990-2020 (B). 
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To investigate the content and common themes of articles published in the field of 
Candida and Lactobacillus research, the most common author’s keywords and their 
correlations were observed (Figure 2.7). Key themes are correlated by colour and 
plotted based on their appearance in the literature. The size and overlap of bubbles 
in this plot represent overlap of themes within the field. Probiotics was identified as 
a ‘basic’ or widespread theme in the bottom right quadrant of Figure 2.7A. Keywords 
associated with the theme of probiotics included “lactic-acid bacteria”, 
“fermentation” and “yeast” (Figure 2.7B). The size and centrality of nodes represents 
their frequency of co-occurrence in the literature. The top right quadrant, indicating 
‘motor’, or re-occurring themes, identified “lactic-acid bacteria” and “Candida 
albicans” as themes in the literature. Keywords associated with “lactic-acid bacteria” 
include “sourdough” and “metabolism”; Keywords such as “saliva”, “lactobacilli” and 
“dental caries” were identified as important in the theme of “Candida albicans”. One 
theme identified as either emerging or declining was “saliva” which was associated 
with keywords such as “Lactobacillus”, “Candida albicans” and “candidiasis”. Finally, 
the theme of “bacteria” was identified as a central theme in Candida and 
Lactobacillus research and is associated with keywords such as “cholesterol” and 
“probiotic”.
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Figure 2.7: Most frequent keywords and their correlations in Candida and Lactobacillus research. 
Thematic map illustrating the relevance of common keywords in Candida and Lactobacillus research (A). Co-occurrence network of the most common author’s 
keywords used in the field (B). Node clustering and size is weighted by co-occurrence and frequency of keywords, respectively. Isolated nodes were removed.
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Next, a second bibliometric search was conducted using the search terms 
“Candida”, “Lactobacillus” and “Biofilm”. This allowed for further insight into which 
fields of research Candida and Lactobacillus research is focused as well as to 
determine whether the impact of biofilms is appreciated in scientific literature. This 
search returned only 188 metadata items, 155 after filtering, significantly fewer 
articles than were found in the previous search (Table 2.1).  
 
When assessing the annual scientific production of Candida and Lactobacillus 
biofilm research between 1990-2020, it was clear that there are much fewer 
publications in this field with no more than 25 articles in any given year (Figure 2.8). 
In-fact, no articles were published in this area pre-1999. Less than 10 articles were 
published in this area throughout the 2000s, however the past decade has shown a 
notable rise in publications since 2014. This increase in interest in the field is evident 
with average annual growth rate over the period from 1999-2020 of 17.42%. A peak 
in annual scientific production is seen in 2016 with 25 articles, however interest 
remained relatively high in the years that followed.
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Figure 2.8: Annual growth of scientific articles published in Candida and 
Lactobacillus biofilm research. Number of articles published in the field of Candida and 
Lactobacillus biofilm research between 1990-2020. 
 
Although relatively few research items were published pre-2014, the impact of these 
research items is strikingly high when observing annual citation statistics (Table 
2.3). There were between 0-3 annual publications throughout the 2000s, despite 
this, there is an average of 23 total citations each year. Although, it is important to 
note that, because these articles were published almost two decades ago, the 
average citations per year remains relatively low. Since 2010, the increase in 
interest in the field is apparent with more publications each year. This is concurrent 
with a notable increase in the total number of citations per year and indeed the 
average citations per article per year. An impressive peak in research interest can 
be seen in 2010 with 92 total citations over 6 articles, resulting in an average of 8 
citations per article. As the number of research items published annually rises, the 
total number of citations remains steadily high with an average of 17 citations 
between 2015-2019. 
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Table 2.3: Annual scientific production and citations in the years between 1999-2020 
in Candida and Lactobacillus biofilm research. 
 
 
 
The most relevant sources of scientific literature and their dynamics in the field of 
Candida and Lactobacillus biofilms were observed (Figure 2.9). This allowed for 
insight into which fields of research articles are being published. Unlike the previous 
search, the most relevant sources of scientific literature were found to be related 
primarily to medicine and oral microbiology (Figure 2.9A). Although PLOS One was 
found to be the most relevant journal, source dynamics show a sharp fall in the 
number of articles published here since 2015 (Figure 2.9B). The second most 
published journal, Archives of Oral Biology, displayed a steady rise in publications 
since 2011. Other journal including the Journal of Applied Microbiology, Journal of 
Dentistry and Microbial Pathogenesis have shown a steady increase in the number 
of publications since 2011, illustrating increased interest in the field.
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Figure 2.9: Most relevant sources of Candida and Lactobacillus biofilm research. 
Top 10 most relevant sources of scientific literature and number of articles published in Candida and Lactobacillus biofilm research between 1999-2020 (A). 
Dynamics of the top 5 most relevant sources in the field between 1999-2020 (B). 
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Differences were also apparent when observing relevant authors in the field and 
their collaborative links compared with the previous search (Figure 2.10). The 
highest publishing authors in the field were found to be Jorge A. O. C., Junqueira J. 
C. and Rossoni R. D., each with 7 articles (Figure 2.10A). These authors were also 
found to have strong collaborative links, appearing together in the red coloured 
network in Figure 2.10B. Further, other relevant authors were also shown to have 
close research links, illustrated in the blue network, including Busscher H. J., Van 
Der Mei H. C, Buijssen K. J. D. A. and Harmsen H. J. M., showing individual 
research groups.
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Figure 2.10: Relevant authors and collaborative links in Candida and Lactobacillus biofilm research. 
Relevant authors based on number of published articles in the field between 1999-2020 (A). Network of collaborations between the most published authors 
(B). Node size is weighted by author contribution; Closed networks of one colour represent closely linked collaborative groups. Isolated nodes were removed.
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Production of scientific literature in the field of Candida and Lactobacillus biofilms 
was then observed with respect to the corresponding author’s home country (Figure 
2.11). The majority of research was found to be published in South America, the 
USA, South-Eastern Asia and the UK, illustrated by a dark blue shading. Areas with 
a smaller contribution included Australia and areas within Europe. Africa and central 
Asia were largely found to have no contribution to the field.
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Figure 2.11: Scientific production by country of Candida and Lactobacillus biofilm 
research. Scientific contribution by country indicated by dark blue (large contribution), light 
blue (small contribution) and grey (no contribution) to Candida and Lactobacillus biofilm 
research between 1999-2020. 
 
To further investigate the geographical spread of scientific literature, the countries 
with the highest number of articles and their associated citations are shown in Figure 
2.12. Brazil was found to have the highest contribution to the field with a total of 26 
articles (Figure 2.12A). Brazil was also found to have the highest level of 
collaboration with other countries with 7 MCPs. As expected, Brazil was found to 
have the highest number of total citations, however, with only 23 citations, it had 
one of the lowest numbers of citations per article (Figure 2.12B). Other relevant 
countries such as the UK, Germany and China were seen to often publish in 
collaboration with other countries. Conversely, Italy was found to publish exclusively 
as SCPs. Despite not being within the top 10 most published countries, the 
Netherlands was the second most cited country with a substantial 59 average 
citations per article. Other highly cited countries included the UK, Australia and New 
Zealand with a combined average 53 citations per article.
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Figure 2.12:  Relevance of scientific contribution by country. 
Number of articles published by the corresponding author’s country (A). Split bars represent single country publications (SCP) and multiple country 
publications (MCP). Total and average number of citations from the highest published countries between 1999-2020 (B). 
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Analysis of frequently used author’s keywords and their correlations in Candida and 
Lactobacillus biofilm research allowed for an insight into where interest within the 
field lies (Figure 2.13). Themes including “vulvovaginal candidiasis”, “biofilms” and 
“bacteriotherapy” were identified as recurring themes in the field (Figure 2.13A). The 
majority of these themes were found to be associated with keywords related to 
clinical infection research such as “lactobacilli”, “probiotics” and “antimicrobials|” 
illustrated by the red network in Figure 2.13B. Other themes identified by the 
thematic map were classed as ‘basic’ themes and include “Candida albicans”, 
“lactobacilli”, “Streptococcus mutans” and “biofilm”. These were found to be closely 
linked themes in the literature, illustrated by significant overlap of ellipses and 
interlink of keyword networks. Keywords associated with oral microbiology research 
are shown in purple and include “dental plaque” and “gene expression”. The green 
network illustrates keywords associated with a range of research including “anti-
biofilm activity”, “antimicrobial activity” and “essential oil”. 
 
Finally, a third search was carried out to determine levels of interest in the field of 
vaginitis in Candida and Lactobacillus biofilm research (Table 2.1). This search only 
retrieved 8 research items from the Web of Science Core Collection database, 5 of 
which were review papers. For this reason, it was not possible to carry out 
bibliometric analysis using these search terms.
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Figure 2.13: Most frequent keywords and their correlations in Candida and Lactobacillus biofilm research. 
Thematic map illustrating the relevance of common keywords in Candida and Lactobacillus biofilm research (A). Co-occurrence network of the most common 
author’s keywords used in the field (B). Node clustering and size is weighted by co-occurrence and frequency of keywords, respectively. Isolated nodes were 
removed.
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2.4 Discussion 
 
It is now possible for researchers with little knowledge of programming language 
software to quantify and analyse entire fields of scientific literature through the 
application of bibliometric analysis using the open-source web application, 
Biblioshiny®. This ability to gain a wide insight in to developing or declining interest 
and themes within the field of research greatly expands a researcher’s ability to 
review the area. The analysis in this chapter aimed to identify how research of 
interactions between Candida and Lactobacillus has developed over the last three 
decades, as well as to assess which areas of this research biofilms are most 
appreciated. In addition, it aimed to investigate these themes with respect to 
vaginitis. 
 
Assessment of the overall scientific production of literature pertaining to Candida 
and Lactobacillus research between 1990-2020 showed a steady increase in 
interest over time. In-fact, of the 1,860 research items retrieved by the search, 1,142 
of these were published in the most recent decade. This is likely a reflection of 
impactful work published at this time showing in vitro and in vivo anti-Candida 
activity of both oral and vaginal Lactobacillus strains related partly to hydrogen-
peroxide production (Strus et al., 2005, Elahi et al., 2005). Further, it is at the 
beginning of this decade that key publishers in the field including Rossoni R. D. and 
Jorge A. O. C. began investigating the probiotic potential of Lactobacillus species 
against C. albicans in oral candidiasis and their immunological effects in Galleria 
mellonella models. Similarly, the average number of citations per article per year 
has also increased over this period. The high numbers of total citations on earlier 
papers published throughout the 1990s is likely due to the later increase in annual 
publications in the 2000s citing these papers. There are consistently high numbers 
of citations per article throughout the 2000s, indicative of a sharp increase of interest 
in the field. Given the steady rise of interest in this area over time, it is likely that 
numbers of annual publications will continue to increase as understanding of anti-
Candida capabilities of Lactobacillus species grows. 
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Analysis of relevant sources within the field revealed high numbers of publications 
in journals associated with food microbiology. This is likely a result of many highly 
cited publications assessing antagonism between Candida and Lactobacillus with 
respect to food spoilage and the fermentation of sourdough (Venturi et al., 2012, 
Yang and Chang, 2010). However, it is also important to consider the possibility of 
ease of publication within certain fields as a paper detailing treatment of oral 
candidiasis with Lactobacillus probiotics in a murine model is published in a journal 
associated with food spoilage (Wagner et al., 2000). Source dynamics over the 
period from 1990-2020 suggest that the number of publications pertaining to 
Candida and Lactobacillus research in the most relevant journals are declining, with 
an increase in publications in journals such as Food Science and Technology and 
PLOS One. This data suggests that this field of research is still relevant in both the 
food industry and in the field of science and medicine and that these journals will 
likely become the most relevant in years to come. 
 
The most relevant authors in the field were found to have similar numbers of 
published articles with no one author responsible for the majority of publications. 
However, this analysis did identify one key group of researchers with close 
collaborative links, Jorge A. O. C., Junqueira J. C. and Rossini R. D., who have 
collectively published the most in the field. This group is likely responsible for many 
publications from Brazil, illustrated by the dark blue coloration on the map in Figure 
2.5. Another group of collaborative researchers was identified including Bellen G., 
Donders G.G.G. and Vitali B. This is an intercountry collaborative group responsible 
for the majority of publications from Italy and Belgium. Further investigation of each 
country’s contribution revealed China, the USA and Italy as the most highly 
published countries worldwide. However, despite having the highest volume of 
publications, China had the lowest total number of citations, suggesting a potential 
overload of less relevant literature. Although Belgium was not in the top 10 most 
published countries, it had the highest numbers of citations per article, likely a 
reflection of the close collaborative links with Italy. 
 
The final analysis of the first bibliometric search aimed to gain insight into common 
keywords used in Candida and Lactobacillus research. The most widely used theme 
identified was “probiotics”; Although this may indicate the treatment of candidiasis 
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at mucosal sites, common keywords associated with this theme revealed it was 
primarily associated with research of Candida and Lactobacillus in the fermentation 
industry. Overlap of the themes “Candida albicans” and “lactic-acid bacteria” was 
found to be primarily associated with the treatment of oral candidiasis and dental 
caries, and in-part, sourdough fermentation. Overall, this search revealed a growing 
interest in Candida and Lactobacillus research between 1990-2020 with focus on 
the treatment of oral candidiasis and the prevention of food spoilage during 
fermentation. The most impactful publications during this time were from two 
research groups from Brazil and a collaborative group from Belgium and Italy. This 
data suggests that despite the proven probiotic effects of Lactobacillus against 
Candida at mucosal sites, research pertaining to the treatment of vaginal Candida 
infections remained largely understudied during this time. 
 
The next search was carried out to identify which areas of scientific literature 
involving Candida and Lactobacillus appreciate the impact of biofilms on clinical 
treatment and potential microbial interactions. No research items were obtained in 
this search prior to 1999, as such, subsequent analysis was carried out on articles 
published between 1999-2020. Very few articles were retrieved throughout the 
2000s, with a notable spike in publications in 2015 and 2016. All articles published 
in this area received high numbers of citations with an average of 25 citations per 
year. Like the last search, this is likely due to the recent rise in interest in the field 
resulting in increased citations on earlier articles. The rise in interest from 2015 is in 
part a reflection of impactful work by Matsubara et al. showing the first insights into 
the mechanisms of early Candida biofilm inhibition by probiotic L. rhamnosus 
(Matsubara et al., 2016b).  
 
The majority of publications in this area were found to be published in journals which 
publish primarily in oral health and microbiology (Figure 2.9). Similarly to the 
previous search, PLOS One was found to be the most popular source for research 
in this field. However, no sources associated with fermentation or food spoilage 
were identified in this search, suggesting biofilms are not of concern in such areas. 
Source dynamics revealed a sharp decrease in publications to PLOS One and an 
increase in those to the Journal of Dentistry and Archives of Oral Biology, however, 
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given the small number of publications per year, it is difficult to draw definitive 
conclusions from these data. 
 
The most published authors in the field were similar to the previous search, 
however, many more collaborative groups were identified. The most published 
group was Jorge A. O. C.’s research group, again responsible for the high 
contribution to the field and total citations from Brazil. Another relevant collaborative 
group was identified from the Netherlands comprising Busscher H. J., Van Der Mei 
H. C., Buijsen K. J. D. A. and Harmsen H. J. M., who primarily investigate 
polymicrobial biofilm formation of Candida and Lactobacillus on voice prosthesis 
(Buijssen et al., 2007, van der Mei et al., 2014). Despite only 8 publications in the 
field from the Netherlands over this time, these papers were clearly impactful with 
469 total citations. Additionally, an Austrian group who investigate the inhibitory 
properties of Lactobacillus supernatants against Candida biofilms in oral candidiasis 
were identified in this search (Tan et al., 2018). Despite having few publications, the 
UK was also found to be highly cited in the field of Candida and Lactobacillus biofilm 
research. 
 
Finally, analysis of the frequency and co-occurrence of author’s keywords in the field 
revealed various themes. It is clear from the number of widely used and re-occurring 
themes that this search encompasses many different areas of research. Many of 
the re-occurring themes including “lactobacilli” “caries” and “Streptococcus mutans” 
shared significant overlap and were associated with keywords such as 
“mouthwash”, “probiotic” and “candidiasis”. This data shows the majority of Candida 
and Lactobacillus biofilm research focusses on the treatment of oral candidiasis. 
However, one re-occurring theme was identified as “vulvovaginal candidiasis” and 
was associated with the keywords “Candida spp.”, “Candida albicans” and 
“Enterococcus faecalis”. This shows a clear interest in the role of Candida and 
Lactobacillus biofilms in vaginal Candida infections, however as a small subsection 
of the entire field. 
 
Very few articles were retrieved in the third and final search, limiting the amount of 
analysis performed on this search. This is evident of the lack of appreciation of the 
impact of Candida and Lactobacillus biofilms in vaginal infections such as 
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vulvovaginal candidiasis. There is a clear gap in the literature in the understanding 
of consequences of interkingdom interactions between Candida and Lactobacillus 
in vaginitis. Further research could greatly improve current knowledge of the 
pathogenesis of Candida at mucosal sites, predominantly in the understudied field 
of vaginal candidiasis. To this end, clinical studies assessing microbial populations 
in clinical samples of health and RVVC to elucidate potential biofilm formation and 
microbial interactions associated with disease are required. 
 
 
Chapter findings 
 
• The relatively novel open-source Biblioshiny® tool provides researchers with 
a crucial method of handling an expanding pool of scientific literature in a 
meaningful way, without the need to be proficient in programming language 
software. 
 
• Interest in literature throughout the last three decades pertaining to Candida 
and Lactobacillus research has increased significantly with the publication of 
highly impactful articles. This research has a strong focus on the fields of 
food spoilage, fermentation, and oral microbiology. 
 
• More recently, an increased interest in the role of biofilms in Candida and 
Lactobacillus research is evident. This interest in primarily focussed on the 
role and treatment of Candida biofilms with Lactobacillus probiotics in oral 
candidiasis, with a significantly smaller focus on vaginal candidiasis
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3 Identifying biological indicators and 
Candida biofilm formation in RVVC 
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3.1 Introduction 
 
Our current understanding of VVC pathology dictates that VVC is an acute 
inflammatory condition of the vulva and vaginal mucosa due to overgrowth of 
typically asymptomatic commensal Candida species (Fidel et al., 2004). There are 
many hypothesised predisposing factors to VVC onset, including the use of 
antibiotics, uncontrolled diabetes mellitus, sexual activities, and tight-fit clothing 
(Sobel et al., 1998, Sobel, 1997). However, defined triggers for onset and 
recurrence of symptoms remain largely unknown. It has previously been 
hypothesised that the relationship between the presence of Candida in the vagina 
and host susceptibility to infection may be due to the sensitivity of the patient’s 
individual vaginal epithelium (Fidel, 2007). This hypothesis means that the 
‘threshold’ for Candida load to become symptomatic is different in each patient, also 
implying a focus on the requirement for personalised medicine. Despite being 
defined by an overgrowth of Candida, many authors have reported variable results 
when attempting to correlate Candida load with severity of VVC (Hopwood et al., 
1988, Marot-Leblond et al., 2009). It has been suggested that yeast counts of >103 
CFU/mL indicate symptomatic infection and counts less than this cut-off indicate 
commensal carriage (Hopwood et al., 1988). However, there are currently no 
appropriate clinical studies which have investigated this as a potential symptomatic 
threshold. Conversely, studies have found no correlation between a higher Candida 
load and symptomatic infection (Marot-Leblond et al., 2009). If it is possible to 
determine the ‘infection threshold’ for individual patients, it could be possible to 
prevent development of RVVC through appropriate personalised antifungal 
prophylactic maintenance therapies. 
 
Until recent decades, the immunopathology of VVC onset was thought to be 
attributed to a weakened or defective adaptive immune response in patients, similar 
to oral candidiasis (Klein et al., 1984, Fong et al., 1992). However, studies using 
murine models failed to determine a crucial role for cell-mediated immunity in the 
vagina following Candida infection (Fidel et al., 1995, Mendling and Koldovsky, 
1996). Additionally, an innovative study using human participants demonstrated that 
Candida infection resulted in an extensive non-protective influx of leukocytes during 
symptomatic VVC (Fidel et al., 2004). This study also determined that a defective 
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immune response was concurrent with immunity to VVC, contrary to previous 
beliefs. Since this discovery, many studies have been conducted in an attempt to 
identify important immune pathways in VVC pathology. Unlike other human Candida 
infections, VVC occurs in people who are immunocompetent and that do not 
necessarily have underlying health conditions. It is widely accepted that acute 
inflammation in VVC is not due to an abnormal adaptive immune response and 
instead is a result of an aggressive innate response by PMNs (Fidel et al., 2004). 
The chemoattractant responsible for this non-protective influx of PMNs is unknown 
and studies predominantly focus on utilising murine models to elucidate potential 
candidates of PMN influx (Yano et al., 2010, Bruno et al., 2015). To date, no studies 
have assessed inflammatory biomarkers present in clinical samples of VVC/RVVC 
to expose potential biomarkers of disease. Proteomic analysis is a powerful tool and 
has been used successfully to identify biological markers for the detection of 
diseases such as nasopharyngeal carcinoma, meningitis, and infections of the 
central nervous system (Bharucha et al., 2019, Cordeiro et al., 2015, Yang et al., 
2014). Identification of biomarkers for the detection of VVC/RVVC could greatly 
improve diagnosis accuracy allowing patients to receive appropriate treatments to 
prevent failure and recurrence. 
 
Diagnosis of VVC is problematic and can result in inappropriate treatment. It has 
been estimated that up to 77% of VVC cases are misdiagnosed as other 
inflammatory disorders based on clinical evidence alone (Schwiertz et al., 2006). 
The presence or positive culture of Candida itself is not indicative of disease as the 
commensal carriage rate in the vagina is ~30% (Achkar and Fries, 2010a). Further, 
current guidelines fail to consider the Candida species responsible for VVC which 
can result in failed clinical treatment and development of debilitating RVVC, as NAC 
are often less susceptible to conventional antimycotic therapies (Deorukhkar et al., 
2014). Of particular clinical concern are C. glabrata and C. krusei as they are 
intrinsically highly tolerant to azoles (Singh et al., 2002, Vermitsky and Edlind, 2004). 
Antifungal ointments and pessaries used to treat VVC are freely available from over-
the-counter pharmacies, resulting in a higher likelihood of inappropriate treatment 
as well as resulting in impossible to determine rates of infection and recurrence. A 
single dose of oral or topical azole therapy (typically fluconazole) is sufficient to treat 
sporadic C. albicans VVC in 80-90% of cases (Pappas et al., 2009). Treatment of 
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VVC caused by a NAC species is referred to as complicated VVC, requiring 
prolonged suppressive azole therapies, exceeding 6 months in some cases, which 
are frequently unsuccessful contributing to the 8% of women who develop RVVC 
(Sobel et al., 2003a). In recent years, authors have reported an epidemiological shift 
in VVC showing a rise of NAC species (Sherry et al., 2017). The most commonly 
isolated NAC species in VVC is C. glabrata followed by C. tropicalis, C. parapsilosis, 
C. dubliniensis, C. krusei, C. kefyr and C. guilliermondii (Deorukhkar et al., 2014). 
The global prevalence of NAC species in VVC has previously been estimated to be 
10-20%, however this is highly geographically dependant (Fidel et al., 1999). 
Generally, there are very few reports of the prevalence of NAC species within 
women in the UK. However, our group has previously observed a prevalence of 29% 
NAC species among women with VVC in the UK (Sherry et al., 2017). The lowest 
proportions of NAC species reported have been in China, Brazil, Belgium, Italy and 
Turkey which all reported >75% of VVC episodes caused by C. albicans (Shi et al., 
2015, Ribeiro et al., 2001, De Vos et al., 2005, Corsello et al., 2003a, Ozcan et al., 
2006). Conversely, studies have shown countries such as India, Nigeria, and 
Ethiopia to have higher rates of NAC species episodes, accounting for up to 40% of 
total cases (Ahmad and Khan, 2009, Bodenham et al., 2020, Bitew and Abebaw, 
2018). This data highlights the importance of consideration of the causative species 
of Candida in individual cases of VVC before decisions for clinical treatment are 
made. 
 
Despite the ability of Candida species to readily form dense biofilms and their impact 
on clinical treatment (Ramage et al., 2012a), the presence of biofilms on vaginal 
epithelium in VVC/RVVC is disputed by some authors (Swidsinski et al., 2019, 
Sobel, 2015b). Although they have been shown to form both in vitro and in vivo, 
vaginal Candida biofilms remain unrecognised when making decisions to treat VVC 
(Harriott et al., 2010b, Sherry et al., 2014, Paiva et al., 2012). Unfortunately, there 
are no vaginal biopsy studies for VVC on a scale similar to those conducted for BV 
research, and as such the hypothesis of vaginal biofilms in VVC remains unclear. 
Although some studies have identified biofilm-related gene expression in clinical 
isolates of VVC (Khosravi Rad et al., 2016, Gao et al., 2016), none have aimed to 
find evidence of expression of these genes in clinical samples of VVC/RVVC. 
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Hypotheses and aims 
Despite exceptionally high case rates of up to 75% of all women of child-bearing 
age, the triggers for onset of VVC/RVVC remain largely unknown. Additionally, 
possible causes of failed clinical treatment are understudied in the field and better 
understanding could greatly improve treatment prospects for women with recurrent, 
azole-resistant episodes. Therefore, the main aims of this chapter were to: 
 
• Gain insights in to states of health and RVVC through analysis of 
demographic data from patients recruited for this study. 
• Observe and compare the immunological and microbiological biomarkers of 
healthy patients and those with RVVC. 
• Evaluate the presence of vaginal biofilms and their impact on RVVC 
treatment. 
• Assess alternative potential sources of failed clinical treatment reported in 
RVVC. 
 
It is hypothesised, based on previous research, that an increased fungal load and 
elevated levels of inflammatory biomarkers in samples from diseased women will 
be indicative of RVVC. Additionally, it is theorised that the ability of Candida clinical 
isolates to form biofilms with increased antifungal tolerance and express key biofilm-
related genes, has the potential to cause failed treatment in clinical settings. 
 
Work from this chapter has been presented at the following 
workshops/conferences: 
University of Glasgow postgraduate prize seminar, May 2019, Glasgow, UK 
Eurobiofilms Conference, September 2019, Glasgow, UK 
Federation of Infection Societies Conference, November 2019, Edinburgh, UK 
 
Work from this chapter has been published in mSystems: 
McKloud E, Delaney C, Sherry L, Kean R, Williams S, Metcalfe R, Thomas R, 
Richardson R, Gerasimidis K, Nile CJ, Williams C, Ramage G. Recurrent 
Vulvovaginal Candidiasis: A Dynamic Interkingdom Biofilm Disease 
of Candida and Lactobacillus. mSystems. 2021 Aug 10:e0062221. doi: 
10.1128/mSystems.00622-21.   
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3.2 Materials and methods 
 
3.2.1 Clinical sample processing and analysis 
 
3.2.2 Patient recruitment 
One hundred women aged 18 and over attending Glasgow Sandyford Sexual Health 
Clinic between February 2017 and June 2018 were enrolled in the study. Patients 
presenting with symptomatic RVVC were recruited (n=40) as well as healthy women 
attending the clinic for contraceptive intrauterine device (IUD) implantation as a 
control cohort (n=60). This removed bias of the study to solely recruit women with 
symptomatic disease. This study was granted ethical approval by the Sheffield 
Research Ethics Committee (16/YH/0310). Dr Rebecca Metcalfe (Specialist 
Registrar), or another doctor trained in this study was responsible for patient 
recruitment and obtaining informed consent from prospective participants after they 
had read the patient information sheet. If the patient chose to participate, a 
questionnaire was completed and given to the clinician in charge of the study, Dr 
Rebecca Metcalfe. Dr Rebecca Metcalfe or a qualified research nurse was 
responsible for sample collection during routine examination. Patients were 
excluded from the study if they had active bacterial vaginosis, were pregnant, 
immunosuppressed, menstruating, menopausal or had taken antibiotics/antifungals 
within 7 days prior to sampling. 
 
3.2.3 Collection of clinical samples 
During routine examination, a sterile speculum was used to obtain two high vaginal 
swabs (HVS) from each patient. One swab formed part of routine care which was 
sent for organism identification at the NHS Greater Glasgow and Clyde (GGC) labs, 
the other was used in this study. Additionally, a cervico-vaginal lavage (CVL) was 
collected using 5 mL of sterile water, allowing the fluid to pool prior to removal. Swab 
samples were submerged in 500 µL of PCR grade water, contained within a 
universal collection tube. Samples were then vortexed for 30 s before being 
transferred to cryovials and stored at -80°C. Lavage samples were transferred to 
cryovials and stored at -80°C. Supernatants collected from lavage samples were 
used to measure vaginal pH. 
 
Chapter 3 – Identifying biological indicators and Candida biofilm formation in RVVC  
75 
 
3.2.4 Collection of patient data 
Potential participants attending the clinic were either referred by their GP or self-
referred. Once in the clinic, they were provided information on the study and if 
informed consent was obtained, they were provided with a questionnaire (See 
appendices i-v). The patient questionnaire collected data on patient’s RVVC history, 
including number of episodes within the previous 12 months, treatment regimens, 
and any contraception currently used by the patient. Patients were allocated a 
unique study code using a numbering system with a letter to identify disease status 
(SVS001A for the first healthy patient, SVS001B for the first RVVC patient, etc.) 
which was used to identify each sample during subsequent analysis. A graphical 
representation of sample collection and processing can be found in Figure 3.1. 
 
 
Figure 3.1: Illustrative representation of clinical study sample collection and 
processing. After distribution of information sheets and collection of informed consent, 
patient questionnaires were completed. Both high-vaginal swab and cervico-vaginal lavage 
samples were collected. Swab samples were used to extract DNA for microbial profiling. 
Lavage samples were used for species ID and isolation and visualisation of Candida. 
Created with Biorender.com. 
 
3.2.5 Quantification of microbial load by real-time PCR 
Candida and bacterial burdens were determined by extracting DNA from swab 
samples and analysing using qPCR. Samples were transferred to Eppendorf tubes 
and centrifuged, the resulting pellet was then enzyme-treated with lysozyme (10 
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mg/mL in 10 mM Tris-HCL pH 8) for 1 h at 37°C and proteinase K (20 mg/mL in 
5.5% SDS) for 1 h at 55°C. DNA was extracted using the QIAmp DNA mini kit, as 
per manufacturer’s instructions (Qiagen, Crawley, UK) and qPCR used to quantify 
fungal and bacterial load in each sample. Primers specific to the conserved Candida 
ITS rRNA gene were used to determine Candida load. For bacterial load, primers 
and a Taqman probe specifically targeting the prokaryotic 16S rRNA gene were 
used. Primer sequences are presented in Table 3.1. 
 
Table 3.1: qPCR primer sequences for microbial quantification 
 
 
Total qPCR reaction volume was 20 µL, with 1 µL of extracted DNA, 500 nM of 
forward/reverse primers and UV-treated RNase free H2O. For 16S, 250 nM of probe 
and 2X TaqmanTM Universal PCR Master Mix (ThermoScientific, Loughborough, 
UK) was used, 2X Fast SYBRTM Green PCR Master Mix (ThermoScientific, 
Loughborough, UK) was used for ITS primers. qPCR was performed using an 
Applied Biosystems™ StepOne™ Real-Time PCR System (Life Technologies, 
Paisley, UK) with the following thermal conditions: an activation step of 50°C for 2 
min and 95°C for 10 min followed by 40 cycles of 95°C for 10 s and 60°C for 30 s. 
Standard curves constructed from serially diluted DNA of C. albicans SC5314 
(Appendix 5) and Escherichia coli K12 (Appendix 6) were used extrapolate Candida 
and bacterial colony forming equivalents (CFE/mL), respectively, as described 
previously  (O'Donnell et al., 2015). 
 
3.2.6 Detection of inflammatory biomarkers in CVL with Olink Proteomics 
CVL supernatants were recovered by centrifugation for proteomic analysis. Initially, 
10 healthy and 10 samples from RVVC patients were selected and analysed using 
the commercially available Olink ProseekTM Multiplex Inflammation I (v.3012) panel 
(Olink Proteomics, Uppsala, Sweden) (Assarsson et al., 2014, Moen et al., 2016). 
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This panel screens for the presence of 92 preselected proteins related to 
inflammation (Table 3.2). A proximity extension assay (PEA) was performed, 
allowing for high throughput multiplexing to measure levels of 92 biomarkers 
simultaneously.  
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Table 3.2: List of inflammatory biomarkers detected by Olink proteomic panel. 
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Briefly, two oligonucleotide-labelled antibodies (or “probes”) bind to the target 
protein in the sample. The proximity of the probes to each other allows a new PCR 
target sequence to form using a proximity-dependant DNA polymerase. This 
sequence is then detected and quantified using qPCR to assess biomarker levels. 
A graphical overview of this process is presented in Figure 3.2. 
 
 
Figure 3.2: Graphical illustration of Olink biomarker detection and analysis pipeline. 
Created with Biorender.com. 
 
3.2.7 Detection of inflammatory biomarkers by ELISA 
Three of the inflammatory chemokines, CXCL9, CXCL10 and IL-8, detected at 
significantly higher levels in RVVC compared with health were analysed in all CVL 
samples by Enzyme-Linked Immunosorbent Assay (ELISA) (Invitrogen, Paisley, 
UK). For detection of levels of IL-8, 96-well plates (Costar 9018, Corning, USA) were 
coated with anti-human IL-8 antibody (1:250 dilution) overnight at 4°C. Following 
washing with 250 µL of 1× PBS, 0.05% Tween™ 20  3-5 times and blocking non-
specific sites for 1 h, 100 µL of 1:2 diluted CVL supernatant samples and IL-8 
standards (250 – 3.9 pg/mL) were added and incubated at room temperature for 2 
h. Plates were washed before addition of biotin-conjugated anti-human IL-8 antibody 
(1:250 dilution) for 1 h, followed by another wash step and addition of avidin bound 
to the enzyme, Horse Radish Peroxidase (HRP) (1:250 dilution) for 30 min. Plates 
Chapter 3 – Identifying biological indicators and Candida biofilm formation in RVVC  
81 
 
were washed a final time and 1× tetramethylbenzidine (TMB) substrate was added, 
colour was allowed to develop for around 15 min before 50 µL of 1 M HCl was added 
to stop the reaction. Absorbance was then measured using a spectrophotometer at 
450 nm and 570 nm.  
 
For detection of CXCL9 and CXCL10, ELISA kits pre-coated with anti-human 
CXCL9/CXCL10 antibody were used. Briefly, CVL samples (1:2 dilution) and 
standards were added to 96-well plates (Costar 9018, Corning, USA) and incubated 
at room temperature for 2.5 - 3 h. Biotinylated antibody targeting CXCL9/CXCL10 
was then added, and plates incubated for 1 h before addition of streptavidin-HRP 
for 30 min. After a final wash step, TMB (CXCL9) or stabilised chromogen (CXCL10) 
was incubated for around 30 min before 1 M HCL was added to stop the reaction. 
Absorbances were read spectrophotometrically at 450 nm and 550 nm. Standard 
curves were constructed using the absorbance readings for the standards and 
biomarker levels in CVL samples were calculated from the curve and multiplied by 
the appropriate dilution factor. Each sample was assessed in triplicate and 
appropriate negative controls were included throughout. 
 
3.2.8 Clinical isolate in vitro biofilm formation 
 
3.2.9 Visualisation of C. albicans filamentation in CVL 
For visualisation of Candida aggregates, 30 µL of CVL from a patient with RVVC 
was stained with calcofluor white (CFW) (Invitrogen, Paisley, UK) to a final 
concentration of 0.06 µg/mL. CFW stains cellulose and chitin in the fungal cell wall 
allowing for fluorescent visualisation of both yeast cells and hyphae. Samples were 
incubated for 1 h at 37°C before being imaged using the EVOS live cell imaging 
system at an excitation/emission wavelength of 357/447nm (ThermoScientific, 
Loughborough, UK). 
 
3.2.10 Identification of Candida species from cervico-vaginal lavage 
Samples were screened for presence and identification of Candida species using 
Colorex Candida chromogenic agar (E&O Laboratories Ltd, Bonnybridge, UK) and 
Matrix Assisted Laser Desorption/Ionization – Time Of Flight (MALDI-TOF) mass 
spectrometry. For culture identification, 20 µL of CVL sample was spread across the 
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surface of a chromogenic agar plate before 48 h incubation at 30°C. The colour of 
the colonies cultured was used to determine Candida species, colony numbers were 
used to calculate the number of colony forming units per millilitre (CFU/mL). Purity 
plates were made for each Candida isolate by sub-culturing 3 distinct colonies from 
the chromogenic agar plate to fresh Sabouraud dextrose agar (SAB [Merck, 
Gillingham, UK]) and incubating for 48 h at 30°C. Clinical isolates were then stored 
on beads in glycerol in Microbank® vials (Pro-Lab Diagnostics, Cheshire, UK) at -
80°C. 
 
As a more accurate method of identification, MALDI-TOF mass spectrometry was 
used to confirm the identify of all cultured species. MALDI-TOF analysis was 
performed at Glasgow Royal Infirmary laboratories under the supervision of Dr Mary 
Ann Ritchie. Candida isolates were cultured from beads to SAB agar plates and 
incubated for 48 h at 30°C to achieve single colony growth. Isolate identities were 
confirmed by MALDI-TOF analysis using a Bruker Microflex, comparing recorded 
spectra to the Bruker database. Briefly, MALDI-TOF analysis for yeasts involves 
pre-treating the cells with 70% formic acid, coating the sample for detection with a 
matrix and allowing it to crystalise. The sample entrapped within the matrix is then 
ionised using a laser, generating singly protonated ions from the sample. These ions 
are then fired at a fixed point where and can be measured based on the time taken 
for the ion to travel to the end of the flight tube and pass the detector (Singhal et al., 
2015). 
 
3.2.11 Screening of RVVC clinical isolates for biofilm formation 
Candida clinical isolates were assessed for biofilm forming capabilities by crystal 
violet and [2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxanilide] (XTT) metabolic activity assays (Kuhn et al., 2003, Feoktistova et al., 
2016). Candida isolates (n=33) were cultured from lavage samples on SAB agar for 
48 h at 30°C. For biofilm formation, overnight cultures were grown in yeast extract 
peptone dextrose (YPD) at 30°C with shaking at 180rpm. Cultures were washed 
twice with PBS and standardised in RPMI 1640 medium (Merck, Gillingham, UK) to 
a final cell density of 1x106 CFU/mL. Eight biofilms of each isolate were grown in 
96-well, flat bottomed microtitre plates for 24 h at 37°C before washing and 
metabolic activity was measured by the  (XTT) reduction assay (Pierce et al., 2008). 
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Briefly, 100 µL of XTT with 1 µM menadione was added to each biofilm and 
incubated at 37°C for 90 min before 75 µL of each supernatant was transferred to a 
fresh 96-well flat-bottomed microtitre plate and metabolic activity measured 
spectrophotometrically at 492 nm. Biofilms were then allowed to dry for 24 h at room 
temperature before biomass was measured by the crystal violet assay (Ramage et 
al., 2001a). Briefly, wells were flooded with 0.05% crystal violet solution for 20 min 
at room temperature. The stain was removed, and biofilms washed with water to 
remove excess stain before 100 µL of 100% ethanol was added to remove bound 
stain from biofilms. 75 µl of supernatant was then transferred to a fresh 96-well flat-
bottomed microtitre plate and biomass measured spectrophotometrically at 570 nm. 
For each isolate, 8 biofilms were assessed, and negative controls were included 
throughout.  
 
3.2.12 RVVC clinical isolate antifungal susceptibility testing 
For antifungal susceptibility testing of Candida clinical isolates, overnight cultures 
were washed and standardised in RPMI 1640 media to a final cell density of 2×104 
CFU/mL for planktonic cells and 1x106 CFU/mL for sessile cells. For planktonic 
testing, fluconazole, miconazole and clotrimazole were made to a working 
concentration of 64 µg/mL in RPMI 1640 media before 200 µL was added to the first 
column of a 96-well round-bottomed microtitre plates and serially diluted from 64 
µg/mL to 0.126 µg/mL in RPMI 1640 medium. Then, 100 µL of Candida suspensions 
were added and treatments were incubated for 24 h at 37°C before minimum 
inhibitory concentrations (MICs) were visually assessed at 50% and 90% inhibition, 
respectively. For biofilm susceptibility, 200 µL of Candida suspensions were added 
to 96-well flat-bottomed microtitre plates and incubated at 37°C for 24 h to allow 
biofilm formation. Biofilms were then washed twice with 200 µL PBS before addition 
of 200 µL of treatment was added, as described above, and serially diluted in RPMI 
1640 from 32 µg/mL to 0.063 µg/mL. Treatments were then incubated at 37°C for a 
further 24 h. Treatments were then removed, and biofilms washed twice with PBS 
before sessile MICs determined using the XTT metabolic reduction assay, as 
described above. Ten technical replicates were performed for each isolate 
assessed. Positive untreated controls and negative media controls were included 
throughout. 
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3.2.13 Biofilm-related transcriptional analysis of cervico-vaginal lavage samples 
CVL samples were used to analyse expression levels of key Candida biofilm-related 
genes. Samples were centrifuged, and supernatants recovered before pellets were 
stored in RNAlater® (QIAgen, Manchester, UK) at -80°C. To extract RNA, pellets 
were subjected to enzyme treatment using lysozyme and proteinase K before cells 
were homogenised using lysis buffer and 3 × 30 s cycles in a BeadBug™ microtube 
homogeniser (Merck, Gillingham, UK). RNA was then purified using the PureLinkTM 
RNA Mini kit (ThermoScientific, Loughborough, UK), as per manufacturer’s 
instructions and quality and quantity was assessed using a Nanodrop 
spectrophotometer (ND-1000, ThermoScientific, Loughborough, UK). High quality 
RNA was retained if the 260/280 value was between 1.8 - 2.2. cDNA was then 
synthesised from 160 ng of total RNA using a High-Capacity cDNA Reverse 
Transcription kit (Life Technologies, Paisley, UK) in a MyCycler PCR machine (Bio-
Rad Laboratories, Hertfordshire, UK), following manufacturer’s instructions. Cycle 
conditions were 10 min at 25°C, 2 h at 37°C and 5 min at 85°C, samples were then 
held at 4°C. For samples which contained <16 ng/µL RNA (4.02 – 15.5 ng/µL) after 
extraction, 10 µL of undiluted RNA was added to the cDNA reaction. No reverse 
transcriptase controls were included. 
 
Genes assessed included ECE1 which encodes candidalysin and has been 
extensively studied for its crucial involvement in Candida pathogenicity in a range 
of infection models including oral candidiasis (Birse et al., 1993, Moyes et al., 2016). 
HWP1 (Hyphal Wall Protein) is an adhesin involved in hyphal morphogenesis and 
tissue invasion in Candida infections (Sundstrom et al., 2002). ALS3 (Agglutinin-
Like Sequence) is another adhesin and plays an important role in attachment to 
epithelium and in Candida biofilm formation (Liu and Filler, 2011). SAPs (secreted 
aspartyl proteinases) expressed by Candida are extracellular hydrolytic enzymes 
involved in invasion, tissue damage and evasion of host response (Hube, 1996). 
Primers were selected and are listed in Table 3.3. qPCR reactions were constructed 
with 160 ng of RNA, 2× Fast SYBR® Green PCR Master Mix (ThermoScientific, 
Loughborough, UK), 10µM forward/reverse primers and UV-treated RNase-free 
H2O to carry out qPCR with the following cycle conditions: 2 min at 50°C, 2 min at 
95°C and 40 cycles of 10 s at 95°C and 30 s at 60°C. Reactions were carried out in 
duplicate and no reverse transcription (NRT) and no template controls (NTC) were 
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included throughout. Gene expression was normalised to the ITS housekeeping 
gene and calculated using the ΔΔCt method (Winer et al., 1999). 
 
Table 3.3: qPCR primer sequences for gene expression analysis 
 
 
 
3.2.14 Statistical analysis 
Figures for analysis of Olink proteomic data were constructed in RStudio (Version 
3.12.0). All other figures and analyses were performed in GraphPad Prism (Version 
8, La Jolla, California, USA). Statistical significance was measured using unpaired 
t-tests with Welch’s correction to compare the means of two samples and regression 
or Mann-Whitney if data was not normally distributed. One-way ANOVAs were used 
to compare the means of multiple samples. Statistical significance was achieved if 
P<0.05.  
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3.3 Results 
 
3.3.1 Clinical sample processing and analysis 
Swab and lavage samples were collected from 100 patients, 60 of which were 
healthy individuals and 40 were women suffering from RVVC. Demographic data 
collected through the patient questionnaire and presence/absence of Candida is 
reported in Table 3.4. Additionally, data related to types of contraception used at the 
time of sampling were collected and used for correlation analysis. 
 
Table 3.4: Patient demographics of women recruited for the study. 
 
*Patients defined as suffering from RVVC had presented at GP clinics with symptoms of VVC four 
or more times within one year. 
 
Vaginal dysbiosis is often alleged to coincide with an elevated vaginal pH in 
diseases such as BV and occasionally in RVVC.  
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Figure 3.3: The pH of vaginal lavage is unchanged in RVVC. Vaginal lavage 
supernatants were recovered by centrifugation before the pH was measured (n=93). Data 
represents mean ± SD. 
 
Assessment of vaginal lavage supernatant pH levels observed no significant 
differences between health and RVVC in this study (Figure 3.3). Both cohorts were 
found to range from a pH of ~3.5 to ~6.7. The mean pH of healthy samples was 
observed at 4.81 and 4.97 for RVVC samples (P=0.43). 
 
3.3.2 Quantification of microbial load 
The mechanisms behind the shift in Candida from asymptomatic commensal to 
pathogenic yeast seen in VVC onset remains poorly understood. The events leading 
to infection are likely multifactorial and here we aimed to assess whether fungal load 
may influence disease state. To this end, levels of Candida present in the swab 
samples were measured using both the plate-dilution method to assess culturable 
Candida and by real-time qPCR via amplification of the ITS region (Figure 3.4). 
Additionally, levels of bacteria were also measured molecularly in swab samples to 
assess potential differences between the two cohorts and to allow for normalisation 
of bacterial-Candida levels (Figure 3.5). 
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Figure 3.4: Fungal burden is elevated in women with RVVC. To determine fungal load, 
patient lavage was incubated on Candida chromogenic agar plates and CFU/mL evaluated 
after 48 h (A) For calculation of CFE/mL, the ITS region of Candida was amplified using 
genus-specific primers (B). Data represents the mean ± SD (*, P<0.05, **, P<0.01); 
Statistical significance was calculated using unpaired t-tests with Welch’s correction as data 
did not share equal standard deviations. 
 
 
Candida CFU/mL was significantly increased in samples from patients with RVVC 
to 2.3 × 104 CFU/mL from 2 × 103 CFU/mL in healthy patients (P<0.01) (Figure 
3.4A). Molecular analysis allowed for inclusion of Candida which are viable but not 
culturable by quantification of total Candida DNA in swab samples. When assessed 
by real-time qPCR, a similar significant increase of around 1.3-log was observed in 
patients with RVVC to 3.8 × 105 CFE/mL (P<0.05) (Figure 3.4B).  
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Figure 3.5: Bacterial load remains unchanged in RVVC. Levels of bacterial DNA present 
in swab samples were assessed molecularly by amplification of the 16S rRNA region (A); 
Correlation between bacterial and fungal burden was also observed (B). Data represents 
the mean ± SD (***, P<0.001); Statistical significance was calculated using unpaired t-tests 
with Welch’s correction as data did not share equal standard deviations. 
 
 
Bacterial load was found to be comparable between the two disease states and 
correlation of bacterial-Candida levels confirmed the observed increase in fungal 
load in RVVC samples (Figure 3.5). This data suggests that increased levels of 
Candida could be a contributing factor to disease pathology and may be an indicator 
for RVVC onset and subsequent recurrence.  
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As these are clinical samples, it was hypothesised that patient behaviour could 
influence the observed fungal load. To investigate this, culturable and detectable 
Candida levels were observed with respect to how long patients had suffered from 
RVVC (Figure 3.6 and Figure 3.7).  
 
 
Figure 3.6: Correlation of culturable Candida load with length of time with RVVC. 
Comparison of culturable Candida load in patients with RVVC (A) and linear regression 
analysis of Candida load over time (B). Data represents mean + SD. 
 
 
Although a slight reduction from ~1 × 105 to 1 × 104 CFU/CFE/mL is observed in 
patients with disease for over 7 months, this was not significant for either culturable 
(P=0.28) or detectable (P=0.08) Candida levels (Figure 3.6A and 3.7A, 
respectively). Regression analysis confirmed this showing a slight decrease in 
Candida load over time (Figure 3.6B and 3.7B). This data suggests that fungal 
burden is not necessarily a key factor in disease progression, and it may be more 
important to investigate factors such as biofilm formation and transcriptional 
changes. 
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Figure 3.7: Correlation of detectable Candida load with length of time with RVVC. 
Comparison of detectable Candida load in patients with RVVC (A) and linear regression 
analysis of Candida load over time (B). Data represents mean + SD. 
 
 
To investigate whether antifungal treatment of patients could have affected Candida 
load, the length of time since patients had been treated was compared with levels 
of culturable and detectable Candida (Figure 3.8 and Figure 3.9). 
 
 
 
Figure 3.8: Correlation of culturable Candida load with treatment time. Culturable 
Candida load was analysed with respect to the length of time since patients had received 
RVVC treatment (A). Linear regression of Candida load against time since treatment (B). 
Data represents mean + SD (*, P<0.05), statistical analysis was performed using unpaired 
t-tests. 
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A significantly decrease of around 1-log of culturable fungal load was observed in 
patients who had received treatment within one month of sample collection 
compared to those treated less frequently (P<0.05) (Figure 3.8A). Although not 
significant when measured by qPCR, a similar trend was observed (P=0.23) (Figure 
3.9A). Additionally, regression analysis confirmed this showing a positive correlation 
between Candida load and the number of months since treatment was given (Figure 
3.8B and 3.9B). 
 
 
Figure 3.9: Correlation of detectable Candida load with treatment time. Detectable 
Candida load was analysed with respect to the length of time since patients had received 
RVVC treatment (A). Linear regression of Candida load against time since treatment (B). 
Data represents mean + SD (*, P < 0.05), statistical analysis was performed using unpaired 
t-tests. 
 
 
3.3.3 Detection of inflammatory biomarkers 
 
A subset of samples was selected for Olink analysis to assess levels of inflammatory 
biomarkers present in CVL supernatant (n=20). The top ten samples with highest 
levels of detectable Candida were selected from each patient cohort for this 
analysis. Proteomic analysis allowed for the identification of potential specific 
biomarkers associated with RVVC (Figure 3.10). 
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Figure 3.10: Inflammatory profile of health and RVVC. 
Proteomic analysis was performed on lavage supernatant of healthy (n=10) and RVVC (n=10) samples. Bar plot representing proteins, which are significantly 
differentially expressed between health and RVVC.  T-tests using FDR-corrected P-values <0.05 were considered to be significant.
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Proteomic analysis revealed significantly higher levels of inflammatory biomarkers 
in samples from patients with RVVC including a series of chemokines: IL-8, CCL-
23, CXCL6, CXCL9 and CXCL10 (Figure 3.10). Further, some of the assessed 
inflammatory biomarkers were found to be higher in health compared with RVVC 
including IL-18, IL-33, and CSF-1. This elevation in healthy controls may be due to 
underlying autoimmune or inflammatory diseases which were not controlled for in 
this study. For example, IL-18 is associated with various diseases including 
influenza virus infections and Crohn’s disease (Yasuda et al., 2019), elevated IL-33 
has been linked to asthma and atopic dermatitis (Miller, 2011), and elevated CSF-1 
has been associated with general inflammation (Hume and MacDonald, 2012). 
 
Multivariate analysis by Principal Component Analysis (PCA) was performed to 
identify clusters of inflammatory profiles between health and RVVC (Figure 3.11).   
 
 
Figure 3.11: Clustering of inflammatory profiles of health and RVVC. Principal 
Component analysis (PCA) with ellipse showing clusters of biomarkers associated with 
health or RVVC (B). PC1 shows the largest variance (52.27%) along the x-axis and PC2 
displays the second largest variance (11.59%) on the y-axis. 
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This analysis revealed two major clusters with cluster 1 comprising predominantly 
healthy samples and cluster 2 containing mainly those from patients with RVVC. 
Clear separation of biomarker clusters was observed with some overlap between 
the two clusters. 
 
To further investigate this pattern of inflammatory chemokine upregulation in RVVC 
observed here, ELISAs were performed on the remaining CVL supernatants of all 
samples to assess levels of CXCL9, CXCL10 and IL-8 (Figure 3.12).
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Figure 3.12: Pro-inflammatory cytokines are elevated in patients with RVVC. 
Vaginal lavage supernatant samples were assessed by ELISA for levels of the inflammatory chemokines, CXCL9 (A), CXCL10 (B) and IL-8 (C) (n=98). 
ELISAs were performed in triplicate (**, P<0.01; ****, P<0.0001); Statistical significance was measured by Mann Whitney tests as data was not normally 
distributed. Data represents mean ± SD.
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Analysis of levels of inflammatory chemokines in all CVL supernatants revealed 
elevated levels of all assessed biomarkers in RVVC compared with health (Figure 
3.12). Around a 1-log increase in chemokine levels was observed in RVVC for all 
chemokines assessed: CXCL9 (P<0.01), CXCL10 (P=0.169) and IL-8 (P<0.0001).  
 
Additionally, chemokine levels were observed with respect to the presence or 
absence of culturable Candida in the samples (Figure 3.13).  
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Figure 3.13: The presence of Candida elevates levels of pro-inflammatory chemokines in RVVC lavage samples. 
Heatmaps were constructed to observe levels of (A) CXCL9, (B) CXCL10 and (C) IL-8 with respect to presence/absence of culturable Candida. (**, P<0.01); 
Statistical significance compared chemokine levels in RVVC in the presence and absence of Candida by Mann Whitney tests as data was not normally 
distributed.
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Interestingly, this analysis revealed a pattern by which CXCL9 and CXCL10 
chemokine levels in RVVC are elevated further when Candida is culturable in the 
sample. This was significant for CXCL9 (P<0.01), but not for CXCL10 (P=0.1). This 
trend was not observed in IL-8, where observed chemokine levels were comparable 
in the presence and absence of Candida.. 
 
3.3.4 Assessing Candida biofilm formation in clinical isolates 
 
One common cause of failed clinical treatment is the formation of microbial biofilms, 
although this is highly disputed in RVVC research. To observe evidence of Candida 
aggregation and filamentation in CVL samples, lavage was stained and incubated 
with CFW before being imaged under a light microscope (Figure 3.14). 
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Figure 3.14: Candida filamentation and aggregation is present in RVVC lavage. 
Vaginal lavage was stained with CFW for 1 h at 37°C before fluorescent imaging. Images 
are representative of C. albicans aggregates and hyphae observed in lavage from a patient 
with a high biofilm forming isolate. White arrows represent pseudo-hyphal/hyphal formation 
and red arrows depict cell aggregates. 
 
As depicted in Figure 3.14, clear evidence of C. albicans hyphal morphogenesis and 
aggregation can be seen in lavage fluid from a patient with RVVC. This strengthens 
previous evidence that Candida forms biofilms in the vagina during RVVC and may 
be an underappreciated reservoir for antifungal resistance and failed clinical 
treatment. 
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Given the biofilm phenotype observed above, to further assess the potential impact 
of Candida biofilms within our sample subset, we observed the species distribution 
and biofilm forming capabilities of the vaginal isolates (Figure 3.15). C. albicans is 
the most isolated causative organism in VVC, the importance of non-albicans 
Candida species (NACs) should not be underestimated. Candida clinical isolates 
were obtained from lavage samples by culture on Candida chromogenic agar. After 
incubation, a total of 33 isolates were obtained, 9 from healthy individuals and 24 
from patients with RVVC. Isolate speciated by chromogenic agar were confirmed to 
species-level using MALDI-TOF. A large area of controversy in VVC research is the 
presence of Candida biofilms on vaginal epithelium and their contribution to failed 
clinical treatment. For this reason, following identification, Candida clinical isolates 
were screened for their in vitro biofilm forming capabilities (Figure 3.15).  
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Figure 3.15: Vaginal Candida isolates from patients with RVVC are capable of 
heterogeneous biofilm formation. MALDI-TOF was used to identify each isolate to 
species level and assess species distribution (‘others’ are comprised of 1 isolate of: C. 
dubliniensis, C. parapsilosis and C. krusei) (A). Candida isolates from health (n=9) and 
RVVC (n=24) were assessed for biofilm forming capabilities and metabolic activity by crystal 
violet staining and XTT assays, respectively (B and C). Data represents the mean ± SD 
(****, P<0.0001), statistical analysis was performed using unpaired t-tests. 
 
Consistent with previous RVVC studies, C. albicans was found to be the most 
prevalent Candida species isolated within our patient subset. Other NAC species, 
more commonly associated with complicated VVC, accounted for the remaining 
27% (Figure 3.15A). C. albicans was capable of forming dense biofilms with clear 
heterogeneity between isolates. A wide range of OD values between 0.13 and 1.067 
was observed for C. albicans biofilm formation with a mean OD of 0.695. Little 
biomass was observed in other species (Figure 3.15B). Similarly, C. albicans 
biofilms displayed the highest variation of metabolic activity amongst RVVC isolates. 
Metabolic activity of C. albicans isolates ranged from an OD of 0.079 and 2.162 with 
a mean OD of 0.943. Notably, although they did not form robust biofilms, some C. 
C 
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glabrata isolates were highly metabolically active ranging from 0.082 and 2.192 with 
a mean of 2.11 (Figure 3.15C). 
 
One of the main aims of this study was to determine potential factors contributing to 
failed clinical treatment of RVVC within our patient subset. To assess antifungal 
resistance to clinically relevant concentrations (Up to 32 µg/mL) of frontline 
antifungals such as fluconazole, miconazole and clotrimazole within clinical isolates, 
MICs were determined for each drug for both planktonic and sessile cells (Table 
3.5).  
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Table 3.5: Sensitivity profiles of Candida clinical isolates to azole antifungals. 
 
F, M, C: fluconazole, miconazole and clotrimazole, respectively. 
* 50% planktonic minimum inhibitory concentration 
$ planktonic minimum inhibitory concentration 
# 50% sessile minimum inhibitory concentration 
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Antifungal susceptibility testing revealed 50% inhibition of all planktonic isolates at 
concentrations ≤32 µg/mL for fluconazole, with the exception of two C. albicans 
RVVC isolates (SVS002B and SVS010B). Additionally, 50% planktonic inhibition of 
all isolates was achieved for miconazole and clotrimazole at ≤8 µg/mL and ≤1 
µg/mL, respectively. Fluconazole was the least effective treatment against 
planktonic Candida isolates achieving 90% inhibition in just 24% of isolates. 
Furthermore, 34% and 29% of isolates contained populations of cells which resisted 
90% inhibition with miconazole and clotrimazole at concentrations up to 32 µg/mL, 
respectively. Finally, fluconazole was also the least effective antifungal against 
Candida biofilms, achieving 50% inhibition in just 21% of isolates. Miconazole and 
clotrimazole were more effective against sessile cells, however, 12% and 32% of 
isolates, respectively, remained viable following treatment. 
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Finally, to further investigate the potential impact of Candida biofilm formation in 
RVVC, levels of expression of key biofilm-related genes in C. albicans were 
measured by real-time qPCR in a subset of samples (n=20) (Figure 3.16). The 
selected sample subset used contained the 10 highest levels of Candida DNA for 
each cohort. 
 
 
Figure 3.16: Candida biofilm-related genes are not up-regulated in lavage from 
women with RVVC. Total RNA was extracted from patient lavage before being reverse 
transcribed to cDNA for gene expression analysis.  Samples from healthy (n=10) and RVVC 
(n=10) patients were assessed for expression of key Candida biofilm-related genes relative 
to expression of the ITS housekeeping gene. Expression levels were measured by 
percentage expression (A) and fold change from health (B). Data represents the mean ± 
SD (*P<0.05; ** P<0.01), statistical analysis was performed using unpaired t-tests with 
Welch’s correction. 
 
Gene expression analysis was measured as both percentage expression relative to 
the housekeeping ITS gene (Figure 3.16A) and as fold change in RVVC from health 
(Figure 3.16B). Genes assessed, including ECE1 and HWP1, were found to have 
similar levels of expression to the housekeeping gene in healthy samples with mean 
expression levels of 70% and 99%, respectively. All other genes were 
downregulated in healthy samples with <55% expression relative to ITS. In RVVC 
samples, ECE1, SAP4, SAP5 and SAP6 were undetectable. Significantly lower 
levels of expression of HWP1 and ALS3 were observed compared with healthy 
controls (P<0.05, P<0.01, respectively). This is clearly reflected in Figure 3.16B 
where the fold change of HWP1 and ALS3 relative to expression in healthy samples 
is around 1-fold, whereas the rest of the genes fall below 0.55-fold. 
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3.4 Discussion 
 
Despite surprisingly high numbers of cases around the globe annually, VVC and 
subsequent RVVC remains largely understudied in the field of women’s health. For 
this reason, further research to understand the onset and progression of disease is 
paramount for the development of much needed future therapeutics. This chapter 
evaluated a panel of clinical samples from healthy women and those with RVVC. 
This was achieved through a variety of microbiological, molecular, and proteomic 
approaches. Women were recruited for the study if they had visited their GP surgery 
with complaint of VVC four or more times within one year or were self-referred. 
Additionally, healthy women attending clinics for an IUD to be fitted were recruited 
as healthy controls for the study.  
 
The estimated vaginal commensal carriage rate of Candida is 33%. The presence 
of Candida was observed by both culture and by qPCR which observed 15% and 
60% of healthy and RVVC samples had culturable Candida, respectively. All but 2 
samples were positive by qPCR. In vaginitis caused by bacterial vaginosis (BV), 
dysbiosis of the vaginal microbiome is thought to result in an increase in pH (pH >5) 
due to a reduction in lactic acid bacteria, particularly Lactobacillus species (Wilson, 
2004). Conversely, the pH during VVC is often reported to be normal (pH 4-4.5) 
(Linhares et al., 2011). Here it is shown that patients suffering from RVVC had 
comparable vaginal lavage pH levels with those from healthy patients. The pH range 
varied from around pH 4 to 7 and may simply vary by patient. It is thought that a low 
vaginal pH contributes to a eubiotic environment due to its inhibitory properties to 
many pathogens including Candida (O'Hanlon et al., 2011, Gong et al., 2014, Zangl 
et al., 2019). Low pH environments have been shown to be fungistatic, inhibiting 
Candida hyphal morphogenesis and biofilm formation (Parolin et al., 2015). Despite 
the evidence, the pH in this study was found to be non-specific to the disease status 
of patients. A likely explanation for this outcome is the method of collection of CVL 
samples; unlike swab samples or the direct collection of vaginal fluid, CVL are 
collected by pooling and removing sterile water (pH 7) from the vagina of the patient. 
It is likely that this method of collection increased or neutralised the acidic pH of the 
vaginal fluid in this study. 
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Although authors have suggested that an increased fungal load may be correlated 
with symptomatic VVC, very few studies have investigated Candida counts in their 
sample cohorts (Hopwood et al., 1988). To investigate the influence of fungal load, 
levels of Candida in swab samples were measured by plate dilution and molecularly 
This investigation found significantly higher levels of 1 or 2-log of Candida in 
samples from patients with RVVC compared with healthy patients. Increases in 
Candida culture positive samples have been reported previously in RVVC and is 
confirmatory of disease state (Bauters et al., 2002). However, these authors did not 
measure Candida load by cell count, only determining whether patients were culture 
negative or positive. Despite the applications of real-time qPCR to accurately 
quantify Candida load in patient samples, it is not FDA-approved, and culture 
remains the “gold standard” for VVC diagnosis (Chatzivasileiou and Vyzantiadis, 
2019). Bacterial levels in each cohort were found to be comparable, suggesting 
Candida does not replace the vaginal microbiome during disease, but may instead 
impact the diverse bacterial composition resulting in symptoms of disease. Patient 
questionnaires were used to collect data on patient’s disease and treatment 
histories and this allowed for assessment of fungal burden data with respect to 
disease severity and treatment regimens. This data revealed a positive correlation 
with increasing levels of Candida since antifungal treatment. This suggests 
antifungal treatment may temporarily decrease levels of Candida and alleviate 
symptoms of RVVC, however without effective clearing and with the presence of 
resistant communities of cells Candida is able to regrow and cause recurrence of 
symptoms. This data also revealed a slight reduction in Candida levels over time 
with disease. Future studies may wish to use larger sample groups to determine 
whether this is consistent. It is also important to consider that these are clinical 
samples from women regularly attending sexual health clinics, and those who have 
suffered from RVVC for longer are more likely to be receiving antifungal treatment. 
There is clear lack of studies investigating fungal load of patients with RVVC 
compared with healthy controls in the literature. In fact, to our knowledge this is the 
first study reporting yeast counts during RVVC since 1988. Further investigation 
could elucidate whether an “infection threshold” exists for RVVC and could improve 
diagnostic practices through measuring and maintaining Candida levels within the 
vagina. 
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VVC is an inflammatory disorder, characterised by extensive mucosal inflammation 
of the vulva as a result of leukocyte influx in response to hyphal invasion of local 
epithelium and expression of Candida virulence factors (Rosati et al., 2020). This 
study found a pattern of elevated pro-inflammatory cytokine levels in patients with 
RVVC. Similar trends have been shown in vitro when treating both vaginal epithelial 
cells and murine models of VVC with candidalysin, a crucial virulence factor in 
Candida (Richardson et al., 2018). Many of the inflammatory biomarkers found to 
be upregulated in RVVC samples have been previously described in inflammatory 
diseases such as psoriasis, rheumatoid arthritis and hepatitis (Abji et al., 2016, Kuan 
et al., 2010, Zeremski et al., 2011). Data reported in this chapter also reports 
elevated levels of pro-inflammatory cytokines in patients with culturable Candida. 
This trend was not seen when assessing IL-8 levels, however, this biomarker is 
often elevated due to non-specific inflammation (Schroder, 1992). 
 
Consistent with recent epidemiological reports, >70% of isolates from patients were 
C. albicans with the remainder comprised primarily of C. glabrata. These results are 
also consistent with the recently reported increase in NAC species in VVC. Although 
it has been historically reported that C. albicans is the causative organism in up to 
90% of VVC episodes, recent evidence has suggested a higher prevalence of NAC 
in the community. It is possible that this assumption that almost all cases are due to 
C. albicans has led to inappropriate treatment, driving higher rates of NAC RVVC. 
The clinical significance of C. glabrata and, to a lesser extent C. krusei as it is rarely 
the causative organism of VVC, should not be underestimated due to their intrinsic 
resistance to azole antifungals (Singh et al., 2002). The prevalence of NAC species 
is thought to increase with each recurrent episode of RVVC. One study aiming to 
quantify the rate of increase estimated a 10% increase in NAC species prevalence 
with each subsequent VVC episode (Sobel, 2002). As all patients in this study 
presented with RVVC, this is a potential explanation for the high occurrence of NAC 
species seen here.  
 
Though C. albicans has been shown to form biofilms on vaginal mucosa and 
Candida clinical isolates shown to form biofilms in vitro (Harriott et al., 2010b, Sherry 
et al., 2017, Swidsinski et al., 2019), the presence of biofilms during RVVC is still 
disputed. Data in this chapter shows clear evidence of C. albicans filamentation and 
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aggregation in lavage fluid from a patient with RVVC that was visualised 
fluorescently. Furthermore, this study observed heterogeneous biofilm formation in 
C. albicans isolates as well as highly metabolically active C. albicans and C. glabrata 
biofilms. Further, a recent study found both wild type and clinical isolates of C. 
albicans are capable of biofilm formation and epithelial infiltration of vaginal 
epithelium using the murine model developed by Harriott et al, 2010 (Wu et al., 2020, 
Harriott et al., 2010b). This data strengthens the argument that Candida biofilm 
formation within the vagina during VVC should not be discounted as a potential 
cause of failed clinical treatment as suggested by some authors (Swidsinski et al., 
2019, Sobel et al., 1998) 
 
Antifungal susceptibility testing found significant levels of resistance of Candida 
clinical isolate biofilms to frontline antifungals used to treat VVC. The significance of 
antifungal resistance in RVVC has been disputed, with one study showing 
planktonic susceptibility of 117 C. albicans isolates to various prolonged azole 
treatments (Lynch et al., 1996). This study failed to consider substantially increased 
antifungal resistance observed in sessile cells compared to their planktonic 
counterparts. Biofilm resistance to these azoles was high, as expected, however 
interestingly, total killing of planktonic cells was achieved in only 24%, 34% and 29% 
of isolates treated with up to 32 µg/mL of fluconazole, miconazole and clotrimazole, 
respectively. These communities of resistant “persister cells” are another potential 
reservoir for failed clinical treatment and have been described in previous studies. 
One study using VVC clinical isolates recovered up to 3% of cells from biotic biofilms 
which persisted through overnight treatment with 100 µg/mL amphotericin B (Wu et 
al., 2020). This highlights an important caveat in RVVC research which could lead 
to more appropriate treatment for women with biofilm-forming, antifungal resistant 
isolates. More recently, studies have focussed on the potential efficacy of probiotic 
treatment and the prospect of a vaccine against VVC (Schmidt et al., 2012, Xie et 
al., 2017). The potential VVC vaccine, NDV-3, has been shown to significantly 
reduce fungal burden in a murine model and further research could result in this 
becoming a safe and effective treatment to prevent VVC and recurrent episodes 
(Ibrahim et al., 2013). Recently, a new antifungal was FDA-approved for the 
treatment of vaginal yeast infections, Ibrexafungerp. This drug is the first of the 
enfumafungin-derived triterpenoid family of antifungals as well as the first oral (1-3)-
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β-D-glucan synthase inhibitor (GSIs) (Ghannoum et al., 2020). This drug has been 
shown to be effective against a range of Candida isolates, including those displaying 
resistance to azoles and echinocandins (Jimenez-Ortigosa et al., 2014). 
Additionally, it has shown efficacy against C. albicans and C. glabrata biofilms in 
vitro, with lower MICs than those seen with fluconazole (Marcos-Zambrano et al., 
2017). These are very promising results and with granted FDA-approval this drug 
has potential to greatly improve treatment options and reduce recurrence rates of 
RVVC. 
 
To further investigate biofilm formation in RVVC, expression of key biofilm-related 
genes was assessed. Expression analysis found relatively low levels of expression 
in RVVC samples for all genes assessed compared with the housekeeping ITS 
gene. Despite this, data in this chapter is one of the few reports of detectable levels 
of biofilm-related genes in clinical samples of RVVC. One study quantifying SAP 
expression from vaginal swabs reported SAP1-10 expression to be unchanged 
during vaginitis with the exception of SAP5, which was significantly upregulated 
(Naglik et al., 2008). Data from this chapter suggests, although Candida biofilms are 
present during RVVC, very low levels of biofilm-related gene expression are 
detectable from patient lavage. One possibility for this result is the length of time 
these clinical samples had been stored and number of freeze-thaw cycles prior to 
RNA extraction. Future studies utilising whole-genome transcriptome sequencing 
are required to fully elucidate the significance of biofilm-related gene expression in 
RVVC. 
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Chapter findings 
 
• Data from this chapter demonstrated that, though unchanged throughout 
disease progression, an increased Candida load may be indicative of RVVC. 
Further, an increase in pro-inflammatory cytokine levels in lavage fluid may 
strengthen diagnosis.  
 
• There is potential for failure to eradicate Candida following clinical treatment 
as although Candida load is reduced, resistant communities of cells persist 
and can re-establish RVVC. Further, data in this chapter is consistent with 
recent reports of an increase in the prevalence of NAC in RVVC. These 
clinical isolates display resistance to clinically relevant concentrations of 
frontline azole treatments. Collectively, these data are indicators of Candida 
biofilm formation during RVVC. 
 
• Through biomass and viability assays of clinical isolates, imaging of lavage 
and detection of biofilm-related gene expression in lavage, there is clear 
evidence of biofilm formation amongst RVVC clinical isolates. As such, it is 
crucial to consider Candida biofilm formation, and the repercussions this may 
have, when making clinical decisions for treatment of RVVC.
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4 The importance of Lactobacillus species 
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4.1 Introduction 
The development of molecular methods of bacterial identification like 16S ribosomal 
RNA (rRNA) sequencing has dramatically improved our ability to identify and 
understand organisms within niches of the human body. The 16S rRNA gene is 
present in all bacteria and its combination of conserved and hypervariable regions 
make it an ideal candidate for identification of different bacteria via polymerase chain 
reaction (PCR) (Wilson et al., 1990). This becomes more important in less diverse 
and anaerobic niches where many of the microorganisms present are unculturable. 
The vaginal microbiome is somewhat unique in that a ‘healthy’ microbiome is 
generally associated with a less diverse community of microbes, predominantly 
lactobacilli, namely; L. crispatus, L. iners, L. gasseri and L. jensenii (Ravel et al., 
2011a). Dysbiosis of the vaginal microbiome therefore results in an increase in 
species diversity, with fewer lactobacilli and greater levels of pathogenic anaerobes 
such as Gardnerella and Prevotella species (Liu et al., 2013b, Jian et al., 2015). In 
VVC, although unconfirmed, disease onset is thought to be attributed this loss of 
lactobacilli and a concomitant overgrowth of commensal Candida species (Bradford 
et al., 2017). This facilitates a pathogenic shift in Candida allowing hyphal 
morphogenesis, cell damage and activation of the immune response, causing 
symptoms of vaginitis.  
 
In healthy women, lactic acid bacteria (LAB) are thought to be responsible for 
maintaining a homeostatic microbiome by inhibiting growth and adhesion of other 
microbes via the production of secreted metabolites such as lactic acid, 
biosurfactants, bacteriocins and hydrogen peroxide (H2O2) (Redondo-Lopez et al., 
1990, Jeavons, 2003). Of the four most common Lactobacillus species in the healthy 
microbiome, L. crispatus, L. gasseri and L. jensenii produce both D- and L-isomers 
of lactic acid as well as H2O2 (Reid, 2018, van der Veer et al., 2019). Although both 
isomers afford protection from pathogenic invasion, the L-lactic acid isomer has 
been extensively studied for its ability to lower vaginal pH, elicit anti-inflammatory 
responses and inhibit microbial colonisation (Hearps et al., 2017, O'Hanlon et al., 
2013). Conversely, lactic acid lowers the pH of the vaginal environment which could 
result in Candida stress responses leading to hyphae formation and release of 
virulence factors. This was shown by Beyer and colleagues (Beyer et al., 2018a) 
where the MAP kinase CgHog1 of C. glabrata was upregulated in response to 
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clinically relevant concentrations of lactic acid. CgHog1 increases the ability of C. 
glabrata to persist within the body, suggesting this could contribute to severity of 
RVVC. 
 
Unlike other vaginal diseases such as bacterial vaginosis (BV) and Chlamydia 
trachomatis, microbiome studies have not been able to determine a distinct profile 
of disease for RVVC compared to health (Ceccarani et al., 2019). The widely 
accepted hypothesis of RVVC pathology is a reduction in Lactobacillus, however, 
studies have observed mixed results when investigating this. Some studies have 
identified reduced levels of Lactobacillus during VVC/RVVC (McClelland et al., 
2009, Liu et al., 2013b), whereas other authors report similarly high levels of 
Lactobacillus found in both health and RVVC (Macklaim et al., 2015, Zhou et al., 
2009a). For this reason, the functional capacity of lactobacilli to inhibit pathogens 
and prevent vaginal dysbiosis has been questioned. A common feature of many 
microbiome studies is a change in the Lactobacillus population at species-level. 
These studies have identified a consistent reduction in L. crispatus levels in RVVC 
concomitant with an increase in rates of L. iners (Ravel et al., 2011a, Ceccarani et 
al., 2019). With this, it is important not to discount the potential influence of 
Lactobacillus in RVVC pathology and re-establishing a healthy microbiome. Instead, 
studies should focus on the intimate interactions between Candida and these 
Lactobacillus species in order to determine how they impact states of health and 
disease. 
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Hypotheses and aims 
Potential interkingdom interactions occurring as a result of Candida overgrowth in 
the vagina during disease onset is vastly understudied in RVVC research. It is 
largely unknown how this increase in fungal load may influence the diversity and 
microbial interactions within the vaginal microbiome. Identifying mechanisms by 
which microbes of the healthy vaginal microbiome may attempt to maintain 
homeostasis, as well as those leading to adverse interactions in disease, could 
elucidate potential probiotic therapeutic targets, expanding and improving future 
treatment options. Therefore, this chapter aimed to: 
 
• Compare bacterial taxa identification at family and genus-level using OTU 
and ASV analysis pipelines. 
• Identify how Candida overgrowth in the vagina affects the bacterial diversity 
and composition of the microbiome. 
• Compare short-read Illumina sequencing with sequencing of ultra-long reads 
using the Oxford Nanopore Technologies MinION platform. 
• Utilise patient metadata in an attempt to identify how the microbiome is 
affected over time, antifungal treatment regimens and what influence 
contraception may have during RVVC. 
 
It is hypothesized that lactic-acid bacteria associated with inhibition of pathogens 
will be reduced in RVVC compared with health. Additionally, it is expected that 
differences in disease-associated microbiome profiles will be seen with respect to 
patient metadata collected at the time of sampling.  
 
Work from this chapter has been presented at the following workshops/conferences: 
Eurobiofilms Conference, September 2019, Glasgow, UK 
Federation of Infection Societies Conference, November 2019, Edinburgh, UK 
 
Work from this chapter has been published in mSystems: 
McKloud E, Delaney C, Sherry L, Kean R, Williams S, Metcalfe R, Thomas R, Richardson 
R, Gerasimidis K, Nile CJ, Williams C, Ramage G. Recurrent Vulvovaginal Candidiasis: a 
Dynamic Interkingdom Biofilm Disease of Candida and Lactobacillus. mSystems. 2021 Aug 
10:e0062221. doi: 10.1128/mSystems.00622-21.   
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4.2 Materials and methods 
 
4.2.1 Amplification of the 16S V4 region for Illumina sequencing 
Sequencing of the 16S rRNA gene was performed to determine the bacterial 
communities present in health and RVVC. For this analysis, DNA from swab 
samples collected as described in section 3.2.3 of this thesis were used. The 16S 
V4 region of DNA was amplified using a 7500 Real-Time PCR System (Applied 
Biosystems, UK). The 25µl reaction was prepared by addition of 2µl of DNA to a 
master mix of 12.5µl NEBNext® Ultra™ II Q5® Master Mix (New England Biolabs, 
UK), 6.5µl nuclease-free water, 1µl of forward/reverse primers and 2µl of bovine 
serum albumin (BSA, 10mgmL). Amplification of the V4 region was achieved using 
the same 16S rRNA forward primer in each sample 
(AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMG
CCGCGGTAA) with unique fusion Golay adaptors barcoded on the reverse strand 
(Quince et al., 2015). Samples were then amplified using the following thermal 
profile: An initial denaturation at 95°C for 5 min followed by 30 cycles of 98°C for 20 
s, 60°C for 15 s to anneal and 72°C for 40 s for extension and a final extension step 
of 72°C for 1 min. Reactions were performed in triplicate, on one occasion and 
included no template controls (NTC) 
 
4.2.2 Isolation and purification of DNA. 
To separate DNA bands for excision of the 16S rRNA, a 1% agarose gel was 
prepared in 1X Tris-acetate-EDTA (TAE) buffer (w/v). Agarose was weighed before 
being dissolved in 1X TAE buffer in a microwave. Once cool, 25µl of SyberSafe DNA 
stain (1µl/10mL) (Invitrogen, Paisley, UK) was added and the solution poured into a 
gel tray. The gel was allowed to set for 20 min and the gel tank was assembled 
according to manufacturer’s instructions (Anachem, Leicester, UK). The gel was 
then placed into the tank and covered with 1X TAE buffer. Loading dye (6X) was 
added to each sample before 75µl was loaded in to each well. The gel was then run 
for 1 h at 100V before being visualised under UV light.  
 
DNA bands observed at 378bp were excised from the gel using a sterile scalpel and 
transferred to a RNase-free tube. DNA was extracted from the agarose gel using 
the Zymoclean Gel DNA Recovery Kit (Cambridge Bioscience, UK) following 
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manufacturer’s instructions. Each tube was weighed and 3 volumes (3x w/v) of 
agarose dissolving buffer (ADB) was added to the DNA fragment and incubated at 
50°C for 10 min until completely dissolved. The melted agarose was loaded on to a 
Zymo-spin column in a collection tube and centrifuged at 13,000rpm for 30 s. The 
flow-through was discarded and 200µl of DNA wash buffer added to the column 
before being centrifuged for another 30 s at 13,000rpm. The wash step was 
repeated, and the column transferred to a sterile microfuge tube. To elute the DNA, 
12µl of elution buffer was added directly to the column matrix and centrifuged for 1 
min at 13,000rpm.  
 
4.2.3 Pooling DNA library for sequencing and data analysis pipeline. 
Bacterial 16S rRNA concentrations were quantified using the high sensitivity 
fluorometric Invitrogen Qubit® assay, following manufacturer’s instructions 
(ThermoScientific, Loughborough, UK). For library preparation, the concentration of 
the amplicons for each sample was standardised to 5 ng/mL in nuclease free water. 
Finally, 2µl of each sample was transferred to a single DNA low-bind Eppendorf 
tube, forming the final amplicon pool. The 16S rRNA V4 region was then amplified 
using the Illumina MiSeq sequencing platform (Edinburgh Genomics) using 
2x250bp paired-end reads (University of Edinburgh, 2021). 
 
Figure 4.1: Experimental design for 16S rRNA microbiome sequencing using Illumina 
MiSeq sequencing platform. Created with BioRender.com. 
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QC of reads was performed within the R package DADA2 (v1.14.1). Reads were 
filtered and trimmed using standard error rates before reads were denoised, merged 
and chimeric sequences removed. Amplicon sequence variants (ASV) were 
annotated by the silva 132 16s rRNA database with an exact match to the ASV. Dr 
Christopher Delaney (University of Glasgow) performed quality control, sequence 
trimming and read alignment and enumeration. ASV and taxonomic assignments 
were utilised for downstream data analysis. 
 
4.2.4 Amplification of DNA for Nanopore sequencing 
Samples were prepared for sequencing using the Oxford Nanopore Technologies 
(ONT) MinION® platform using the 16S Barcoding Kit 1-24 (Oxford, UK), with some 
modifications. Previously extracted DNA from swab samples was diluted in 
nuclease-free water to a concentration of 15ng/µl. For each sample a master mix 
was prepared containing 5µl nuclease-free water, 25µl LongAmp Hot Start Taq 2X 
Master Mix (New England Biolabs) and 10µl input DNA (150ng). To each sample, 
10µl of universal 16S barcodes were added: 27F: AGAGTTTGATCMTGGCTCAG 
and 1492R: CGGTTACCTTGTTACGACTT to amplify the full 16S region. Each 
primer pair includes a unique barcode sequence which allows for sample 
identification following sequencing. The 16S region was then amplified using the 
following thermal profile: Initial denaturation for 1 min at 95°C then 30 cycles of 
denaturation for 20s at 95°C, annealing for 30s at 55°C and extension for 2 mins at 
65°C, followed by a final extension step for 5 mins at 65°C. 
 
 
Figure 4.2: Experimental design for 16S rRNA microbiome sequencing using 
Nanopore MinION® sequencing platform. Created with BioRender.com. 
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4.2.5 Purification and pooling of DNA libraries. 
To clean the DNA, PCR products were then transferred to fresh DNA LoBind 
Eppendorf tubes and 30µl of AMPure XP beads added to each sample and 
incubated with rotation for 5 mins. These beads bind the DNA and, when placed on 
a DynaMag™-2 Magnet (Fisher Scientific, UK), allow the DNA to be washed while 
bound. With the samples on the magnet, 200µl of freshly prepared 70% ethanol was 
run down the side of the tube to wash the beads before being removed. This step 
was repeated before eluting the beads in 10µl of 10mM Tris-HCl pH 8.0 with 50mM 
NaCl warmed to 37°C and incubated at room temperature for 2 mins. The samples 
were then placed back on the magnet and the clear eluate recovered. 
 
The DNA concentration of each sample was measured with a Qubit® 4 fluorometer 
(Fisher Scientific, UK) using the broad range sensitivity kit, following manufacturer’s 
instructions. Barcoded libraries were then pooled in a 1:1 ratio to a total of 50-100ng 
in 10mM Tris-HCl pH 8.0 with 50mM NaCl solution. Finally, 1µl RAP was added, 
incubated at room temperature for 5 mins and the prepared library stored at -20°C 
for sequencing. 
 
4.2.6 Priming and loading the MinION flow cell. 
Before sequencing, the flow cell was primed, following manufacturer’s instructions. 
The flow cell priming mix was prepared by adding 30µl flush tether directly to a tube 
of flush buffer and mixing thoroughly. Then, 800µl of priming mix was added through 
the flow cell priming port and incubated for 5 mins. The sequencing library was then 
prepared with 34µl Sequencing Buffer, 25.5µl Loading Beads, mixed immediately 
before use, 4.5µl Nuclease-free water and 11 µl DNA library. The SpotON port was 
then opened and 200µl priming mix added through the priming port to complete 
priming the flow cell. The library was then loaded in a dropwise fashion in to the 
SpotON port. Both ports were then closed, and the sequencing run started. A 
graphical illustration of the ONT MinION® sequencing preparation can be visualised 
in Figure 4.2. 
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4.2.7 Statistical analysis. 
Microbiome figures were created using the online platform, MicrobiomeAnalyst 
(Chong et al., 2020) and GraphPad Prism (Version 9, La Jolla, California, USA). All 
other figures and analyses were performed in GraphPad Prism. 
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4.3 Results  
Key organisms that secrete protective metabolites important to preventing 
overgrowth of Candida in the vagina remain largely understudied. Identifying 
bacteria which possess mechanisms to maintain vaginal health may lead to 
improved treatment options for VVC. To observe bacterial taxa present in healthy 
women and those with RVVC, 16S rRNA sequencing was performed on DNA 
extracted from high-vaginal swab samples (n = 100). In order to ensure accurate 
bacterial taxa identification to species-level, two analyses were performed on 
Illumina sequencing data. 
 
4.3.1 Assessing OTU and ASV analysis pipelines at family and genus-level 
 
The first analysis implemented on Illumina sequencing data using closed reference 
operational taxonomic unit (OTU) clustering allowing for identification of bacterial 
taxa present in swab samples to family and genus-level only (Figure 4.3 and 4.4). 
This analysis observed slightly greater bacterial diversity at both family and genus-
level in samples from healthy patients compared with those suffering from RVVC 
(Figure 4.3A and 4.4A). Further comparison of healthy and diseased samples by 
principal coordinates analysis (PCoA) could not identify distinct clusters of bacterial 
taxa at either family or genus-level using this analysis with high levels of overlap 
between groups (Figure 4.3B and 4.4B). 
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Figure 4.3: Analysis of diversity and Principal Coordinates Analysis of the vaginal microbiome at family-level by Illumina sequencing via closed 
reference OTU clustering.  
DNA extracted from swab samples was used for 16S rRNA Illumina sequencing (n=100). Bacterial diversity in health and RVVC was measured by Shannon 
index (A). PCoA with Bray-Curtis index to assess variances between health and RVVC (B). 
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Figure 4.4: Analysis of diversity and Principal Coordinates Analysis of the vaginal microbiome at genus-level by Illumina sequencing via closed 
reference OTU clustering. 
DNA extracted from swab samples was used for 16S rRNA Illumina sequencing (n=100). Bacterial diversity in health and RVVC was measured by Shannon 
index (A). PCoA with Bray-Curtis index to assess variances between health and RVVC (B).
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To investigate differences between the microbial composition during health and 
RVVC, microbial populations were next identified to family and genus-level using 
this analysis (Figure 4.5). At family-level, a Lactobacillaceae-dominated 
environment was found in samples from both healthy and diseased patients 
accounting for 73% and 76% of the population, respectively (Figure 4.5A). Other 
bacteria identified included predominantly members of the Bifidobacteriaceae, 
Atopobiaceae and Prevotellaceae families. Few differences in taxa abundances 
were observed between health and RVVC at this level. At genus-level, Lactobacillus 
was found to govern the microbiome of both healthy and diseased patients 
accounting for >70% of the total population (Figure 4.5B). Other prevalent genera 
included Gardnerella, Atopobium and Prevotella. Similarly to family-level, few 
notable differences in taxa abundance present in health and RVVC were found at 
genus-level. However, abundances of Atopobium were found to be slightly higher in 
healthy patients and Bifidobacterium slightly lower. 
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Figure 4.5: Composition of bacterial taxa present in health and RVVC at family and 
genus-level by Illumina sequencing via closed reference OTU clustering. Bacterial 
taxa identification to family (A) and genus-level (B) with percentage abundances of microbial 
populations present in health and RVVC. 
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The second analysis of Illumina sequencing data utilised inferred amplicon 
sequence variants (ASVs) to allow for confirmation of family and genus-level taxa 
as well as allowing for observation of species-level taxa present. This analysis 
observed slightly greater diversity in microbial populations at both family and genus-
level in healthy patients compared with diseased (Figure 4.6A and 4.7A). Analysis 
by PCoA to identify distinct clusters of bacterial taxa at family and genus-level found 
overlap of groups with no clear distinction between health and RVVC (Fig 4.6B and 
4.7B).   
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Figure 4.6: Analysis of diversity and Principal Coordinates Analysis of the vaginal microbiome at family-level by Illumina sequencing via inferred 
amplicon sequence variants (ASV). 
Bacterial diversity in health and RVVC measured by Shannon index (A) and PCoA with Bray-Curtis index to assess variances between health and RVVC (B). 
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Figure 4.7: Analysis of diversity and Principal Coordinates Analysis of the vaginal microbiome at genus-level by Illumina sequencing via inferred 
amplicon sequence variants (ASV) 
Bacterial diversity in health and RVVC measured by Shannon index (A) and PCoA with Bray-Curtis index to assess variances between health and RVVC (B). 
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Observation of the bacterial taxa identified to family and genus-level using this 
analysis found few differences between health and RVVC (Figure 4.8). Again, a 
Lactobacillaceae-dominated environment was seen in both healthy and RVVC 
samples accounting for up to 74% of the microbiome. Various levels of vaginal 
anaerobes were also found including those from the Bifidobacteriaceae, 
Atopobiaceae and Prevotellaceae families (Figure 4.8A). At genus-level, 
Lactobacillus was found to be the dominant genera in both cohorts with no 
difference in abundance (Figure 4.8B). Both analyses found slightly higher levels of 
Gardnerella and Atopobium present in healthy samples.  
 
Overall, as expected at family and genus-level, this analysis showed similar results 
for diversity and taxa abundance to the previous analysis using OTU clustering. This 
is confirmatory of accurate bacterial taxa identification at these levels using both 
analyses. Crucially, this second analysis allowed for species-level identification of 
microbial populations present during health and RVVC.
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Figure 4.8: Composition of bacterial taxa present in health and RVVC at family and 
genus-level by Illumina sequencing via inferred ASVs. Bacterial taxa identification to 
family (A) and genus-level (B) with percentage abundances of microbial populations present 
in health and RVVC. 
 
 
4.3.2 Observing bacterial taxa present in health and RVVC at species-level 
 
Species-level identification of the microbial populations present between health and 
RVVC was imperative for this study to identify potential interkingdom interactions 
with Candida which could influence RVVC pathogenesis. Initial observation of 
species diversity using the Shannon diversity index found no significant differences 
between health and disease (Figure 4.9A). Further analysis by PCoA showed 
clustering of healthy and diseased samples with no clear definition of each cohort 
(Figure 4.9B).
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Figure 4.9: Diversity and Principal Coordinates Analysis of vaginal microbiome at 
species-level. Bacterial diversity measured by Shannon index (A) and PCoA with Bray-
Curtis index to assess variances between health and RVVC at species-level. 
 
Analysis of the species-level composition of the microbiome of healthy and RVVC 
patients revealed subtle key differences in bacterial taxa, particularly amongst 
Lactobacillus species (Figure 4.10). One limitation of this analysis was the inability 
of the data to accurately distinguish between certain Lactobacillus species. For this 
reason, some species are grouped as one or more possible species. The group 
labelled “L. spp. Incl. L. crispatus” comprised the following species; L. crispatus, L. 
acidophilus, L. casei and L. gasseri. The most notable difference identified was the 
reduction in levels of specific Lactobacillus species including L. jensenii and, to a 
greater extent, L. crispatus which fell from 44% in health to 30% in RVVC (Figure 
4.10A and 4.10B). These are Lactobacillus species commonly associated with a 
homeostatic, healthy vaginal flora and are thought to reduce risk of dysbiosis 
through secreted metabolites such as H2O2. Interestingly, this reduction was 
coupled with an increase in L. iners from just 19% in health to 40% in RVVC. Unlike 
the other species, L. iners does not produce H2O2 and its presence is becoming 
recognised as a marker of dysbiosis in the vaginal microbiome. Further, when 
predicted using a random forest plot, abundance of L. iners was found to be the 
most important feature in distinguishing between the microbiome of health and 
RVVC (Figure 4.10C). A summary of the bacterial taxa identified to family, genus 
and species-level and their relative abundances is shown in Table 4.1.
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Figure 4.10: Hydrogen peroxide-producing lactobacilli strains are reduced during RVVC resulting in an L. iners-dominated microbiome. 
Species-level identification of bacterial taxa present in health (A) and RVVC (B). Random forest plot showing the most distinct species-level taxa present 
between health and RVVC (C).
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Table 4.1: Percentage relative abundance of most prevalent bacterial taxa at family, 
genus and species-level between health and RVVC. 
 
 
 
To ensure identity specificity of bacterial identification at species-level, the 
microbiome of a subset of samples was analysed using the Oxford Nanopore 
Technologies MinION sequencer (Tyler et al., 2018). For this purpose, ten samples 
with the highest Lactobacillus counts were selected from each cohort (n = 20). This 
sequencer, unlike Illumina sequencing platforms, sequences the full variable region 
of the 16S rRNA gene allowing for high-specificity, accurate identification to species-
level. Sequencing this subset of samples allowed for direct comparison of Illumina 
and Nanopore sequencing platforms as well as ensuring accurate species-level 
identification had been achieved before further analysis. Comparing the two 
sequencing techniques at genus-level revealed some differences in composition 
(Figure 4.11). Although both analyses found a Lactobacillus-dominated environment 
in both health and RVVC, sequencing 
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with Nanopore was able to identify higher numbers of other genera. Further, where 
Illumina showed almost identical levels of Lactobacillus in health and RVVC, 
Nanopore sequencing observed an increase in Lactobacillus levels from 85% to 
96% in RVVC. Other genera identified by Nanopore sequencing included 
Streptococcus, Haemophilus and Campylobacter. 
 
 
Figure 4.11: Specificity of genus-level identification is comparable across Illumina 
and Nanopore sequencing platforms. Bacterial taxonomy identification by Illumina to 
genus-level (A) compared with Nanopore MinION identification to genus-level (B). 
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At species-level, further differences can be seen between sequencing platforms 
(Figure 4.12). Where Illumina sequencing found 47% of the sample subset to be 
comprised of Lactobacillus species, including L. crispatus in both health and RVVC, 
Nanopore identified a slight difference of 4% between the cohorts. Further, 
Nanopore sequencing allowed for more accurate distinction between genetically 
similar Lactobacillus species, meaning certain species did not require grouping for 
this analysis. This is seen in Illumina data where much higher levels of L. iners are 
found in both cohorts, however Nanopore has identified some of these microbes as 
L. amylovorus, L. kitasatonis and L. jensenii. Overall, although there is some 
fluctuation in abundances, this analysis confirmed that accurate identification of 
Lactobacillus species by Illumina sequencing. 
 
 
Figure 4.12: Specificity of species-level identification is comparable across Illumina 
and Nanopore sequencing platforms. Bacterial taxonomy identification by Illumina to 
species-level (A) compared with Nanopore MinION identification to species-level (B). 
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4.3.3 The influence of lifestyle and treatment on the microbiome 
 
To investigate the influence of bacterial taxa further, microbial populations were next 
observed with respect to patient metadata. At genus-level, patients with culturable 
Candida compared with those who were culture-negative showed a reduction in 
composition of Lactobacillus from 76% to 68% (Figure 4.13A). Further, patients with 
no culturable Candida have slightly higher levels of Atopobium. These observations 
for patients with culturable Candida are similar to those seen in diseased patients. 
At species-level, a reduction in Lactobacillus species including L. crispatus from 
44% to 29%, coupled with an increase in L. iners from 23% to 35% was observed 
(Figure 4.14A). Additionally, levels of G. vaginalis were 3% lower in culture-negative 
patients with higher quantities of L. formicalis/jensenii and A. vaginae. This 
observation is again similar to that of the RVVC profile seen when comparing health 
and disease. Further, random forest plots were constructed to predict the most 
important feature in distinguishing between the two cohorts. This analysis found high 
levels of Gardnerella, followed by low level of Lactobacillus, to be the most important 
features in identifying patients with culturable Candida (Figure 4.13B). The most 
important features to identify Candida-positive samples at species-level were 
predicted to be high levels of L. iners and low levels of Lactobacillus species 
including L. crispatus and L. formicalis/jensenii (Figure 4.14B).
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Figure 4.13: Genus-level taxa abundance relative to presence/absence of culturable 
Candida. Bacterial taxa present based on presence/absence of culturable Candida at 
genus-level (A). Random forest plots showing bacterial taxa ranked by their contribution to 
each classification (B). 
 
 
 
Figure 4.14: Species-level taxa abundance relative to presence/absence of culturable 
Candida. Bacterial taxa present based on presence/absence of culturable Candida at 
species-level (A). Random forest plots showing bacterial taxa ranked by their contribution 
to each classification (B). 
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Next, the bacterial composition of the samples was assessed with respect to the 
form of contraception used by patients at the time of sampling. At genus-level, few 
differences in bacterial composition were observed between contraception types 
(Figure 4.15A). In all cases, Lactobacillus accounted for around 73% of the 
composition, followed by Gardnerella at 11-17%.  At species-level, some substantial 
differences can be seen between health and different contraception types (Figure 
4.16A). Most notably is the similarity observed in the composition of healthy patients 
and those using hormonal contraception in contrast with patients using a 
contraceptive device or no contraception. A sharp decrease in levels of 
Lactobacillus species including L. crispatus is observed from 44% in health to 15% 
and 20% in patients using a contraceptive device or no contraception, respectively. 
This trend is absent in patients using hormonal contraceptives where levels increase 
slightly to 48%. This decrease is coupled with an increase of L. iners from 18% in 
health to 57% and 44% in patients using device or no contraception, respectively. 
Further, levels of A. vaginae and L. formicalis/jensenii were reduced from 4% and 
10%, respectively, in health to <2% in patients using contraceptives. At genus-level, 
Lactobacillus, Gardnerella and Prevotella were predicted to be the most important 
features to distinguish between different forms of contraception (Figure 4.15B). The 
most important feature identified at species-level was predicted to be A. vaginae 
(Figure 4.16B). It is predicted that this organism is higher in healthy patients and 
those using hormonal contraceptives, and lower in patients using either no 
contraception or contraceptive devices. Additionally, a contrasting pattern is shown 
for L. iners, which is predicted to be highest in patients using contraceptive devices.
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Figure 4.15: Genus-level taxa abundance relative to contraception used. Bacterial taxa 
present based on the contraception used by patients at genus-level (A). Random forest 
plots showing bacterial taxa ranked by their contribution to each classification (B). 
 
 
 
Figure 4.16: Species-level taxa abundance relative to contraception used. Bacterial 
taxa present based on the contraception used by patients at species-level (A). Random 
forest plots showing bacterial taxa ranked by their contribution to each classification (B). 
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The microbiome of patients was then assessed with respect to how recently patients 
had received antifungal intervention to treat RVVC. Few changes were noted at 
genus-level between health and treatment times (Figure 4.17A). However, 
Lactobacillus was slightly increased to 76% in those treated more recently and 
reduced to 69% in patients treated >1 month before sampling. At species-level, a 
gradual reduction in Lactobacillus species including L. crispatus can be seen from 
44% in health to 34% and 23% in patients treated within a month and over a month 
before sampling, respectively (Figure 4.18A). Further, those treated more recently 
had 5% higher levels of G. vaginalis and 6% lower levels of L. formicalis/jensenii. 
High levels of Prevotella and Atopobium were predicted to be the most important 
feature in defining health with low levels being more closely associated with those 
treated within one month of sampling (Figure 4.17B). Conversely, L. iners was 
predicted to be higher in patients treated within one month and lower in health 
(Figure 4.18B). Patients treated over one month before sampling were predicted to 
have an intermediate profile between health and those treated more recently.
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Figure 4.17: Genus-level taxa abundance relative to how recently patients had 
received antifungal treatment. Bacterial taxa present based on time since antifungal 
treatment (1 = ≤1 month and 4 = >1 month prior to sampling) at genus-level (A). Random 
forest plots showing bacterial taxa ranked by their contribution to each classification (B). 
 
 
Figure 4.18: Species-level taxa abundance relative to how recently patients had 
received antifungal treatment. Bacterial taxa present based on time since antifungal 
treatment (1 = ≤1 month and 4 = >1 month prior to sampling) at species-level (A). Random 
forest plots showing bacterial taxa ranked by their contribution to each classification (B). 
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When observed with respect to the length of time patients had suffered from RVVC, 
an intermediate profile between health and disease was observed in patients with 
disease for <6 months. An initial increase in Lactobacillus was noted from 73% in 
health to 83% in patients with disease for ≤6 months, followed by a decrease to 66% 
in patients with disease for >6 months (Figure 4.19A). Additionally, levels of 
Bifidobacterium were increased from <1% to 8% in patients with RVVC for >6 
months. This intermediate profile was also noted at species-level where levels of 
Lactobacillus including L. crispatus are reduced from 44% in health to 39% in 
patients with disease for <6 months, followed by a sharp decrease to 22% in patient 
with RVVC for >6months (Figure 4.20A). This is once again coupled by an increase 
in L. iners composition from 18% in health to 36% and 44% in patients with disease 
for <6 month and >6months, respectively. Additionally, levels of L. formicalis/jensenii 
and A. vaginae are also reduced over time from 7% in patients with disease for 
<6month to <0.5% in patients with RVVC for >6months.  Lactobacillus was predicted 
to be the most important feature in distinguishing between disease profiles with 
higher levels found in healthy patients and those with disease for <6months (Figure 
4.19B). This was closely followed by Atopobium, Gardnerella and Prevotella which 
were predicted to be highest in healthy patients and lowest in patients with disease 
for <6months. The most important species identified were L. iners, where high levels 
indicate patients with disease for longer, and L. formicalis/jensenii where high levels 
are associated with health (Figure 4.20B).
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Figure 4.19: Genus-level taxa abundance relative to how long patient had suffered from RVVC. 
Bacterial taxa present based on length of time with disease (6 = ≤6 months and 12 = 7-12 months) 
at genus-level (A). Random forest plots showing bacterial taxa ranked by their contribution to 
each classification (B). 
 
Figure 4.20: Species-level taxa abundance relative to how long patient had suffered 
from RVVC. Bacterial taxa present based on length of time with disease (6 = ≤6 months 
and 12 = 7-12 months) at species-level (A). Random forest plots showing bacterial taxa 
ranked by their contribution to each classification (B). 
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Finally, correlation between the vaginal microbiome and Candida load (CFE/mL) 
was observed with respect to patient metadata (Figure 4.21). Megasphaera, often 
associated with vaginal dysbiosis, was found to be significantly positively correlated 
with increased fungal load (P < 0.05). Although not significant, genera such as 
Dialister, Bacteroides and Shuttleworthia were correlated with higher fungal loads 
in RVVC. Further, Lactobacillus was significantly negatively correlated with Candida 
in health, and to a lesser extent in RVVC (P < 0.05). Although none were found to 
be significant, correlations observed with respect to recent treatment identified slight 
negative correlations between genera such as Streptococcus, Gardnerella and 
Lactobacillus with increasing time since last RVVC intervention. Conversely, genera 
such as Prevotella, Morganella and Sneathia were found to be positively correlated 
with increasing time since treatments. Streptococcus, Prevotella and Clostridium 
were found to be positively correlated with increased RVVC episodes. However, 
genera such as Shuttleworthia, Lactobacillus and Atopobium were found to be 
negatively correlated with increasing RVVC episodes.
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Figure 4.21: Correlation of the microbiome and fungal load with patient metadata. 
Heatmap displaying correlations between bacterial genera present and Candida load (CFE/mL), recent treatment and number of episodes of RVVC. 
Significance was measured using Pearson correlation tests (*, P < 0.05).
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4.4 Discussion 
Unlike vaginitis caused by BV, the microbial communities present during VVC have 
been shown to be similar to those present in health at the family and genus-level 
(Ceccarani et al., 2019, Ma et al., 2016). For this reason, the potential importance 
of interkingdom interactions with Candida species during VVC has remained largely 
overlooked. Elucidating organisms which have the potential to prevent or disrupt 
vaginal overgrowth of Candida, as well as those which do not have protective 
properties. may pave the way to future therapeutic options involving probiotic 
treatments for women with debilitating RVVC.  
 
Initially, diversity analysis of Illumina sequencing data via closed reference OTU 
clustering found similarities at both family and genus-level of bacterial taxa present 
in health and RVVC. This data suggests there were no differences between bacterial 
richness or evenness between health and RVVC in this patient group. Further, 
analysis by PCoA with Bray-Curtis index found no significant variations between 
grouping of bacterial taxa in health and RVVC. These findings were confirmed with 
a second analysis of Illumina sequencing data via inferred ASVs. Authors have 
previously reported that biodiversity is augmented in vaginal diseases such as BV 
and C. trachomatis compared with health (Ceccarani et al., 2019, Filardo et al., 
2017). However, the diversity profile seen in VVC has been identified to be not 
significantly different from health or, in some cases, intermediate to the disease 
profile (Ceccarani et al., 2019, Liu et al., 2013b, Macklaim et al., 2015). When 
observing the bacterial taxa present in health and RVVC at family and genus-level, 
a Lactobacillus-dominated environment with members of the Bifidobacteriaceae, 
Atopobiaceae and Prevotellaceae families comprising Gardnerella, Atopobium and 
Prevotella was found in both cohorts with no significant differences. Gardnerella, 
although primarily associated with biofilm formation in BV, was found to account for 
~15% of the microbiome of both healthy and RVVC patients in this study. Although 
this could be an indicator of disease caused by both BV and VVC, it is more likely 
that this is due to asymptomatic colonisation and has been identified previously in 
vaginal microbiome studies (Ceccarani et al., 2019, Liu et al., 2013b). Taxonomic 
identification and abundances were confirmed in the second analysis using inferred 
ASVs. Although it is hypothesised that VVC results from a reduction of Lactobacillus 
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due to overgrowth of Candida in the vagina, microbiome studies have often found 
there to be no significant reduction in Lactobacillus in diseased women (Zhou et al., 
2009a, Macklaim et al., 2015, McClelland et al., 2009). As a result, these authors 
have rejected this hypothesis and disregarded the potential health benefit of 
probiotic therapies using Lactobacillus species. However, this observation does not 
account for potential fluctuations in abundances of individual Lactobacillus species 
which may provide protection against dysbiosis and onset of vaginitis. This suggests 
that the functional capacity of the bacterial species found in health and RVVC may 
play a more crucial role in disease pathology. 
 
Carrying out the second analysis of Illumina sequencing data proved crucial in 
identifying key Lactobacillus species present in health and RVVC. A limitation of the 
microbiome analysis was the inability to distinguish between some Lactobacillus 
species (including L. acidophilus, L. casei and L. gasseri). For this reason, these 
species are grouped as ‘L. spp, incl. L. crispatus’. Initially, diversity analysis showed 
similar levels of species richness and consistency between health and RVVC with 
significant overlap of ellipses when viewed by PCoA. However, although equally 
diverse, analysis of the species present between the two cohorts revealed important 
differences, particularly amongst Lactobacillus species. The reduction seen in 
protective H2O2-producing species such as L. crispatus and L. jensenii has been 
reported previously in patients with disease (Ceccarani et al., 2019). Additionally, 
inhibitory properties of L. crispatus against C. albicans have been demonstrated 
(Wang et al., 2017, Jang et al., 2019). It is thought that this protective characteristic 
may be, in part, due to the ability of L. crispatus to produce both the L- and D-lactic 
acid isomers (Amabebe and Anumba, 2018). This data also found an elevation in 
the non-H2O2-producing strain L. iners in patients with RVVC. Authors have 
previously reported this increase in L. iners, although non-pathogenic in itself, to be 
an indicator of dysbiosis of the vaginal microbiome (Ceccarani et al., 2019). One 
explanation for L. iners’ lack of protection is that out of the four most common vaginal 
Lactobacillus species, L. iners is the only species incapable of producing the more 
protective L-isomer of lactic acid (Witkin and Linhares, 2017, Witkin et al., 2013). 
Although consistent, the trends identified in this study were not statistically 
significant. This is likely due a to a relatively limiting sample size. It is becoming 
more widely recognised that although an overall reduction in Lactobacillus is not 
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seen in VVC episodes, important fluctuations in key Lactobacillus species have 
been found. Therefore, it is proposed that L. crispatus could contribute to 
maintenance and restoration of vaginal homeostasis during vaginal disease such as 
RVVC. To investigate this hypothesis, in depth analyses of the interkingdom 
interactions between L. crispatus and Candida species using sequencing 
technologies, such as those carried out in Chapter 5 of this thesis are required. A 
deeper understanding of these mechanisms could lead to greatly improved 
treatment options through L. crispatus probiotic therapies. 
 
To remove ambiguity of the Lactobacillus species that could not be distinguished by 
Illumina sequencing, a subset of samples was sequenced using the Oxford 
Nanopore Technologies MinION sequencing platform to confirm accurate 
identification. Similar studies have compared both platforms for the analysis of the 
nasal microbiome as well as environmental communities (Heikema et al., 2020, 
Nygaard et al., 2020). Our analysis found overall consistency between genus and 
species-level identification across the two sequencing platforms with some variation 
in abundances. Despite these fluctuations, both platforms confirm decreased levels 
of L. crispatus and increased levels of L. iners in RVVC compared with health. This 
data could suggest Illumina overestimates the quantity of one bacterial genus when 
it accounts for significant proportions of the microbiome. This would propose that 
Nanopore may be a better tool when accurate identification to species-level is 
required. Although assumptions can be made, it is impossible to determine which 
analysis was more accurate in this study. Nanopore is capable of a more accurate 
species identification as it sequences all nine 16S rRNA hypervariable regions 
compared with only the V4 region utilised by Illumina in this study. However, 
Nanopore is still a relatively new technology and its accuracy of ~95% is still 
considerably lower than 99.9% of the Illumina MiSeq platform (Santos et al., 2020). 
This is mainly a result of longer reads introducing errors through insertions/deletions 
(Cole et al., 2007). This is likely why species such as L. amylovorus and L. 
kitasatonis, which are not commensals of the human vaginal environment, were 
identified by this method. Further, analysis tools for data produced by Nanopore 
sequencers are limited meaning one limitation of this study is the potential for 
misinterpretation of Nanopore sequencing data due to the analysis employed 
(Santos et al., 2020). When more appropriate tools are developed for this analysis, 
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future studies directly comparing these platforms using known polymicrobial 
communities are required to determine variances in identification and abundance at 
species-level. This technology is still very much evolving and requires optimisation 
before it can be confidently used for clinical analyses. 
 
To investigate the role of the microbiome in RVVC further, bacterial taxa present 
were observed with respect to patient metadata collected via questionnaires. 
Although not all diseased patients had culturable Candida (40% negative), and not 
all healthy patients were culture-negative (15% positive), microbiome analysis found 
patients with culturable Candida to have a similar microbial profile to those with 
symptomatic disease. A similar trend of increased L. iners and decreased L. 
crispatus was seen in patients with culturable Candida. This suggests that even 
commensal carriage of Candida in the vagina, estimated to be >20%, could cause 
shifts in the microbiome predisposing patients to RVVC onset (Barousse et al., 
2004). These findings are contrary to a previous clinical study showing patients who 
were absent for L. crispatus and L. jensenii were more often found to be culture 
positive for Candida compared with those who were L. iners negative. However, this 
could be due to geographical variations in prevalent vaginal Lactobacillus species 
as this study assessed samples from Kenyan and American women (Eastment et 
al., 2020). The findings in this chapter are consistent with previous studies which 
show the inhibitory properties of H2O2-producing Lactobacillus against Candida 
(Parolin et al., 2015, Jang et al., 2019). To investigate the significance of these 
findings, longitudinal clinical studies assessing the microbiome of patients before 
and after RVVC onset are required. 
 
Analysis of the microbiome with respect to the form of contraceptive used by the 
patient revealed additional potential predisposing factors to RVVC. A notable shift 
in the microbiome to favour L. iners and lower other Lactobacillus species including 
L. crispatus was observed in those using both contraceptive devices and no 
contraception, this microbial shift was not observed in patients with RVVC using 
hormonal contraceptives. This proposes hormonal contraceptives may be less 
dysbiotic to the vaginal flora or have the potential to maintain a more health-like 
microbiome than contraceptive devices. Although important features were predicted 
at genus-level, given how slight the differences were between microbiomes it would 
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likely be impractical to attempt to distinguish contraceptive types based on this data. 
However, important features predicted at species-level found health-associated 
organisms like A. vaginae to be higher in healthy patients and those using hormonal 
contraceptives. Conversely, L. iners, associated with a dysbiotic microbiome was 
found to be lower in these patient groups. Although onset of VVC has been linked 
to increased oestrogen levels, no defined link between use of hormonal 
contraceptives and VVC has been identified (Geiger and Foxman, 1996). For this 
reason, it has been suggested that women suffering from frequent VVC episodes 
may wish to consider using a progestogen-only alternative (Dennerstein, 1986). 
However, the findings of this study suggest a more protective quality of hormonal 
contraceptives. Conversely, no protection was observed in women using 
contraceptive devices such as intrauterine devices (IUDs). Previous studies have 
shown IUDs provide a reservoir for Candida biofilm formation in vivo which may 
facilitate persistence of RVVC (Auler et al., 2010, Chassot et al., 2008). To 
investigate whether hormonal contraceptives have protective properties to maintain 
vaginal homeostasis, longitudinal studies of the vaginal microbiome are required. 
One study observed variations in the vaginal microbiome following introduction of 
hormonal contraceptives over 6 months, with respect to BV-associated microbes 
(Achilles et al., 2018). This study identified an increased prevalence of BV-
associated bacteria in women with copper IUDs, however hormonal contraceptives 
did not shift the microbiome towards disease. Additionally, a robust meta-analysis 
identified a negative correlation between the use of hormonal contraceptives and 
the occurrence and recurrence of BV (Vodstrcil et al., 2013). Further studies 
monitoring the vaginal microbiome before and after RVVC treatment are required to 
determine whether hormonal contraceptives provide protection against dysbiosis. 
 
Analysis of the microbiome with respect to how recently patients had received 
antifungal treatment revealed a potential risk of recurrence of disease. This analysis 
found women who were treated within one week of sampling to have a microbiome 
more similar to healthy women. However, women treated over one week before 
sampling were found to have a more dysbiotic microbiome associated with higher 
levels of L. iners and lower levels of Atopobium vaginae and L. crispatus. Similarly, 
a gradual decline towards dysbiosis was seen over time with RVVC. An intermediate 
profile in patients with disease for <6 months to a more severe dysbiosis in patients 
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with RVVC for >6 months was observed. Patients with disease for >6 months 
showed a higher association with L. iners and Bifidobacterium species and a lower 
associated with L. crispatus, L. jensenii and A. vaginae than women with RVVC for 
longer. This data suggests that, although somewhat effective, the current antifungal 
treatments for RVVC do not alter the microbiome to a sufficient level to reintroduce 
a health-like state. This results in the microbiome reverting to favour a disease-like 
environment after one month. This is similar to results found by another author 
investigating the microbiome of VVC patients before and after treatment with 
fluconazole; The authors reported a transition to a state between disease and health 
following treatment as opposed to returning to a healthy microbiome (Liu et al., 
2013b).  
 
Although not associated with vaginal dysbiosis, the genus Shuttleworthia was 
positively correlated with Candida load and increased time between treatments and 
is often observed in high levels in vaginal microbiome studies (Manzoni et al., 2006). 
Regardless of disease status, Lactobacillus was negatively correlated with the 
presence of Candida as well as increased numbers of episodes and time between 
treatments, indicating the potential protection from Candida overgrowth provided by 
vaginal lactobacilli. It is becoming more widely recognised that current treatments 
for RVVC are insufficient and may even exacerbate symptoms and length of 
disease, however, there remain few options for women with debilitating recurrent 
cases. In this disease, it is important to consider both the microbiome of each 
individual patient as well as the Candida isolate before appropriate treatment should 
be administered. The prospect of bench-side sequencers and personalised 
medicine could greatly improve treatment options as well as reduce the high rates 
of recurrence seen in VVC episodes. 
 
It is hypothesised that changes within Candida allow for it to shift from asymptomatic 
commensal to pathogenic yeast in the vaginal environment. It may now be more 
important to study RVVC with specific focus on the microbes present during RVVC, 
specifically Lactobacillus, and interkingdom interactions which may influence this 
pathogenic shift in Candida. The efficacy of Lactobacillus probiotics to treat RVVC 
have been shown in various clinical studies (Murina et al., 2014, Wang et al., 2017, 
Vladareanu et al., 2018). A study to investigate both the microbiome and mycobiome 
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of healthy women and those with RVVC before and after treatment could elucidate 
important interkingdom interactions in the disease. Further, it could identify 
candidates for probiotic therapies as well as molecular targets in Candida which 
could be targeted with future antifungals. By investigating these protective vaginal 
Lactobacillus species to gain a deeper understanding of their role in maintaining 
vaginal health, it may be possible to determine a suitable probiotic therapeutic to 
effectively treat RVVC and re-establish a healthy microbiome. 
 
 
Chapter findings 
• There is not an overall reduction in the abundance of Lactobacillus during 
RVVC compared with health, however, the functional capacity of key 
organisms is lost during disease as a result of a reduction in protective 
Lactobacillus species including L. crispatus and L. jensenii. Additionally, the 
presence of high quantities of L. iners in the vaginal environment indicates a 
dysbiotic microbiome. 
 
• Although more appropriate analysis tools are required before it should be 
used for clinical studies, the Oxford Nanopore Technologies MinION may be 
more suited to the study of diseases that require accurate species-level 
identification than the Illumina MiSeq platform. 
 
• Women with RVVC using hormonal contraceptives have a more similar 
bacterial profile to healthy women, suggesting they may provide protection 
from dysbiosis through maintenance of the microbiome during disease. 
 
• The importance of the interactions of Lactobacillus and Candida in RVVC 
research has been underappreciated and a deeper understanding of how 
certain Lactobacillus species maintain health could greatly improve future 
treatment options through the use of Lactobacillus probiotics.
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5.1 Introduction 
 
The causative organism of VVC, Candida spp., are biofilm-forming, opportunistic 
pathogenic yeasts with a commensal carriage rate in pre-menopausal women of up 
to 33% (Achkar and Fries, 2010a). Reportedly, VVC will affect 75% of women during 
their child-bearing years with C. albicans isolated in up to 90% of cases (Linhares 
et al., 2001, Sobel, 2007). Frontline antifungal treatments for VVC include the use 
of various azoles, however, resistance and subsequent recurrence of disease is well 
documented (Sobel, 2016, Whaley et al., 2016). Despite this, the interactions within 
the vaginal environment which allow for Candida spp. to become pathogenic, 
initiating VVC onset, are yet to be determined. 
 
The predominant bacterial taxa in the vaginal environment is Lactobacillus, namely 
L. crispatus, L. gasseri. L. iners and L. jensenii (Petrova et al., 2015). Dysbiosis of 
the vaginal environment is often attributed to a loss or reduction in lactobacilli 
species which, coupled with an increase in vaginal pH, is thought to allow 
overgrowth of pathogenic microbes such as Gardnerella vaginalis in bacterial 
vaginosis (BV) and C. albicans in VVC (Liu et al., 2013b, Oakley et al., 2008). In 
healthy women, lactic acid bacteria (LAB) are thought to be responsible for 
maintaining a homeostatic microbiome by inhibiting growth and adhesion of other 
microbes via the production of secreted metabolites such as lactic acid, 
biosurfactants, bacteriocins and hydrogen peroxide (H2O2) (Figure 5.1). However, 
the mechanisms behind the influence these metabolites have on Candida remains 
largely unknown.  
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Figure 5.1: Inhibition of Candida adhesion to vaginal epithelium by Lactobacillus. 
Created with BioRender. 
 
L. crispatus is a prominent commensal of the healthy vaginal environment in various 
microbiome studies and produces both lactic acid and H2O2 (Reid, 2018, van der 
Veer et al., 2019). Additionally, L. crispatus secretes the L-lactic acid isomer which 
has been extensively studied for its ability to lower vaginal pH, elicit anti-
inflammatory responses and inhibit microbial colonisation (Hearps et al., 2017, 
O'Hanlon et al., 2013). H2O2 is an oxidising agent which is toxic to catalase-negative 
bacteria and C. albicans (Eschenbach et al., 1989). It is thought that women with 
high levels of H2O2-producing lactobacilli species (L. acidophilus, L. crispatus and 
L. jensenii) gain a degree of protection against herpes simplex virus type 2 and BV 
(Matu et al., 2010, Conti et al., 2009). However, H2O2 is not required by Lactobacillus 
to inhibit C. albicans as the non-H2O2 producing L. rhamnosus GR-1 strain has been 
shown to inhibit both C. albicans and C. glabrata (Kohler et al., 2012, Chew et al., 
2015). Additionally, the protective role of H2O2 against infection is controversial in 
the hypoxic vaginal environment as it is produced predominantly under aerobic 
conditions (Tachedjian et al., 2017). 
 
Candida and lactobacilli species are often found to co-inhabit various niches 
throughout the human body including the oral cavity, gut and vagina (O'Donnell et 
al., 2015, Mason et al., 2012, Zhou et al., 2009a). Although antagonism between L. 
crispatus and C. albicans has been well documented, showing a reduction in both 
Candida growth and hyphae formation, the specific genes and pathways 
responsible for these observations remain undefined (Jang et al., 2019, Matsuda et 
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al., 2018a, Wang et al., 2017). One study assessing the effects of cell-free 
supernatants (CFS) of a vaginal isolate of L. crispatus against C. albicans noted 
downregulation of hyphae-specific genes including ALS3, HWP1 and ECE1 (Wang 
et al., 2017). These findings support the probiotic potential of L. crispatus to inhibit 
C. albicans biofilm formation and prevent infection in the vaginal environment. 
Notably, these studies focus solely on the effects of Lactobacillus CFS on C. 
albicans, potentially ignoring crucial direct interactions between the two microbes. 
Furthermore, a caveat of these studies is the lack of powerful RNA sequencing 
technologies with the potential to expose novel mechanisms and pathways by which 
C. albicans may be inhibited by Lactobacillus. Advances in these technologies have 
led to them being more affordable to smaller labs, allowing for the production of 
large data sets analysing genome-wide transcripts.  
 
In the era of antibiotic and antifungal resistance, the use of lactobacilli species as 
probiotics for the treatment of Candida infections has become increasingly attractive 
(Matsubara et al., 2016a). Probiotics are defined by the World Health Organisation 
(WHO) as “live microorganisms that are administered in adequate amounts and 
confer a health benefit on the host”. Studies have investigated the probiotic potential 
of commercially available lactobacilli species including L. rhamnosus GR-1 and L. 
reuteri RC-14 against C. albicans as a therapeutic for VVC (Chew et al., 2015, 
Jorgensen et al., 2017, Matsubara et al., 2016b, Lourenco et al., 2018). Although 
these studies have shown some success with impeding C. albicans growth and 
hyphal formation, these species are rarely reported as commensals of the vaginal 
environment and are only capable of transient colonisation during treatment 
(Colodner et al., 2003). Additionally, the molecular mechanisms by which these 
microbes are able to inhibit C. albicans remain largely undefined. 
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Hypotheses and aims 
Although it is becoming more common to consider Lactobacillus probiotics as 
potential therapies for Candida infections such as oral and vaginal candidiasis, the 
mechanisms behind antagonism between Candida and Lactobacillus remain largely 
unknown. A better understanding of these interkingdom interactions at a molecular 
level may be crucial to unearthing potential targets for much-desired therapeutics. 
Therefore, the aims of this chapter were to: 
 
• Investigate antagonism between C. albicans and commonly isolated vaginal 
Lactobacillus species. 
• Elucidate the intimate interactions of the most common causative organism 
in VVC, C. albicans, and one of the most common bacterial species 
associated with vaginal health, L. crispatus, in a biofilm co-culture model. 
• Observe differential expression of specific gene pathways in C. albicans as 
a result of L. crispatus co-culture. 
 
It is hypothesized, based on previous studies, that antagonism between the two 
microbes will result in C. albicans expressing genes associated with stress, possibly 
partially due to lactic acid. Additionally, it is thought that this transcriptome analysis 
may provide potential mechanisms by which L. crispatus could contribute to 
resolution of VVC. To our knowledge, this is the first study to analyse C. albicans 
transcripts following biofilm co-culture with L. crispatus using RNA sequencing 
technology. 
 
 
Work from this chapter has been published in mSystems: 
McKloud E, Delaney C, Sherry L, Kean R, Williams S, Metcalfe R, Thomas R, 
Richardson R, Gerasimidis K, Nile CJ, Williams C, Ramage G. Recurrent 
Vulvovaginal Candidiasis: A Dynamic Interkingdom Biofilm Disease 
of Candida and Lactobacillus. mSystems. 2021 Aug 10:e0062221. doi: 
10.1128/mSystems.00622-21. 
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5.2 Materials and Methods 
 
5.2.1 Strain and culture conditions 
Candida albicans SC5314, Lactobacillus crispatus ATCC 33820, L. casei ATCC 
393, L. fermentum ATCC 14931, L. iners DSMZ 13335, L. salivarius ATCC 11741, 
L. jensenii ATCC 25258 and L. rhamnosus ATCC 7469 were used in this chapter. 
C. albicans was cultured on Sabouraud’s Dextrose (SAB) agar for 48h at 30°C. L. 
crispatus and L. iners species were cultured anaerobically on De Man Rogosa and 
Sharpe (MRS) agar for 48h at 37°C, whilst the remaining lactobacilli species were 
cultured in a 5% CO2 atmosphere. For biofilm formation, overnight cultures of C. 
albicans and Lactobacillus were grown in YPD and MRS media, respectively, under 
appropriate culture conditions. Cultures were washed twice with PBS and 
standardised in 1:1 medium to 1x106 for C. albicans and 1x107 for L. crispatus.  
 
5.2.2 Media preparation 
THB was supplemented with 10µM menadione and 10µg/mL hemin (ThermoFisher) 
and mixed 1:1 with RPMI (referred to as 1:1 medium). 
 
5.2.3 Whole-genome transcriptional analysis 
 
5.2.4 Antagonism between C. albicans and Lactobacillus in co-culture 
The ability of 7 Lactobacillus species to inhibit C. albicans SC5314 biofilm formation 
was assessed. Overnight cultures were grown and standardised as described 
above. Eight biofilms of each C. albicans-Lactobacillus pair were incubated in 5% 
CO2 for 24h. Alternatively, C. albicans biofilms were formed for 4h prior to addition 
of Lactobacillus for 20h before biomass was quantified using the crystal violet assay 
(Feoktistova et al., 2016). Briefly, biofilms were allowed to dry before wells were 
flooded with 0.05% crystal violet and incubated at room temperature for 20 min. 
Biofilms were then washed with water to remove excess dye before bound dye was 
removed with 100% ethanol and absorbance read spectrophotometrically at 570nm.  
 
To assess C. albicans biofilm-related gene expression in the presence of 
Lactobacillus, RNA was extracted from 24h dual species biofilms using the PureLink 
RNA mini kit (ThermoScientific, Loughborough, UK), following manufacturer’s 
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instructions. 2µg of RNA was then converted to cDNA using the high capacity cDNA 
reverse transcription kit (ThermoScientific, Loughborough, UK) and 1µl used in a 
20µl real-time qPCR reaction with 10µl 2X Fast SYBR® Green PCR Master Mix, 1µl 
forward/reverse primer and UV-treated H2O. Primer sequences can be found in 
Table 1. Gene expression was analysed in duplicate on three separate occasions, 
no reverse transcription (NRT) and no template controls (NTC) were included 
throughout. Gene expression was normalised to the ACT1 housekeeping gene and 
calculated using the ΔΔCt method. 
 
Table 5.1: qPCR primer sequences 
 
 
5.2.5 In vitro transcriptomic analysis of C. albicans interactions with L. crispatus 
Overnight cultures were standardised in 1:1 broth as described above, and Candida 
biofilms grown in t75 cell culture flasks (Corning, USA) for 4 h in 5% CO2. After 
incubation, media was removed and biofilms washed with PBS before L. crispatus 
was added for an additional 2, 4 or 20 h. At each time point the media was removed 
and biofilms washed with PBS before being imaged to ensure no contamination and 
scraped in to 1 mL of RNAlater (ThermoScientific, Loughborough, UK). Spent media 
from biofilms was retained and pH monitored throughout the experiment using a pH 
meter. A graphical illustration of the experimental methodology can be found in 
Figure 5.2. 
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5.2.6 RNA extraction from C. albicans/L. crispatus biofilms 
RNA was extracted from microbial biofilms using the RiboPure™ RNA Purification 
Kit for yeast (ThermoScientific, Loughborough, UK), following manufacturer’s 
instructions. Biofilms were centrifuged at >12,000g for 5 min to pellet cells and 
supernatants were discarded. To each sample, 480µL lysis buffer, 48µL 10% SDS 
and 480µL of Phenol:Chloroform:IAA were added before the pellet was 
resuspended by vortexing and the full mixture transferred to bead beating tubes 
containing 750µL of ice-cold zirconia beads. Samples were then beaten for 3x30 
sec cycles using a BeadBug™ microtube homogenizer (Merck, Gillingham, UK) and 
centrifuged at 16,100g for 5 min to separate the RNA containing aqueous layer. The 
aqueous layer was then transferred to a sterile tube before 1.9mL of binding buffer 
and 1.25mL of 100% ethanol was added and gently mixed. The entire sample was 
then passed through a filter cartridge placed in a collection tube and the eluate 
discarded. The filter was then washed with 700µL of wash solution 1, followed by 
washing twice with 500µL of wash buffer 2/3. The filter cartridge was then 
transferred to a fresh collection tube and 25µL of pre-heated elution solution added 
before the sample was centrifuged for 1 min to collect RNA. Finally, a DNase 
treatment reaction was assembled and added to each sample for 5 min. the reaction 
was then pelleted and purified RNA transferred to a sterile Eppendorf tube before 
being stored at -80°C until analysis. Integrity of RNA was assessed using a 
Bioanalyser system (Aligent, USA) to ensure highly intact RNA was sent for 
sequencing analysis. Samples were deemed acceptable if they obtained a minimum 
RNA integrity number (RIN) of 7.0 and a minimum quantity of 2.5µg. Genome-wide 
Candida transcripts were sequenced using the Illumina NOVASeq6000 sequencing 
platform (Edinburgh Genomics) to obtain 100bp paired-end reads. 
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Figure 5.2: Experimental design for transcriptomic analysis. Created with 
Biorender.com. 
 
5.2.7 Analysis pipeline 
Genome-wide Candida transcripts were sequenced using the Illumina 
NOVASeq6000 sequencing platform (Edinburgh Genomics). FastQC and 
trimmomatic were implemented to score quality of raw fastq reads and remove 
adaptors, primers and poor-quality reads with a Phred score <30 (Bolger et al., 
2014). High quality reads were aligned to the C. albicans SC5314 genome (Candida 
Genome database) using HISAT2. Aligned reads that mapped to features on the 
genome were enumerated using HTSeq and counts imported into R for differential 
expression analysis based on the DESeq2 package. Dr Christopher Delaney 
(University of Glasgow) performed quality control, sequence trimming and read 
alignment and enumeration. A summarised illustration of the bioinformatics 
pipelines can be found in Figure 5.3. Figures were constructed and statistical 
analysis performed using R, GraphPad Prism 8 and Biorender. 
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Figure 5.3: Bioinformatic pipeline for transcriptomic analysis. Created with 
Biorender.com. 
 
5.2.8 Investigating the probiotic potential of L. crispatus in a complex biofilm 
model 
Mature 11-species biofilms were formed as described previously by our group with 
slight modifications (Sherry et al., 2016). The model included  the following type 
strains: Streptococcus mitis NCTC 12261, Streptococcus intermedius ATCC 27335, 
Streptococcus oralis ATCC 35037 and Aggregatibacter actinomycetemcomitans 
OSM 1123, C. albicans 3153A, Fusobacterium nucleatum ATCC 10596, F. 
nucleatum ssp. vincentii ATCC 49256, Actinomyces naeslundii ATCC 19039, 
Veillonella dispar ATCC 27335, Prevotella intermedia ATCC 25611 and 
Porphyromonas gingivalis W83. Overnight broths of each organism were 
standardised in 1:1 medium prior to addition to the biofilm on hydroxyapatite (HA) 
discs. For probiotic treatment, each biofilm was treated bi-daily (12-hour intervals) 
with 5x107 CFU/mL of L. crispatus for 5 mins before treatment was removed, 
biofilms washed 3 times in PBS and fresh media replaced. On day 3, after 4 probiotic 
treatments, 48h biofilms were removed for compositional analysis. On day 5, after 
8 probiotic treatments, 96h biofilms were removed for compositional analysis. At 
each timepoint, biofilms were washed 3 times and sonicated in 1mL of PBS at 35 
KHz for 10 min to remove biomass. Sonicates were split in two and to one sample 
5µl of 10mM propidium monoazide (PMA) was added to quantify live C. albicans 
DNA. The other sample allowed for quantification of total C. albicans DNA per 
biofilm. All samples were incubated in the dark for 10 min then placed on ice and 
exposed to a 650W halogen light for 5 min. DNA was then extracted using the 
QIAmp DNA mini kit, as per manufacturer’s instructions (Qiagen, Crawley, UK). To 
a 20µl qPCR reaction, 1µl of biofilm DNA was added to: 10µl Fast SYBR™ Green 
Master Mix, 1µl of 10µM C. albicans forward/reverse primers and UV-treated 
nuclease-free water. Primer sequences can be found in Table 1. The following 
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thermal profile was used: 95°C for 2 minutes, 40 cycles of 95°C for 3 seconds 
followed by 55°C for 30 seconds. Samples were assessed in duplicate from 2 
separate experiments. Standard curves constructed from serially diluted DNA of C. 
albicans SC5314 were used extrapolate Candida colony forming equivalents 
(CFE/mL), respectively as described previously (O'Donnell et al., 2015). 
 
5.2.9 Statistical analysis 
Transcriptome pipeline figures were constructed using BioRender and differential 
gene expression plots using the DESeq2 package in RStudio. Gene ontology 
networks were constructed using ClueGO software, available through Cytoscape 
(Shannon et al., 2003). All other figures and analyses were performed in GraphPad 
Prism (Version 8, La Jolla, California, USA). Statistical significance was measured 
using t-tests to compare the means of two samples or one-way ANOVA to compare 
the means of multiple samples. Statistical significance was achieved if P < 0.05. 
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5.3 Results 
 
5.3.1 Investigating antagonism between C. albicans and vaginal lactobacilli 
 
To assess potential antagonism between Lactobacillus and C. albicans, 7 
Lactobacillus species were selected and their effects on C. albicans biofilm-
formation in co-culture observed (Figure 5.4). When grown together for 24h, a 
reduction in biomass was observed in all Lactobacillus species, particularly L. 
rhamnosus (Figure 5.4A). However, when C. albicans was allowed to form a biofilm 
before addition of Lactobacillus, this effect was less pronounced, and for L. iners 
and L. fermentum, absent (Figure 5.4B). To further analyse this antagonistic effect, 
C. albicans biofilm-related gene expression was assessed after co-culture with L. 
rhamnosus and L. iners. L. rhamnosus is often studied for its probiotic effects 
against C. albicans in mucosal environments (Mailander-Sanchez et al., 2017). 
Conversely, high levels of L. iners is hypothesised to indicate vaginal dysbiosis due 
to loss of protective lactobacilli. The two organisms interacted with C. albicans 
differently, i.e., L. rhamnosus down-regulated all biofilm-related gene expression 
after incubation for 20h and 24h (Figure 5.4C and 5.4D). L. iners down-regulated 
expression of ECE1 and, to a lesser extent, HWP1 after incubation for 24h. 
However, when added to a pre-existing C. albicans biofilm, L. iners resulted in up-
regulation of ece1 and ALS3. Although L. rhamnosus was able to inhibit C. albicans 
biofilm formation more than the other lactobacilli species tested, L. crispatus was 
selected for further RNA sequencing analysis. This is because L. rhamnosus is not 
a commensal of the vaginal environment and is only capable of transient 
colonisation. Furthermore, L. crispatus is one of the most prevalent Lactobacillus 
species in the vaginal microbiome and its antagonism with C. albicans has been 
displayed in previous studies.  
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Figure 5.4: Lactobacillus species display antagonism with C. albicans in vitro. To 
observe inhibitory effects of Lactobacillus against C. albicans biofilm formation, C. albicans 
and a panel of Lactobacillus species were co-cultured together in 1:1 media in 5% CO2 
either for 24h (A) or C. albicans was grown for 4h prior to addition of Lactobacillus species 
for 20h (B). C. albicans biofilm-associated gene expression was measured in the presence 
L. rhamnosus (CA+LR), which is associated with ‘health’, and L. iners (CA+LI), which is 
hypothesised to indicate dysbiosis. The mean log fold-change relative to single species C. 
albicans biofilms is shown (C). Breakdown of expression values for gene expression 
analysis (D). Data represents the mean + SD.  
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Spent media from dual species biofilms was retained to monitor pH throughout the 
experiment (Figure 5.5). Both C. albicans single and dual species biofilms had a 
slightly reduced pH at 6 and 8h timepoints compared with media controls. At 24h 
however there was a small increase in pH in both single and dual species biofilms. 
Overall, the pH of the transcriptome model was relatively stable between a pH of 
6.5 to 7. 
 
 
Figure 5.5: pH levels are relatively stable throughout C. albicans and L. crispatus 
biofilm co-culture. Overnight cultures of C. albicans and L. crispatus were standardised to 
1x106 and 1x107, respectively. Candida biofilms were grown for 4h before addition of L. 
crispatus for 2, 4 or 20h. After incubation, media was removed, and pH levels of media and 
single/dual species biofilms measured. Experiments were carried out in triplicate, on three 
separate occasions. Bars represent mean + SD, statistical significance compared biofilms 
with media controls at each time point using t-tests or one-way ANOVA (*, P<0.05, #, 
P<0.0001). 
 
 
5.3.2 Differential expression analysis of co-culture model 
 
Extracted biofilm RNA was used to assess transcriptional changes in C. albicans 
between single and dual-species biofilms with L. crispatus. Initially, differential 
expression analysis was performed in R using the DESeq2 package to observe 
transcriptional changes between single and dual species biofilms at each time-point. 
Multivariate analysis by Principal Component Analysis (PCA) showed mixed 
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grouping of gene expression in early single and dual species biofilms (6h and 8h) 
(Figure 5.6). At 24h there is separation along the y-axis of gene expression between 
single and dual-species biofilms, suggesting greater differences will be observed at 
this time point. 
 
 
Figure 5.6: Principal Component Analysis grouping of samples based on variance in 
expression. PCA analysis of differential gene expression in single and dual species C. 
albicans and L. crispatus biofilms. PC1 shows the largest variance (56%) along the x-axis 
and PC2 displays the second largest variance (22%) on the y-axis 
 
Heatmap analysis of normalised Log2 fold change in gene expression was utilised 
to determine the top 50 differentially expressed genes at each timepoint (Figure 5.7). 
As predicted by previous analysis, expression in early dual species biofilms was 
similar to that observed in single species C. albicans biofilms (Figure 5.7A and 
5.7B). However, this analysis revealed many genes involved in amino acid 
biosynthesis and breakdown (ARG8, ILV1, HIS5) upregulated in 24h dual species 
biofilms (Figure 5.7C). CAR1 and CAR2, which are found in significantly lower levels 
in dual species biofilms, are involved in arginine breakdown. These data suggest it 
may be advantageous for L. crispatus to suppress expression of these genes, 
increasing access to arginine. Interestingly, the PRY1 and GTT1 genes, which are 
co-expressed and code for a secreted protein associated with virulence in the 
presence of lactate in C. albicans was found to be downregulated in dual species 
biofilms (Log2 fold change = -5.35).
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Figure 5.7: Differential expression analysis of C. albicans single and C. albicans + L. 
crispatus dual species biofilms. Heatmaps displaying the top 50 differentially expressed 
genes in C. albicans between single and dual species biofilms at 6h (A), 8h (B) and 24h 
(C). 
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To observe specific significantly differentially expressed genes between single and 
dual species biofilms at each timepoint volcano plots were constructed (Figure 5.8). 
Here it is evident that no genes in early biofilms passed the Log2 fold change and 
adjusted P value cut offs for significance (Figure 5.8A and 5.8B). Subsequently, 
further analysis compared expression in mature 24h single and dual species biofilms 
only. A list of some of the key genes upregulated in 24h biofilms and their functions 
can be found in Table 5.2. Many of these genes are related to amino acid 
biosynthesis, metabolism, and breakdown as well as some involved in 
acetyltransferase activity and ubiquitination (ATF1 and BUL1, respectively). 
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Figure 5.8: Differential gene expression occurs in mature 24h C. albicans/L. crispatus 
dual-species biofilms Volcano plots showing differentially expressed genes in 6h (A), 8h 
(B) and 24h (C) biofilms. Positive Log2 fold change values correspond to upregulation in 
dual species biofilms; Negative Log2 fold change values depict upregulation in C. albicans 
only biofilms. Significance was achieved if Log2 fold change >1.5 or < -1.5 (Green) and 
adjusted P value < 0.05 (Red). 
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Table 5.2: Up-regulated genes in 24h dual-species biofilms associated with amino 
acid biosynthesis and/or breakdown. 
 
 
 
5.3.3 Functionality of differentially expressed genes 
 
Gene set enrichment analysis (GSEA) was used to perform Gene ontology (GO) 
term analysisto determine the functionality of differentially expressed genes in single 
and dual species 24h biofilms. Differentially expressed genes were assigned to GO 
terms based on function. The 36 identified differentially expressed genes were 
assigned to 25 GO terms. These functions are characterised by a larger network of 
amino acid biosynthesis, metabolism and breakdown processes and a smaller 
network of transaminase processes (Figure 5.9A). Analysis of overrepresented GO 
terms showed an increase particularly in arginine and histidine biosynthetic and 
metabolic processes with >35% of associated genes upregulated (Figure 5.9B).  
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Figure 5.9: Gene networks of Gene Ontology (GO) terms and over-represented GO terms. 
Constructed gene networks of GO terms in 24h biofilms (A) and significantly overrepresented GO terms in 24h dual species biofilms compared with single 
species (B). All GO terms have an adjusted P value < 0.05. Nodes are coloured by significance. Networks were created using ClueGO software available 
through Cytoscape.
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Some of the key overrepresented pathways upregulated in 24h biofilms are 
highlighted in Figure 5.10. Despite upregulation of α-amino acid biosynthesis and 
metabolism pathways in C. albicans, expression of BAT21 and ILV1 in dual-species 
biofilms suggests C. albicans is in a state of amino acid starvation during co-culture 
with L. crispatus (Figure 5.10B). Additionally, genes involved in production of 
arginine and histidine were highly upregulated in dual species biofilms (Log2 fold 
change >3).  
 
 
 
Figure 5.10: Genes involved in α-amino acid biosynthesis and breakdown are 
upregulated in C. albicans/L. crispatus biofilms. Important biological and molecular 
functions in dual species biofilms (A). Log2 fold change of key gene expression in C. 
albicans from single to dual species biofilms (B). All GO terms have an adjusted P value < 
0.05. 
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5.3.4 Probiotic effect of L. crispatus against C. albicans  
 
Given the antagonism observed between C. albicans and L. crispatus, the next aim 
was to investigate the in vitro probiotic potential of L. crispatus against C. albicans 
infection in a complex biofilm model (Figure 5.11). After 2 consecutive days of 
probiotic treatment, a slight reduction in total and live C. albicans composition within 
the biofilm is seen, however this was not significant (P = 0.55, P = 0.16, respectively) 
(Figure 5.11A and 5.11B). Following a 4-day treatment regimen with L. crispatus, 
total C. albicans composition significantly decreased (P < 0.05) with reduced levels 
of live fungal DNA. When assessing the total fold reduction in C. albicans from 
untreated biofilms, the greatest probiotic effect is observed at 48h post-treatment 
(Figure 5.11C). 
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Figure 5.11: Bi-daily addition of L. crispatus reduces C. albicans load within a 
complex biofilm model in vitro. The potential probiotic properties of L. crispatus against 
C. albicans were assessed in a 11-species biofilm model treated twice daily with L. 
crispatus. Live/Dead qPCR allowed for quantification of percentage composition of total (A) 
and live (B) C. albicans DNA within the biofilm. Average fold change in the C. albicans 
percentage composition from the untreated 11-species biofilm is also shown (C). Data 
represents mean + SD. Statistical analysis compared treated and untreated biofilms at each 
time point using paired t-tests comparing raw CFE values (*, P < 0.05). 
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5.4 Discussion 
 
Initially, the ability of 7 Lactobacillus species to inhibit C. albicans biofilm formation 
in co-culture was assessed. L. rhamnosus has been studied extensively for its 
potential as a probiotic and has been shown to prevent adhesion of C. albicans to 
mucosal surfaces (Manzoni et al., 2006). This data confirms these findings with L. 
rhamnosus displaying the greatest ability to inhibit biofilm formation. Interestingly, 
when added to a pre-formed C. albicans biofilm, the ability of all species assessed 
to inhibit biofilm formation is suppressed. This is likely due to the thick nature of C. 
albicans biofilm formation with secreted metabolites from Lactobacillus unable to 
penetrate the ECM and disrupt the biofilm. Although this suggests Lactobacillus 
probiotics may be ineffective against C. albicans biofilms, this phenomenon may not 
be observed in a polymicrobial in vivo setting where C. albicans biofilms are less 
confluent. Additionally, the ability of L. rhamnosus to down-regulate C. albicans 
biofilm-related gene expression was also shown. L. iners is isolated from the vagina 
of 50% of both healthy and diseased woman but, unlike other vaginal lactobacilli, is 
not thought to contribute to maintaining health (Petrova et al., 2017). This is due to 
its notably small genome compared to other species which brings researchers to 
assume it may be parasitic or symbiotic in nature. For this reason, high levels of this 
microbe are thought to increase risk of vaginal disease and potentially indicate 
dysbiosis. Additionally, L. iners results in up-regulation of both ALS3 and ECE1 and 
as such, should not be considered as a probiotic treatment for C. albicans infections. 
 
L. crispatus is increasingly becoming recognised as a health-associated 
Lactobacillus species in the vaginal microbiome and may be important in preventing 
RVVC. As well as being associated with health, L. crispatus has been shown to 
promote stability of the vaginal microbiome in longitudinal studies (Antonio et al., 
1999, Verstraelen et al., 2009). The aim of this transcriptomic experiment was to 
elucidate possible antagonism between C. albicans and L. crispatus. The in vivo 
vaginal pH is thought to be <4.5, however, in this dual species model the pH was 
sustained between 6-7. Previously, vaginal L. crispatus isolates have been shown 
to acidify growth media to levels comparable to that of the in vivo vaginal 
environment (Boskey et al., 1999). Although using different growth media, it is likely 
that the presence of C. albicans in this model is responsible for the increased pH. 
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Vaginal disease is often coupled with an increase in vaginal pH, due to reduction in 
lactobacilli, allowing for pathogens such as C. albicans to gain a niche. Further, this 
is evidence of antagonism between C. albicans and L. crispatus as C. albicans has 
been shown to neutralise the pH of growth media in order to facilitate hyphal 
morphogenesis (Vylkova et al., 2011). It is possible that, in the presence of other 
lactic acid bacteria, the low environmental pH could play a role in Candida 
pathogenesis. Nonetheless, the stability of the neutral pH throughout this 
experiment dictates that any transcriptomic changes observed are not due to 
acidification of the media and are a result of interactions between C. albicans and 
L. crispatus. 
 
This study found that in a co-culture model with L. crispatus, C. albicans does not 
begin to display any alterations in gene expression until 24h of incubation. It has 
previously been shown in Lactobacillus clinical isolates that secreted metabolites 
can remain at low levels until up to 72 or 120h incubation, which may account for 
the delay in interaction seen here (Ogunshe et al., 2011). Out of 6,221 genes in the 
Candida genome, 26 were found to be upregulated specifically in dual species 24h 
biofilms. Similarly, 10 genes were found to be upregulated in single species 24h 
biofilms compared to dual species (Adjusted P < 0.05). Gene transcripts associated 
with amino acid biosynthesis and transaminase activity were prominent in L. 
crispatus dual-species biofilms. Transaminase activity is primarily associated with 
α-amino acid breakdown and biosynthesis. It has been shown in a model of 
Saccharomyces cerevisiae, L. lactis and L. plantarum, that in nitrogen rich 
environments yeasts secrete an array of metabolites, primarily amino acids, thereby 
facilitating the growth of lactobacilli (Ponomarova et al., 2017). The upregulation of 
various amino acid biosynthesis processes in our study may be attributed to this 
nutrient cross-feeding. However, this may also be a deliberate process by which L. 
crispatus is able to drive synthesis of amino acids in C. albicans, as well as 
suppressing CAR1 and CAR2, associated with arginine breakdown, in order to 
sequester them for metabolism and facilitate its own growth. The upregulation of 
BAT21 and ILV1 in dual species biofilms is associated with amino acid starvation in 
C. albicans, suggesting that despite the upregulation of various amino acid 
biosynthesis processes, C. albicans is unable to utilise them. This may be a 
contributing factor in the process by which L. crispatus is able to out-compete 
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Candida during VVC and potentially re-establish a healthy microbiome. Additionally, 
amino acids are a key source of nitrogen for C. albicans and starvation of these 
nutrients has been shown to induce hyphal morphogenesis (Tripathi et al., 2002). It 
is possible that this starvation caused by L. crispatus contributes to the pathogenic 
shift in C. albicans and onset of VVC. Furthermore, the PRY1 gene, associated with 
virulence in the presence of lactate, was found to be downregulated in dual species 
biofilms. Thus, L. crispatus may possess a mechanism by which it can suppress 
lactate-associated virulence in C. albicans. Interestingly, genes associated with 
resistance to lactic acid such as mig1 and cyb2 were not found to be differentially 
expressed in our co-culture study (Cottier et al., 2017, Ueno et al., 2011). This 
suggests a classical weak organic acid stress response in C. albicans is not being 
triggered by the presence of L. crispatus alone. Given that the media in this 
experiment was not acidified, this concludes that antagonism between C. albicans 
and L. crispatus is not purely due to a reduction in environmental pH. The influence 
of other secreted metabolites of L. crispatus such as H2O2 and bacteriocin-like 
substances on C. albicans requires further research to fully illustrate antagonism 
between the two organisms. These data show a potentially probiotic effect of L. 
crispatus against C. albicans in non-acidic environments. This antagonism is 
governed by the over-production of amino acids from C. albicans which may 
facilitate restoration of a healthy microbiome through lactobacilli proliferation. 
 
This study focusses on the interactions of C. albicans with one Lactobacillus 
species. It may however, be beneficial for future studies to assess Candida gene 
expression in the presence of a relevant model of the vaginal microbiome in vitro. 
Additionally, this study, and many others, focuses on the interactions between 
Lactobacillus and C. albicans. However, in recent decades there has been a global 
increase in the prevalence of non-albicans Candida (NAC) species in VVC, up to 
45%, commonly associated with antifungal resistance and recurrence 
(Narayankhedkar et al., 2015). To understand these more complicated cases of 
VVC, further studies are required to assess interactions between lactobacilli and 
NAC species in the vaginal environment.  
 
Finally, the potential probiotic effect of L. crispatus against C. albicans within a 
complex biofilm model was investigated. Although studies have assessed the 
Chapter 5 – Lactobacillus crispatus exploits Candida albicans gene expression to facilitate 
its own growth 
183 
 
inhibitory effect of L. crispatus against C. albicans mono-species biofilms (Rizzo et 
al., 2013, Li et al., 2019, Wang et al., 2017), to our knowledge, this is the first report 
of L. crispatus reducing C. albicans composition within a polymicrobial biofilm model 
in vitro. This data supports other studies confirming the probiotic potential of L. 
crispatus against C. albicans biofilm infections. More studies are required to assess 
the specific mechanisms of secreted metabolites from L. crispatus responsible for 
the observed inhibition of C. albicans growth and biofilm formation.  
 
Collectively, results from this chapter show a potentially probiotic effect of L. 
crispatus against C. albicans in non-acidic environments and within a complex 
polymicrobial biofilm model. This antagonism is governed by the over-production of 
amino acids from C. albicans which may facilitate restoration of a healthy 
microbiome through lactobacilli proliferation. Elucidating the interactions of health-
associated lactobacilli with NAC species will lead to a better understanding of the 
interactions between Candida and Lactobacillus which allow for VVC onset and 
recurrence.  
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Chapter findings 
 
• When added to pre-formed C. albicans biofilms, the probiotic effect of 
Lactobacillus species is suppressed or absent in vitro. L. iners induces 
biofilm-related gene expression and is not capable of C. albicans biofilm 
inhibition and as such, should not be considered as a candidate for probiotic 
therapies. Although L. rhamnosus is a viable option for probiotic treatment, 
its transient colonisation means other commensals of the vaginal 
environment should be prioritised. 
 
• Antagonism between C. albicans and L. crispatus is present at a neutral pH. 
L. crispatus is able to drive α-amino acid biosynthesis and amino acid 
starvation in C. albicans. This may be a crucial mechanism by which L. 
crispatus is able to out-compete C. albicans during VVC and re-establish 
vaginal health.  
 
• Bi-daily addition of L. crispatus to a complex polymicrobial biofilm model 
reduces C. albicans composition within the biofilm. This strengthens the 
viability of L. crispatus for further probiotic therapeutic trials in vaginally 
relevant biofilm models.
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6.1 Introduction 
The work outlined in this thesis aimed to gain a greater depth of understanding of 
the vaginal environment and the influence of microbial interactions during health 
and RVVC through microbiological and metagenomic assessment of a panel of 
clinical samples. The literature review and bibliometric analysis outlined an 
increased interest in the field of Candida and Lactobacillus research in the past two 
decades. It also identified caveats in our knowledge and appreciation of interactions 
between these microbes and the potential impact of biofilm formation, particularly 
pertaining to vaginal research. Despite claims within the field that Candida does not 
form biofilm on vaginal mucosa, microbiological analysis performed on clinical 
samples revealed various indicators of Candida biofilm formation during RVVC. This 
included an increased Candida load following treatment as a result of resistant 
communities, increased tolerance to antifungals, capability of Candida isolates to 
form biofilms, and for the first time, C. albicans aggregate formation in lavage fluid. 
Analysis of the microbiome of these women revealed subtle but important 
differences between Lactobacillus species present during health and RVVC. 
Additionally, the hypothesis of resistant communities due to biofilm formation was 
strengthened where a more dysbiotic microbiome was observed in women treated 
over one week before sampling. This is the first study to compare the microbiome 
of women with RVVC with respect to length of disease, treatment received, and 
contraception used. Transcriptomic analysis revealed potential probiotic efficacy of 
L. crispatus against C. albicans biofilms in vitro in co-culture and in a complex 
polymicrobial setting. This is the first study to identify a potential α-amino acid 
biosynthesis/starvation mechanism by which L. crispatus may out-compete C. 
albicans during VVC/RVVC to re-establish health. 
 
6.2 Candida biofilm formation in RVVC – a reservoir for failed clinical 
treatment? 
The analysis in Chapter 3 of this thesis utilised microbiological techniques to assess 
a panel of RVVC clinical samples in order to observe potential sources of failed 
clinical treatment reported in practice. An important outcome from this analysis was 
the identification of an increased fungal load in RVVC which is exacerbated in 
women with disease for longer. It has been postulated previously that an increased 
Candida load is indicative of symptomatic VVC/RVVC (Hopwood et al., 1988). 
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However, since this original study, no authors have investigated the influence of 
Candida load in clinical samples of health and VVC/RVVC on disease pathology. 
Although some authors have compared numbers of Candida-positive cultures in 
healthy women and those with symptomatic disease (Bauters et al., 2002), there 
remains very little evidence of quantitative analysis. This is likely a reflection of the 
current FDA-approved “gold standard” for VVC diagnosis being positive Candida 
culture, which is only 65% sensitive for accurate diagnosis (Chatzivasileiou and 
Vyzantiadis, 2019, Sonnex and Lefort, 1999). With the development of real-time 
qPCR over the last two decades as well as the increasing accessibility to species 
identification by 16S/18S sequencing provided by benchtop sequencers, these 
guidelines require revision. With improved diagnostics using qPCR or benchtop 
sequencers it may be possible to develop more appropriate treatments for VVC, 
greatly decreasing recurrence rates and the psychological and economic burdens 
of RVVC. 
 
The analysis in Chapter 3 also identified evidence of inefficient clinical treatment 
where women who received treatment for RVVC more than one week before 
sampling had a higher fungal burden than those treated within one week of 
sampling. Although in most cases one oral dose of 150mg of fluconazole is sufficient 
to treat VVC, failure to eradicate Candida due to insufficient treatment during VVC 
contributes to the 8% of women who subsequently develop RVVC (Sobel et al., 
1998, Dovnik et al., 2015a). Despite the debilitating consequences for women’s 
mental health and the economic burden of RVVC worldwide, treatment options 
remain limited for cases that do not respond to azole therapies. Within the last year, 
a novel drug for the treatment of VVC, Ibrexafungerp, has been developed (Larkin 
et al., 2019). This drug may soon become the new frontline treatment for VVC as it 
has shown efficacy against various Candida isolates, including those resistant to 
fluconazole and echinocandins (Azie et al., 2020, Ghannoum et al., 2019). 
Additionally, it has been shown to successfully inhibit both C. albicans and C. 
glabrata biofilms (Marcos-Zambrano et al., 2017). Although they may not be fully 
accepted or even diagnosed during RVVC, this drug may allow for treatment of 
Candida biofilms in the vagina, significantly reducing rates of failed treatment and 
subsequent recurrence. 
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Finally, another key finding from this study was evidence of the presence of Candida 
biofilms in the vagina during RVVC. Although the study design did not include 
collection of vaginal biopsies to directly imagine Candida biofilms on vaginal 
mucosa, we have shown various indicators of biofilm formation. Data in Chapter 3 
shows microscopic images of C. albicans free-floating aggregates and hyphal 
formation in patient lavage fluid. Dissemination of biofilm to free-floating aggregates 
has been shown previously and these encapsulated communities of cells have the 
propensity to display increased virulence and resistance to antifungals (Uppuluri et 
al., 2010, Wall et al., 2019). Additionally, Candida clinical isolates in this study were 
capable of heterogeneous biofilm formation, displaying increased tolerance to azole 
treatments as sessile cells. This has been shown previously in clinical isolates of 
VVC, further strengthening the potential for these isolates to form biofilms in vivo 
(Sherry et al., 2017). Unlike in VVC, Gardnerella vaginalis biofilm formation during 
BV is well-defined and accepted to cause increased antimicrobial tolerance 
requiring more aggressive treatment (Patterson et al., 2007a, McMillan et al., 2011). 
Despite visualisation of C. albicans biofilms both in vivo and ex vivo in murine 
models of VVC (Harriott et al., 2010b), the presence of these biofilms is largely 
disputed (Swidsinski et al., 2019). Although formation of these biofilms could be a 
source of the failed treatment reported in practice, there are no FDA-approved 
treatments appropriate to diagnose or treat them. Additionally, the dismissal of their 
presence by authors in the field has resulted in a lack of clinical studies assessing 
biofilm formation in RVVC of a similar scale to those carried out for BV (Swidsinski 
et al., 2019). Acceptance of the presence of Candida biofilms on vaginal mucosa 
during VVC/RVVC would allow for more appropriate considerations for antifungal 
treatment, potentially reducing both recurrence rates and rates of development of 
azole-resistance in the community. 
 
 
6.3 The functional capacity of Lactobacillus species is lost during RVVC 
Analysis of the microbiome through 16S rRNA sequencing of all clinical samples in 
Chapter 4 allowed for identification of subtle, key differences in bacterial species 
present during health and RVVC. Data comparing the two cohorts found similar 
Lactobacillus-dominated bacterial profiles at family and genus-level, with notably 
lower levels of H2O2-producing lactobacilli including L. crispatus and L. jensenii in 
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RVVC samples. It has been hypothesised, based on the microbiome observed 
during BV, that levels of Lactobacillus are reduced or absent during VVC (Fredricks 
et al., 2005). Although few studies of the vaginal microbiome during RVVC exist, 
they have failed to observe evidence of an altered microbiome during VVC/RVVC, 
disproving this theory (Zhou et al., 2009a, McClelland et al., 2009). These studies 
resulted in the conclusion that lactobacilli species do not contribute to protection 
from VVC/RVVC. However, the findings in this thesis show that although overall 
levels of Lactobacillus are not altered. the functional capacity of key species is lost 
during RVVC. The presence of high levels of L. iners seen in patients with RVVC is 
thought to be indicative of dysbiosis due to its lack of protective capabilities. 
Although very few studies have investigated bacterial species present during health 
and VVC, similar findings have been shown (Ceccarani et al., 2019). Protection by 
L. crispatus is owed to its high metabolic consumption of glycogen to lactic acid 
reducing vaginal pH, as well as its ability to produce H2O2, and both isomers of lactic 
acid (Amabebe and Anumba, 2018, Foschi et al., 2017, Witkin et al., 2013). The 
efficacy of L. crispatus to inhibit C. albicans growth and biofilm formation has been 
demonstrated (Wang et al., 2017, Jang et al., 2019). Further investigation of this 
interkingdom interaction using large-scale clinical studies of VVC could lead to the 
use of L. crispatus as a probiotic intervention for VVC treatment. Currently, few 
clinical studies assessing the microbiome of women with VVC/RVVC using 16S 
rRNA sequencing exist. As sequencing technologies develop and bacterial 
identification to species-level becomes more accurate, it may be possible to fully 
elucidate key Lactobacillus species which protect against VVC/RVVC. A greater 
understanding of the importance of these species would lead to a deeper knowledge 
of RVVC pathogenesis and potentially allow for the development of targeted 
treatments and sophisticated probiotic therapies. Additionally, identification of 
important lactobacilli would allow for investigation of interactions of these species 
with Candida to exploit mechanisms of the pathogenic switch resulting in VVC onset. 
 
Another key finding from data in Chapter 4 was that those suffering from RVVC 
using hormonal contraceptives had a bacterial profile similar to that of healthy 
women. The shift towards dysbiosis to favour L. iners and lower L. crispatus levels 
seen in women using contraceptive devices or no contraceptives was not observed 
in patients using hormonal preventatives. Onset of VVC is associated with increased 
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levels of oestrogen, suggesting a potential predisposition to disease due to 
hormonal contraceptives, however no clear link has been identified (Geiger and 
Foxman, 1996). Although it has been suggested that women suffering from frequent 
episodes of VVC should switch to a progestogen-only (synthetic form of 
progesterone) contraceptive to prevent VVC onset due to high oestrogen levels 
(Dennerstein, 1986), data in this study suggests potential protection from disease 
by hormonal contraceptives. Although literature surrounding association between 
contraceptive use and VVC is limited, two studies investigating the impact of 
contraceptives on BV onset found either no change or a negative correlation 
associated with use of hormonal contraceptives and disease (Achilles et al., 2018, 
Vodstrcil et al., 2013). Additionally, no protection from dysbiosis was observed in 
women using contraceptive devices. Previous studies have shown IUDs to facilitate 
Candida biofilm formation in the vagina in vivo, potentially predisposing these 
women to persistent RVVC (Chassot et al., 2008, Auler et al., 2010). The potential 
regulatory role of oestrogen provided by hormonal contraceptives requires further 
investigation to determine whether prescription of hormonal contraceptives may 
prevent future recurrence of vaginal diseases. Similar to the increased fungal load 
in patients who were treated over one week before sampling observed in Chapter 
3, the microbiome of these women was found to be more dysbiotic than those 
treated more recently. Very few studies compare the vaginal microbiome before and 
after VVC treatment. One study observed an atypical bacterial profile somewhat 
similar to health following antifungal treatment, suggesting this may be an 
intermediate state between health and VVC (Liu et al., 2013b). Additionally, this 
study observed women with RVVC for longer to have more dysbiotic microbiomes. 
Collectively, these data suggest current antifungal therapies for VVC are insufficient 
to re-establish a healthy microbiome, resulting in a risk of reverting to a pathogenic 
profile. More studies investigating the longitudinal bacterial profiles throughout 
different treatment regimens are required to fully elucidate the role of the 
microbiome during VVC. 
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6.4 The importance of vaginal probiotic Lactobacillus 
A key finding of data in Chapter 5 was the probiotic ability of Lactobacillus species, 
particularly L. rhamnosus, to inhibit C. albicans biofilm formation. Notably, this effect 
was diminished or absent when added to pre-formed C. albicans biofilms. This may 
mean that Lactobacillus probiotics would be ineffective for VVC treatment if C. 
albicans biofilms have formed on vaginal mucosa. This data supports the use of 
Lactobacillus probiotics as an adjuvant therapy used in combination with antifungal 
therapies (Martinez et al., 2009, Strus et al., 2005). However, in an in vivo setting, 
C. albicans may not form as a confluent biofilm as seen in vitro, therefore making it 
more susceptible to probiotic interventions. Although it is not commensal to the 
vaginal microbiome, L. rhamnosus is capable of transient colonisation which may 
allow it to modify the microbial community to favour health (Colodner et al., 2003). 
Additionally, data from this chapter observed a lack of C. albicans biofilm inhibition 
by the non-protective vaginal commensal, L. iners (Petrova et al., 2017). 
Collectively, these data support the use of Lactobacillus probiotics, using species 
such as L. rhamnosus and L. crispatus, for the treatment of VVC but also note 
potential failure to eradicate fungal load due to formation of thick, confluent biofilm 
layers on vaginal mucosa. 
 
Although L. rhamnosus has been extensively studied for its probiotic activity against 
C. albicans, Chapter 5 utilised RNA sequencing to assess the molecular 
interactions between L. crispatus, and C. albicans to examine the probiotic potential 
of a health-associated vaginal commensal. L. crispatus has been shown to inhibit 
C. albicans biofilm formation and promote stability of the healthy vaginal microbiome 
(Antonio et al., 1999, Verstraelen et al., 2009). Data from this experiment revealed, 
for the first time, a potential α-amino acid biosynthesis and amino acid starvation 
driven mechanism by which L. crispatus may out-compete C. albicans to re-
establish a healthy vaginal microbiome. This process of up-regulating genes 
involved in amino acid biosynthesis such as HIS5, ARG3 and LEU42 whilst 
downregulating CAR1 and CAR2, involved in breakdown, allows for an extracellular 
accumulation of amino acids which can be utilised for metabolism by L. crispatus. 
Additionally, it was noted that the two microbes did not begin to interact until 24 h of 
incubation, likely owed to building levels of secreted metabolites of L. crispatus, as 
shown previously (Ogunshe et al., 2011). This result means it may be beneficial for 
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daily addition of L. crispatus probiotics for the treatment of VVC to allow inhibitory 
effects to occur. Further research to elucidate the influence of secreted metabolites 
such as bacteriocins and H2O2, as well as other Candida and Lactobacillus species, 
are required to fully understand the observed antagonism between these microbes 
in the vaginal environment. A greater depth of knowledge would uncover the 
feasibility of Lactobacillus probiotics in the in vivo setting and potentially lead to the 
development of more appropriate therapies to recover a healthy vaginal microbiome 
during VVC. 
 
Another important conclusion from Chapter 5 was the ability of L. crispatus to 
reduce C. albicans composition within a polymicrobial biofilm model. This is the first 
report of C. albicans biofilm reduction by L. crispatus in an in vitro polymicrobial 
biofilm setting. A similar reduction has been shown previously using mono-species 
C. albicans biofilms (Rizzo et al., 2013, Wang et al., 2017, Li et al., 2019). Despite 
various studies investigating C. albicans biofilm reduction by probiotic Lactobacillus 
species, the mechanism of this reduction remains largely unknown. Pre-treatment 
of human epithelial cells with L. crispatus has been shown to maintain immune 
homeostasis by reducing inflammatory biomarker expression as well as C. albicans 
adhesion and virulence (Rizzo et al., 2013, Li et al., 2019). Further transcriptomic 
studies are required to fully elucidate the mechanisms governing recorded 
antagonism between different Candida and Lactobacillus species which could lead 
to the development of novel probiotic therapies or augment current therapies to treat 
VVC. Collectively, the data from Chapter 5 exploits a potential mechanism by which 
L. crispatus strongly supports the use of Lactobacillus probiotics for the positive 
modulation of the vaginal microbiome during VVC. 
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6.5 Future work 
Work from this thesis has identified key caveats in our knowledge pertaining to the 
formation of Candida biofilms on vaginal mucosa during RVVC and the interactions 
between Candida and Lactobacillus. Additionally, it provides a foundation for future 
studies to further investigate the presence of Candida biofilms during RVVC in vivo. 
Vaginal biopsies collected as part of large-scale clinical studies designed to 
visualise Candida biofilm formation should be conducted to conclude their 
importance in RVVC. Further, the microbial populations identified in this PhD study, 
and others, could be used to create an in vitro biofilm model representative of VVC 
which would allow for high-throughput assessment of novel therapeutics and 
compositional analyses. Finally, this study provides the foundation for a greater 
understanding of antagonism between C. albicans and L. crispatus through further 
investigation of the α-amino acid biosynthesis/starvation response identified here. 
Collectively, these findings could greatly improve our understanding of the microbial 
fluctuations leading to RVVC onset, identify the need for specific biofilm treatments 
for RVVC, and lead to the development of more appropriate therapeutics for women 
with recurrent, resistant episodes. 
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6.6 Concluding remarks 
In conclusion, the work from this thesis has investigated the role of Candida biofilm 
formation, the influence of bacterial populations, and important interactions between 
Candida and Lactobacillus during RVVC through a range of microbiological, 
immunological and metagenomic approaches. It is important to note that, whilst 
most episodes of VVC can be treated with current azole therapies, high levels of 
recurrence remain. These debilitating recurrent cases greatly impact women’s 
mental health and have a significant burden on the global economy. Until the 
controversy pertaining to Candida biofilm formation on vaginal mucosa and the 
efficacy of Lactobacillus probiotics is resolved, treatment options will remain limited 
to often unsuccessful, prolonged suppressive therapies. 
 
The key findings of this PhD study are outlined below. A graphical illustration of 
important features identified by the clinical study in this thesis can be found in Figure 
6.1. 
• Clinical samples collected from patients with RVVC show evidence of 
Candida biofilm formation which could greatly impact clinical outcome. 
 
• Specific health-associated Lactobacillus species including L. crispatus and 
L. jensenii are gradually replaced by L. iners during RVVC. 
 
 
• L. crispatus utilises an α-amino acid biosynthesis/starvation driven 
mechanism to reduce C. albicans within an in vitro biofilm model which may 
allow it to re-establish a healthy microbiome. 
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Figure 6.1: Graphical illustration of the key findings of this PhD study. Chapter 3 found 
an increased fungal load and expression of pro-inflammatory cytokines to be associated 
with RVVC. Further, data in this chapter displayed strong evidence of Candida biofilm 
formation during RVVC including biofilm-related gene expression, ability to form biofilms in 
vitro and visualisation of yeast aggregates in lavage fluid. Chapter 4 identified a 
Lactobacillus-dominated community with low levels of vaginal anaerobes in both cohorts, 
with a reduction of protective Lactobacillus species in RVVC. Data in Chapter 5 identified 
an α-amino acid driven mechanism by which L. crispatus can maintain health during 
colonisation with C. albicans, which is lost during disease. Created with Biorender.com.
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Appendix i: Patient information sheet (Health) 
 
Participant Information Sheet (Health group) 
An investigation of recurrent vaginal candidiasis (thrush)– how do 
microorganism communities contribute towards infections? 
 
 
You are being invited to take part in a research study at the Sandyford Sexual 
Health Service. Contact details:  
 
Dr Rebecca Metcalfe 
Specialist Registrar, Sexual Health & HIV 
Sandyford Sexual Health Service 
2-6 Sandyford Place 
Glasgow, G3 7NB 
Tel:0141 211 8130 
 
 
Before you decide whether or not to take part, it is important for you to 
understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study 
if you wish. Contact us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part. 
This is a joint study with NHS Greater Glasgow & Clyde and the School of 
Medicine at the University of Glasgow. 
 
 
What is the purpose of the study? 
To find out if communities consisting of bacteria and fungi, also known as biofilms, 
are present in the vagina, and if they contribute to recurrent vaginal thrush. This will 
be assessed using standard laboratory culture techniques and cutting-edge 
molecular biology methods. 
 
Why have I been asked to take part? 
You have been chosen as you are having an intrauterine device (coil) inserted and 
will serve as a healthy control for this study. Approximately 30% of healthy women 
have fungal communities without active thrush; therefore if it is detected in your 
sample there is nothing to worry about. If your sample does not contain the fungal 
community, no further analysis will be carried out on it. We aim to recruit 60 patients 
with thrush and 60 healthy controls from women who have a coil inserted into this 
study. 
 
 
Do I have to take part? 
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No, it is up to you to decide whether or not to take part. If you do decide to take part, 
you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are still free to withdraw at any time and without giving 
a reason. If you decide not to take part, it will not affect the healthcare that you 
receive in any way. 
 
What will happen if I take part? 
After consenting to take part, you will get ready to be examined as normal. Before 
the usual examination, you will have one swab sample taken from your vagina and 
a vaginal wash will be carried out; this means the doctor will put 5 ml (a teaspoon) of 
sterile water around the vagina to ‘wash’ the area and then remove it all. These tests 
will take about 2 minutes to complete. This sampling process will not cause any 
further discomfort than routine sampling. This will be done before the intrauterine 
device insertion. These samples are purely for research purposes and do not support 
your care. If during examination the clinician detects an infection, you will be informed 
and given appropriate treatment.  
 
The samples that are taken will be analysed anonymously at the School of Medicine, 
University of Glasgow – there will be no way of identifying you or any individuals from 
the samples.  
 
What are the possible benefits of taking part? 
You may not get a direct benefit from taking part in this study, however it will help us 
to find out whether fungal communities are related to recurrent vaginal thrush. This 
may benefit patients in the future with better management of this condition. 
 
What are the possible disadvantages and risks of taking part? 
There should be no disadvantages or risks from taking part. The tests are safe and 
should not cause you any more discomfort than the routine examination you will be 
having today. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone‘s negligence, then you may have grounds for a legal 
action for compensation against NHS Greater Glasgow & Clyde but you may have 
to pay your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate). 
 
What happens when the study is finished? 
The findings will be published in scientific journals and presented at scientific 
conferences. You will not be identified in any report or publication. If you would like 
to know the outcome of the results from your tests, please contact Dr Rebecca 
Metcalfe on the contact details below. 
 
Will my taking part in the study be kept confidential? 
All the information we collect during the course of the research will be kept 
confidential and there are strict laws, which safeguard your privacy at every stage. 
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Your name will be removed from the data and you will be given a unique number so 
that you cannot be recognised from the data. 
 
Who has reviewed the study? 
This study has been reviewed by NHS Greater Glasgow & Clyde Research and 
Development Management Office. In addition, all research in the NHS is looked at 
by an independent group of people, called a Research Ethics Committee, to protect 
your interests. 
 
 
If you have any further questions about the study please contact: 
Dr Rebecca Metcalfe 
Specialist Registrar Sexual Health & HIV 
Sandyford Sexual Health Service 
2-6 Sandyford Place 
Glasgow, G3 7NB 
Tel:0141 211 8130 
 
 
 
 
If you wish to make a complaint at any stage please contact: 
 
Complaints Team 
Glasgow City CHP – North West Sector J B Russell House 
Gartnavel Royal Hospital 
1055 Great Western Road  
Glasgow G12 0XH  
0141 211 0370  
 
 
Thank you for reading this information and considering taking part in 
this research study. 
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Appendix ii: Patient information sheet (RVVC) 
 
Participant Information Sheet (RVVC group) 
An investigation of recurrent vaginal candidiasis (thrush)– how do 
microorganism communities contribute towards infections? 
 
 
You are being invited to take part in a research study at the Sandyford Sexual 
Health Service. Contact details:  
 
Dr Rebecca Metcalfe 
Specialist Registrar, Sexual Health & HIV 
Sandyford Sexual Health Service 
2-6 Sandyford Place 
Glasgow, G3 7NB 
Tel:0141 211 8130 
 
Before you decide whether or not to take part, it is important for you to 
understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study 
if you wish. Contact us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part. 
This is a joint study with NHS Greater Glasgow & Clyde and the School of 
Medicine at the University of Glasgow. 
 
 
What is the purpose of the study? 
To find out if communities consisting of bacteria and yeast, also known as biofilms, 
are present in the vagina, and if they contribute to recurrent vaginal thrush. This will 
be assessed using standard laboratory culture techniques and cutting-edge 
molecular biology methods. 
 
Why have I been asked to take part? 
You have been chosen as you currently suffer from vaginal thrush. We aim to 
recruit 60 patients with thrush and 60 healthy controls from women who have a coil 
inserted into this study. 
 
 
We aim to include 120 patients in this study. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are still free to withdraw at any time and without giving 
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a reason. If you decide not to take part, it will not affect the healthcare that you 
receive in any way. 
 
What will happen if I take part? 
After consenting to take part, you will get ready to be examined as normal. Before 
the usual examination, you will have one swab sample taken from your vagina and 
a vaginal wash will be carried out; this means the doctor will put 5 ml (a teaspoon) of 
sterile water around the vagina to ‘wash’ the area and then remove it all. The tests 
will take about 2 minutes to complete. This sampling process will not cause any 
further discomfort than routine sampling.  This will be done after any other samples 
the doctor wants to take. These samples are purely for research purposes and do 
not support your care. 
 
The samples that are taken will be analysed anonymously at the School of Medicine, 
University of Glasgow – there will be no way of identifying you or any individuals from 
the samples. In addition, if you are having a routine swab taken, it will be analysed 
by NHS GG&C as usual and the results shared with the research group at the 
University of Glasgow. Again, at no point will you be identifiable by these samples.  
 
What are the possible benefits of taking part? 
You may not get a direct benefit from taking part in this study, however it will help us 
to find out whether fungal communities are related to recurrent vaginal thrush. This 
may benefit patients in the future with better management of this condition. 
 
What are the possible disadvantages and risks of taking part? 
There should be no disadvantages or risks from taking part. The tests are safe and 
should not cause you any more discomfort than the routine examination you will be 
having today. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone‘s negligence, then you may have grounds for a legal 
action for compensation against NHS Greater Glasgow & Clyde but you may have 
to pay your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate). 
 
What happens when the study is finished? 
The findings will be published in scientific journals and presented at scientific 
conferences. You will not be identified in any report or publication. If you would like 
to know the outcome of you personal results please contact Dr Rebecca Metcalfe on 
the contact details below. 
 
Will my taking part in the study be kept confidential? 
All the information we collect during the course of the research will be kept 
confidential and there are strict laws, which safeguard your privacy at every stage. 
Your name will be removed from the data and you will be given a unique number so 
that you cannot be recognised from the data. 
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Who has reviewed the study? 
This study has been reviewed by NHS Greater Glasgow & Clyde Research and 
Development Management Office. In addition, all research in the NHS is looked at 
by an independent group of people, called a Research Ethics Committee, to protect 
your interests. 
 
 
If you have any further questions about the study please contact: 
Dr Rebecca Metcalfe 
Specialist Registrar Sexual Health & HIV 
Sandyford Sexual Health Service 
2-6 Sandyford Place 
Glasgow, G3 7NB 
Tel:0141 211 8130 
 
 
 
 
If you wish to make a complaint at any stage please contact: 
 
Complaints Team 
Glasgow City CHP – North West Sector J B Russell House 
Gartnavel Royal Hospital 
1055 Great Western Road  
Glasgow G12 0XH  
0141 211 0370  
 
 
Thank you for reading this information and considering taking part in 
this research study. 
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Appendix iii: Patient consent form 
 
CONSENT FORM 
 
Title of Project: An investigation of recurrent vaginal candidiasis (thrush)– how do 
microorganism communities contribute towards infections? 
 
 
 
Name of Researcher: ……………………………………………………………….. 
 
Please initial box -   
 
I confirm that I have read and understand the patient information sheet dated Version 
06, 08/02/2017) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
I understand that my participation is voluntary and that I am free to refuse sampling 
or withdraw from the study at any time without giving any reason and without my 
medical care or legal rights being affected.  
 
I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by regulatory authorities or from the NHS organisation, where 
it is relevant to my taking part in this research. I give permission for these individuals 
to have access to my records. 
 
I agree to my data being transferred in an anonymised form from NHS Greater 
Glasgow & Clyde to the School of Medicine (University of Glasgow) for analysis. This 
includes the identification of the organism within my samples. 
 
 
I agree to take part in the above study.  
 
 
Name of Patient …………………………………………..   Date…………………  
 
Signature ………………………………………………….. 
 
Name of Person taking consent………………………….  Date………………….  
 
Signature …………………………………………….  
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes. 
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Appendix iv: Patient questionnaire 
 
PATIENT QUESTIONNAIRE 
 
 
Title of Project: An investigation of recurrent vaginal candidiasis (thrush)– how do 
microorganism communities contribute towards infections? 
 
 
 
Please answer the following questions to the best of your knowledge -  
 
 
1. How many times have you suffered from vaginal thrush within the last year? 
 
 
………………………………………………………………………………... 
 
 
 
2. What products have you used to help treat this infection e.g. Canestan? 
 
 
………………………………………………………………………………... 
 
 
 
3. When was the last time you treated this infection? 
 
 
………………………………………………………………………………... 
 
 
 
4. Are you currently on any contraception? If so, what kind? 
 
 
………………………………………………………………………………... 
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Appendix v: C. albicans SC5314 standard curve for qPCR calculations 
 
 
Appendix vi: E. coli K12 standard curve for qPCR calculations 
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Appendix vii: Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom 
Biofilm Disease of Candida and Lactobacillus 
RESEARCH ARTICLE 
 
Recurrent Vulvovaginal Candidiasis: a Dynamic 
Interkingdom Biofilm Disease of Candida and 
Lactobacillus 
Emily McKloud,a Christopher Delaney,a Leighann Sherry,b Ryan Kean,c Shanice 
Williams,a Rebecca Metcalfe,d Rachael Thomas,d Riina Richardson,e Konstantinos 
Gerasimidis,a Christopher J. Nile,f Craig Williams,a Gordon Ramagea 
 
aSchool    of    Medicine,    Dentistry    and     Nursing,     College     of     Medical,     Veterinary     and     Life     
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Health, University of Manchester, Manchester, UK fSchool of Dental Sciences, University of Newcastle, Newcastle 
upon Tyne, UK 
Emily McKloud and Christopher Delaney contributed equally to this work. Author order was determined by drawing straws. 
 
ABSTRACT Despite the strikingly high worldwide 
prevalence of vulvovaginal can- didiasis (VVC), 
treatment options for recurrent VVC (RVVC) remain 
limited, with many women experiencing failed 
clinical treatment with frontline azoles. Further, the 
cause of onset and recurrence of disease is largely 
unknown, with few studies identifying potential 
mechanisms of treatment failure. This study aimed 
to assess a panel of clinical samples from healthy 
women and those with RVVC to investi- gate the 
influence of Candida, the vaginal microbiome, and 
how their interaction influences disease pathology. 
16S rRNA sequencing characterized disease by a 
reduction in specific health-associated Lactobacillus 
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species, such as Lactobacillus crispatus, coupled with 
an increase in Lactobacillus iners. In vitro analysis 
showed that Candida albicans clinical isolates are 
capable of heterogeneous biofilm forma- tion, and 
we found the presence of hyphae and C. albicans 
aggregates in vaginal lavage fluid. Additionally, the 
ability of Lactobacillus to inhibit C. albicans biofilm 
formation and biofilm-related gene expression was 
demonstrated. Using RNA sequencing technology, 
we were able to identify a possible mechanism by 
which 
L. crispatus may contribute to re-establishing a 
healthy vaginal environment through amino acid 
acquisition from C. albicans. This study highlights 
the poten- tial formation and impact of Candida 
biofilms in RVVC. Additionally, it suggests that RVVC 
is not entirely due to an arbitrary switch in C. 
albicans from commensal to pathogen and that 
understanding interactions between this yeast and 
vaginal Lactobacillus species may be crucial to 
elucidating the cause of RVVC and develop- ing 
appropriate therapies. 
IMPORTANCE RVVC is a significant burden, both 
economically and for women's health, but its 
prevalence is poorly documented globally due to the 
levels of self- treatment. Identifying triggers for 
development and recurrence of VVC and the 
pathogenesis of the microbes involved could   
considerably   improve   prevention and treatment 
options for women with recurrent, azole-resistant 
cases. This study therefore aimed to examine the 
interkingdom dynamics from healthy women and 
those with RVVC using next-generation sequencing 
techniques and to further investigate the molecular 
interactions between C. albicans and L. crispatus in 
a rel- evant biofilm coculture system. 
KEYWORDS antifungal resistance, biofilm, Candida, clinical, interkingdom, 
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F 
 
ungal infections are becoming increasingly recognized as a 
substantial health bur- den on the global population. Over 1 billion 
people are estimated to suffer from fungal infections each year, 
resulting in over 1.5 million deaths (1). These infections are 
commonly associated with mucosal sites, such as the vagina, gut, 
and oral cavity. Vaginitis is estimated to account for up to 7% of 
all visits to gynecologists and for up to 10 million general 
practitioner (GP) appointments annually (2). Vulvovaginal candi- 
diasis (VVC) is not a reportable disease and is often self-treated 
with over-the-counter antifungal agents; therefore, its exact 
prevalence and distribution are impossible to determine. VVC is 
reported as the second most common cause of vaginitis, and it 
is estimated that 75% of women will suffer from VVC in their 
childbearing years, with up to 140 million of these women 
developing recurrent VVC (RVVC), defined as $4 cases within 1 
year (3, 4). These recurrent cases are debilitating, impact quality 
of life, and are associated with psychological stress, pruritis, and 
discomfort (5, 6). VVC is associ- ated with various risk factors, 
including the use of antibiotics and contraceptives, new sexual 
partners, and allergic responses to Candida antigens; however, 
no distinguish- 
able cause has been identified (7, 8). 
The biofilm-forming yeast Candida albicans is reported as the 
predominant patho- gen responsible for up to 90% of VVC infections 
(4). C. albicans is commonly isolated from the vagina as an 
asymptomatic commensal with a carriage rate of up to 33% in 
premenopausal women (9). Other non-albicans Candida (NAC) 
species, most com- monly Candida glabrata, C. parapsilosis, C. 
dubliniensis and C. krusei, account for 10 to 20% of VVC infections 
and are associated with complicated VVC, which exhibits less severe 
symptoms than C. albicans VVC but higher recurrence rates (10, 11). 
C. albicans has been shown to form biofilms on vaginal mucosa both 
ex vivo and in vivo by identi- fication of significant fungal load, biofilm 
architecture, and extracellular matrix using confocal and electron 
microscopy (12). This is a possible contributing factor to failed 
clinical treatment resulting in persistent and recurrent VVC. 
Despite the identification of Candida biofilms on vaginal mucosa, the 
predicted therapeutic challenge this presents in VVC is still disputed. 
Other studies challenge the hypothesis of vaginal bio- films and 
instead suggest other factors, such as germ tube formation and 
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polymicro- bial tissue invasion, as more critical features of VVC (13, 
14). 
The vaginal microbiome is somewhat unique in that a healthy 
microbiome is associ- ated with a less diverse community of 
microbes, predominantly lactobacilli such as Lactobacillus crispatus, 
L. iners, L. gasseri, and L. jensenii (15). Dysbiosis of the vaginal 
microbiome leads to an increase in species diversity, with fewer 
lactobacilli and greater numbers of pathogenic anaerobes, such as 
Gardnerella and Prevotella (16, 17). In healthy women, lactic acid 
bacteria (LAB) are thought to be responsible for maintain- ing a 
homeostatic microbiome by inhibiting growth and adhesion of 
other microbes via the production of secreted metabolites, such as 
lactic acid, biosurfactants, bacterio- cins, and H2O2. L. crispatus, a 
potent producer of both D- and L- isomers of lactic acid as well as 
H2O2, is a prevalent commensal of the healthy vaginal environment 
in various microbiome studies (18, 19). Additionally, it is known to 
secrete the L-lactic acid isomer that has been extensively studied for 
its ability to lower vaginal pH, elicit anti-inflam- matory responses, 
and inhibit microbial colonization (20, 21). 
A single dose of oral fluconazole is sufficient to treat sporadic C. 
albicans VVC in 80 to 90% of cases (22). Treatment of VVC caused by 
NAC is more complicated, requiring pro- longed suppressive azole 
therapies, and is often unsuccessful. The efficacy of therapeutics such 
as amphotericin B and boric acid has been assessed for the 
treatment of RVVC. Both drugs when delivered intravaginally for 14 to 
21 days were found to be effective in around 70% of patients (23, 
24). Candida species, predominantly C. albicans, are known to form 
thick tenacious biofilms that dramatically increase tolerance to 
antifungal drugs commonly used in the treatment of VVC, such as 
fluconazole, miconazole, and flucytosine (25). Indeed, sessile cells 
have been shown to tolerate antifungal concentrations 1,000- fold 
greater than their planktonic counterparts (26). Therefore, an 
alternative therapeutic strategy for RVVC may be through 
microbiome replacement therapy in the form of 
 
July/August 2021    Volume 6    Issue 4    e00622-21 msystems.asm.org    2 
Interactions of Candida and Lactobacillus in RVVC 
 
211 
 
 
Lactobacillus probiotics (27). Probiotic therapy involves the 
administration of live microorganisms, which directly results in a 
health benefit for the patient (28). Due to the diversity of 
lactobacilli within the vaginal microbiome, it is difficult to estimate 
which species would be most important to replace with probiotic 
therapy. One study evaluated Lactobacillus plantarum P17630 
combined with the standard treatment of clotrimazole for 3 days 
and concluded a potential resolution of vaginal discomfort (29). 
The probiotic potential of secreted metabolites of Lactobacillus 
against C. albi- cans has been summarized, identifying gaps in our 
knowledge of fungal-Lactobacillus interactions that could lead to 
improved treatment options (30–33). Currently, no probiotic 
therapies have been approved for the treatment of VVC/RVVC. 
Clearly, RVVC is a significant burden, both economically and for 
women’s health, and its prevalence is poorly documented globally 
due to the levels of self-treatment. Identifying triggers for 
development and recurrence of VVC and the pathogenesis of the 
microbes involved could considerably improve prevention and 
treatment options for women with recurrent, azole-resistant cases. 
This study therefore aimed to examine the interkingdom dynamics 
in healthy women and those with RVVC using next-genera- tion 
sequencing techniques and to further investigate the molecular 
interactions between C. albicans and L. crispatus in a relevant 
biofilm coculture system. 
 
RESULTS 
Clinical and microbiological assessment of patient samples. 
The mechanisms behind the shift in candidal species from 
commensal to pathogenic yeast seen in RVVC onset remain poorly 
understood. The cause of infection is likely multifactorial, and here, 
we aimed to assess whether fungal or bacterial load may influence 
disease by using samples collected from healthy individuals (n = 
60) and women with RVVC (n = 40). Clinical assessment was used 
to confirm RVVC diagnosis, which was further validated by 
significantly increased interleukin 8 (IL-8) expression levels (P , 
0.0001) (Table S1). Patient demographic data collected through 
questionnaires found that patients had suffered   from RVVC for 
an average of 8 months,   with an average of 1 month since they 
last received treatment. Although higher numbers of women with 
RVVC had culturable Candida than healthy women, quantitative PCR 
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(qPCR) analysis revealed Candida to be detectable in all but 2 
patients. 
First, the levels of Candida present in the clinical samples were 
quantified by deter- mining numbers of CFU per milliliter, in addition 
to total yeast and bacterial DNA quan- tified by qPCR colony-
forming equivalents (CFE) per milliliter (Fig. 1). Quantities of yeast 
CFU/ml showed a significant increase in Candida load in samples, 
from approxi- mately 2 x 103 CFU/ml in healthy patients to 2.3 
x 104 CFU/ml in RVVC patients (P = 0.0079) (Fig. 1a). Similarly, when 
assessed by qPCR, a significant increase of around 1.3-log was 
observed in patients with RVVC, to 3.8 x 105 CFE/ml (P = 0.024), as 
shown in Fig. 1b. These data suggest that increased levels of Candida 
could be a contributing factor to disease pathology or an indicator 
for VVC onset and subsequent recurrence. Additionally, Candida 
load was observed with respect to patient metadata. Although a 
slight reduction of between 0.5 and 1 log was observed in 
patients with disease for over 7 months, this was not significant 
(data not shown). An increase in fungal load from 1 x 104 to 5 x 104 
CFU/ml was observed in women who had received treatment for 
RVVC longer than 1 month prior to sample collection (P = 0.021) (Fig. 
S2). Bacterial load  was  found  to  be  comparable  at  ;8 x 107   
CFE/ml  between  healthy  women  and those with RVVC (P = 0.779) 
(Fig. 1c). Finally, correlation between bacterial and fungal load 
found significantly higher levels of Candida DNA per CFE/ml of 
bacterial DNA present in RVVC compared with healthy controls (P 
= 0.0001) (Fig. 1d). 
Taxonomic classification of health and RVVC. To determine the bacterial taxa 
present in healthy women and those with RVVC, we performed 
16S rRNA sequencing on DNA extracted from swab samples (Fig. 2). 
At the genus level, a Lactobacillus-domi- nated environment, 
accounting for up to 75% of the microbiome, was observed in 
both cohorts, with similar levels of diversity and the vaginal 
anaerobes Gardnerella and Prevotella (Fig. 2a and b). Atopobium 
was found to be slightly higher in healthy patients 
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FIG 1 Fungal burden is elevated in women with RVVC while bacterial load remains unchanged. To assess fungal 
load, patient lavage was incubated on Candida Chromogenic agar plates and colonies counted after 48 h (a). For 
calculation of CFE/ml, the ITS region of Candida was amplified using genus-specific primers (b). Levels of bacteria 
DNA were also  assessed molecularly by amplification of the 16S rRNA region  (c). Correlation between bacterial 
and fungal burden was also observed (d). Data are means 6 standard deviations (SD). Statistical significance was 
calculated using unpaired t tests with Welch’s correction, as data did not share equal standard deviations (*, P , 
0.05; **, P , 0.01). 
 
and Bifidobacterium slightly lower. A limitation of our microbiome 
analysis was the inability to distinguish between some Lactobacillus 
species (including Lactobacillus aci- dophilus, L. casei, and L. gasseri). 
For this reason, these species are grouped as “Lactobacillus spp., 
including L. crispatus.” However, sequencing of a subset of samples 
using the Oxford Nanopore Technologies MinION sequencer 
confirmed accuracy to the species level (Fig. S3) (34). When viewed 
at the species level, although not signifi- cant following P value 
correction, subtle differences in bacterial taxa were observed 
between healthy controls and RVVC, particularly among 
Lactobacillus species (Fig. 3). Most notable was the reduction in 
levels of specific Lactobacillus species. This included 
L. jensenii and to a greater extent L. crispatus, which fell from 44% 
in healthy patients to 30% in those with RVVC (Fig. 3a and b). 
Interestingly, this reduction was coupled with an increase in L. iners 
from just 19% in healthy samples to 40% in RVVC. Additionally, when 
predicted using random forest plots, levels of L. iners were sug- 
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gested to be the most distinct between samples from healthy 
women and those from women with RVVC (Fig. 3c). 
To investigate the influence of bacterial taxa further, microbial 
populations were observed with respect to patient metadata (Fig. 
4). In patients with culturable Candida compared with those who 
were culture negative, a reduction in Lactobacillus species including 
L. crispatus from 44% to 29%, coupled with an increase in L. iners 
from 23% to 35%, was observed, similar to the RVVC profile (Fig. 4a). 
Further, L. iners was predicted to be the second most likely organism 
to define presence or absence of Candida using ran- dom forest 
analysis to identify important features (Fig. 4c). When observed with 
respect to the length of time patients had had RVVC, an intermediate 
profile between health and disease was observed in patients with 
disease for less than 6 months, showing a slight reduction in L. 
crispatus from 45% to 40% (Fig. 4c). Conversely, patients with 
disease for between 6 and 12 months had a profile similar to that 
seen in RVVC, with increased levels 
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FIG 2 Bacterial genera present in healthy women and those with RVVC. DNA extracted from swab samples was used 
for 16S rRNA Illumina sequencing (n = 100). Bacterial diversity measured by Shannon index (a) and genus- level taxa 
identification and percentage abundance of microbial populations present (b) in health and RVVC. 
 
of L. iners from 19% to 44% (Fig. 4d). Additionally, bacterial 
communities present were observed with respect to contraceptives 
used at the time of sampling (Fig. S4). At the spe- cies level, a notable 
similarity in the composition of healthy patients and those using hor- 
monal contraception, in contrast to patients using a contraceptive 
device or no contra- ception, was observed. The most important 
feature identified at the species level was predicted to be 
Atopobium vaginae. It is predicted that this organism is present in 
higher numbers in healthy patients and those using hormonal 
contraceptives and lower num- bers in patients using either no 
contraception or contraceptive devices. Additionally, a contrasting 
pattern is shown for L. iners, which is predicted to be highest in 
patients using contraceptive devices. The microbiome was then 
observed with respect to how recently patients had received 
antifungal intervention to treat RVVC (Fig. S5). A gradual reduction in 
Lactobacillus species, including L. crispatus, was observed, from 44% 
in healthy samples to 34% and 23% in patients treated within a 
month and more than a month before sam- pling, respectively. 
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Patients treated more than 1 month before sampling were predicted 
to have an intermediate profile between those of healthy women 
and women treated for RVVC more recently. 
Finally, correlation between the vaginal microbiome and Candida 
load (CFE/ml) was observed with respect to patient metadata (Fig. 
S6). Megasphaera, often associated with vaginal dysbiosis, was 
found to be significantly positively correlated with increased 
fungal load (P , 0.05) (Fig. S6). Although not significant, genera such 
as Dialister, Bacteroides, and Shuttleworthia were correlated with 
higher fungal loads in RVVC. Further, Lactobacillus was significantly 
negatively correlated with Candida in healthy samples, and to a 
lesser extent in RVVC (P , 0.05). Although none were found to be 
significant, correlations observed with respect to recent 
treatment identified slight negative correlations between genera 
such as Streptococcus, Gardnerella, and Lactobacillus with 
increasing time since last RVVC intervention. Conversely, genera 
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FIG 3 Hydrogen peroxide-producing lactobacillus strains are reduced during RVVC infection, resulting in an L. iners-dominated microbiome. Species-level identification 
of bacterial taxa present in healthy women (a) and those with RVVC (b). Random forest plot showing the most distinct species-level taxa present between healthy 
women and those with RVVC (c). 
 
such as Prevotella, Morganella, and Sneathia were found to be positively correlated with 
increasing time since treatment. Streptococcus, Prevotella, and Clostridium were found to 
be positively correlated with increased RVVC episodes. However, genera such as 
Shuttleworthia, Lactobacillus, and Atopobium were found to be negatively correlated with 
increasing RVVC episodes. 
Influence of Candida biofilm formation in RVVC. Candida clinical isolates were 
obtained from lavage samples by culture on Candida chromogenic 
agar. Following incubation, a total of 33 isolates were obtained, 9 
from healthy individuals and 24 from patients with RVVC. Isolate 
identification was confirmed for all isolates using matrix- assisted 
laser desorption ionization–time of flight (MALDI-TOF) (Fig. 5a). 
Consistent with previous RVVC studies, C. albicans was found to 
account for 73% of the Candida species isolated within our patient 
subset. Other NAC species, more commonly associ- ated with RVVC, 
accounted for the remaining 27%. Following identification, biofilm 
forming capabilities of clinical isolates was assessed (Fig. 5b). C. 
D
o
w
n
lo
ad
ed
 f
ro
m
 h
tt
p
s:
//
jo
u
rn
al
s.
as
m
.o
rg
/j
o
u
rn
al
/m
sy
st
em
s 
o
n
 1
0
 A
u
g
u
st
 2
0
2
1
 b
y
 2
a0
2
:c
7
f:
8
e6
6
:a
a0
0
:5
d
b
3
:3
7
b
a:
8
1
3
f:
7
0
a4
. 
Interactions of Candida and Lactobacillus in RVVC 
 
218 
 
albicans was capable of forming dense biofilms with clear 
heterogeneity between isolates. Isolates were grouped as low 
biofilm formers (LBF) if the absorbance reading of their total 
biomass fell   below   the   first   quartile   (,0.185).   Similarly,   high   
biofilm   formers   (HBF)   were observed when total biomass was 
above the third quartile (.0.854). Intermediate bio- film formers 
(IBF) had biomass readings between these values. Minimal biomass 
was observed in NAC species. Additionally, when lavage fluid from 
an RVVC patient with a 
C. albicans isolate capable of dense biofilm formation was viewed microscopically, 
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FIG 4 Species-level  taxon  abundance relative to  patient  metadata. Species-level  bacterial  taxa based  on presence/absence  of  Candida (a) and length of time 
with disease (b). Random forest plots showing distinct bacterial taxa present in each analysis (c and d). 
 
hyphal forms and bacterium-yeast aggregates could be clearly 
observed (Fig. 5c). To further investigate and validate that Candida 
biofilms are a defined clinical entity, expression levels of key biofilm-
related genes were measured from patients’ vaginal la- vage fluid. 
These data show detectable levels of expression of genes involved 
in hyphal morphogenesis, biofilm formation, and pathogenesis in 
Candida isolates present in patients with RVVC, including HWP1, 
ECE1, ALS3, and SAP (Table S2). 
Antagonism of Lactobacillus and C. albicans. Next, to assess the interactions 
between Lactobacillus species and C. albicans, 7 Lactobacillus 
species were selected and their effects on C. albicans biofilm 
formation in coculture observed (Fig. 6). When grown together for 
24 h, a reduction in overall biomass was observed in all Lactobacillus 
species from an absorbance reading of 3.0 to approximately 2.5. This 
reduction was particularly prominent in Lactobacillus rhamnosus, 
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where biomass was reduced to an absorbance value of 2.0 (Fig. 6a). 
However, when C. albicans was allowed to form a biofilm before 
addition of Lactobacillus, this effect was less pronounced and in 
some cases absent (Fig. 6b). To further analyze the biomass 
reduction, C. albicans biofilm-related gene expression was 
assessed following coculture with L. rhamnosus and L. iners. L. 
rhamnosus is often studied for its probiotic effect against C. 
albicans. Although L. iners is a vaginal commensal, it has not been 
found to inhibit fungal growth or biofilm formation. The two 
organisms differentially interacted with C. albicans, with L. 
rhamnosus downregulat- ing all biofilm-related gene expression 
after incubation for 20 h and 24 h (Fig. 6c). Gene expression was 
reduced by ;4-fold for HWP1 and between 0.5- and 1-fold for ALS3  
and ECE1 in both growth conditions. L. iners downregulated 
expression of ECE1 and, to a 
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FIG 5 Vaginal Candida isolates from patients with RVVC are capable of heterogeneous biofilm formation. A total 
of 33 Candida clinical isolates were isolated from lavage samples. MALDI-TOF was used to identify each isolate and 
assess species distribution (“Others” comprises 1 isolate each of C. dubliniensis, C. parapsilosis, and 
C. krusei) (a). Candida isolates from healthy women (n = 9) and those with RVVC (n = 24) were assessed for biofilm-
forming capabilities by crystal violet staining (b). Vaginal lavage was stained with calcofluor white (CFW) for 1 h at 
37°C before imaging (c). Images are representative of C. albicans aggregates and hyphae observed in lavage fluid 
from a patient with an HBF isolate. White arrows represent pseudohyphal/hyphal formation, and red arrows 
depict cell aggregates. Data are means 6 SD. Statistical analysis was performed using unpaired t-tests (****, P , 
0.0001). 
 
lesser extent, HWP1 after incubation for 24 h. However, when added to a preexisting C. 
albicans biofilm, L. iners resulted in upregulation of ECE1 and ALS3. 
To further understand how antagonistic features of Lactobacillus impact C. albicans, we 
utilized transcriptome sequencing (RNA-Seq) of C. albicans following coculture with 
L. crispatus. L. crispatus was selected for RNA sequencing analysis, 
as opposed to L. rhamnosus, as it is not a commensal of the vaginal 
environment and is capable of only transient colonization. Further, 
L. crispatus is one of the most prevalent Lactobacillus species in the 
vaginal microbiome, and its antagonism toward C. albicans has been 
demonstrated in previous studies (31–33, 35). Initially, multivariate 
analysis by princi- pal-component analysis (PCA) was unable to 
identify distinct clusters of gene expres- sion in early dual-species 
biofilms (Fig. S8). Subsequently, there was no significant up- or 
downregulation in early dual-species biofilm transcripts compared 
to single-species controls (P . 0.05). For this reason, further 
analysis compared expression in mature 24- h single- and dual-
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species biofilms only. Heat map analysis of normalized log2 fold 
change in gene expression between single- and dual-species 24-h 
biofilms with L. crispatus revealed upregulation of many genes 
involved in amino acid biosynthesis and breakdown in dual-species 
biofilms (ARG8, ILV1, and HIS5) (Fig. 7). Interestingly, the PRY1 
gene, which codes for a secreted protein associated with virulence 
in the presence of lactate in C. albicans, was found to be 
downregulated in dual-species bio- films (log2 fold change = 25.35). 
A list of some of the key genes and their functions is presented in 
Table 1. Gene ontology (GO) term analysis was utilized to determine 
the functionality of differentially expressed genes in single- and 
dual-species 24-h biofilms. 
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FIG 6 Lactobacillus species display antagonism with C. albicans in vitro. To observe inhibitory effects of 
Lactobacillus against C. albicans biofilm formation, C. albicans and a panel of Lactobacillus species were 
cocultured in THB/RPMI (1:1) medium in 5% CO2 for 24 h (a), or C. albicans was grown for 4 h prior to 
addition of Lactobacillus species for 20 h (b). C. albicans biofilm-associated gene expression was measured 
in the presence of L. rhamnosus, which is associated with health, and L. iners, which is hypothesized to 
indicate dysbiosis. The mean log fold change relative to single species C. albicans biofilms is shown (c). Data 
are means and SD. 
 
Genes expressed in L. crispatus dual-species biofilms were mainly 
responsible for amino acid biosynthesis and some metabolic and 
transaminase activity (Fig. 8a and b). Despite upregulation of these 
amino acid biosynthesis and metabolism pathways in C. albicans, 
expression of BAT21 and ILV1 in dual-species biofilms suggests that 
C. albicans was in a state of amino acid starvation (Fig. 8c). 
Given the antagonism observed between the two organisms, we 
next aimed to investigate the in vitro probiotic potential of L. 
crispatus against C. albicans infection in a complex biofilm model 
(Fig. 9). After 2 consecutive days of probiotic treatment, a slight 
reduction in total and live C. albicans composition within the biofilm 
was observed; however, this was not significant (P = 0.55 and P = 
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0.16, respectively) (Fig. 9a and b). Following a 4-day treatment 
regimen with L. crispatus, total C. albicans compo- sition decreased 
(P , 0.05), with reduced levels of live fungal DNA. When the total 
fold reduction in C. albicans from untreated biofilms was assessed, 
the greatest probiotic effect was observed at 48 h posttreatment 
(Fig. 9c). 
 
DISCUSSION 
Unlike systemic and oral candidiasis, RVVC affects 
immunocompetent women with an incidence rate of up to 8% in 
women of child-bearing age; hence, it is the most 
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FIG 7 Differential expression analysis of C. albicans single-species and C. albicans–L. crispatus dual-species biofilms. Heat map displaying the top 50 
significantly differentially expressed genes in C. albicans between single- and dual-species 24-h biofilms (P , 0.05). 
 
prevalent human infection caused by the pathogenic yeast, with 
approximately 140 million cases annually (36). Despite this, the 
disease remains largely understudied in the field of women’s 
health. A better understanding of RVVC at a molecular level may 
be crucial in unearthing potential targets for much-desired 
therapeutics. This study aimed to assess a panel of 100 clinical 
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isolates to investigate fungal influence and changes in bacterial 
communities and to use an RNA sequencing approach to analyze 
potential interkingdom interactions contributing to pathology. 
Clinical and microbiological assessment of patient samples. The estimated vagi- 
nal commensal carriage rate of Candida is 33% (9). We observed the presence of 
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TABLE 1 Upregulated genes in 24-h dual-species biofilm associated with amino acid biosynthesis 
and/or breakdown 
 
Gene name 
 
Function 
Log2 fold 
change 
arg3 Arginine and citrulline biosynthesis 3.72897 
his5 Histidine biosynthesis 3.47441
5 
lys22 Lysine biosynthesis 3.46901
3 
bul1 Protein ubiquitination 3.25467
1 
arg4 Arginine biosynthesis/metabolism 2.81015
8 
atf1 N-Acetyltransferase activity 2.70428
1 
arg8 Arginine biosynthesis/metabolism 2.69588
5 
aro3 Phenylalanine, tyrosine, and tryptophan biosynthesis 2.41157
3 
his4 Histidine, purine, and pyrimidine biosynthesis 2.35265
4 
his3 Histidine, purine, and pyrimidine biosynthesis 2.34044
6 
bat21 Leucine, valine, and isoleucine biosynthesis/breakdown 2.28467
7 
ilv1 Leucine, valine, and isoleucine biosynthesis, threonine 
breakdown 
2.04984
5 
leu42 Leucine, valine, and isoleucine biosynthesis 1.94549
6 
 
 
Candida both by culture and by qPCR and found that 15% and 60% 
of samples from healthy women and those with RVVC had 
culturable Candida, respectively, and all but 2 samples were positive 
by qPCR. As expected, levels of the inflammatory biomarker IL-8 and 
Candida DNA were found to be significantly higher in patients with 
RVVC, con- firmatory of clinical diagnosis. It is important to note 
that these clinical samples are from women regularly attending 
sexual health clinics, and those who have suffered from RVVC for 
longer may be more likely to be receiving antifungal treatment. This 
should be considered when interpreting Candida CFE/ml data in this 
study, as untreated RVVC may present differently. 
Taxonomic classification of health and RVVC. Unlike the vaginal microbiome dur- 
ing bacterial vaginosis (BV), the microbial communities present 
during VVC have been shown to be similar to those present in 
healthy women at the phylum and genus levels (37, 38). Our study 
confirms these findings, as we report a Lactobacillus-dominated 
population with vaginal anaerobes, including Gardnerella, 
Prevotella, and Atopobium, with no significant differences in 
diversity or composition between the two cohorts at the genus level. 
This suggests that the functional capacity of the bacterial species 
found in healthy women and those with RVVC may play a more 
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crucial role in pathol- ogy. We observed a reduction in specific 
Lactobacillus species, including those associ- ated with maintaining 
health due to their ability to produce L-lactic acid and H2O2, such 
as L. crispatus and L. jensenii. This reduction coupled with an 
increase of L. iners has been shown previously and is thought to 
be indicative of vaginal dysbiosis (37). We report that this loss of 
health-associated Lactobacillus species and increase of L. iners is 
also seen specifically in patients with positive Candida cultures and 
those who have suffered from RVVC for .6 months. 
We show an L. iners-dominated microbiome in women using 
contraceptive devices or no contraception, which suggests that 
hormonal contraceptives may be less dysbiotic to the vaginal flora or 
have the potential to maintain a more health-like microbiome than 
contraceptive devices. Additionally, recent antifungal use revealed 
a microbial pro- file similar to those of healthy patients, suggesting 
that, although somewhat effective, the current antifungal 
treatments for RVVC do not alter the microbiome to a sufficient level 
to reintroduce a health-like state. This is evident with the 
microbiome reverting to favor a disease-like environment after less 
than 1 month. This is similar to results found by other authors, who 
reported a transition from disease to an intermediate state follow- 
ing fluconazole treatment (16). Although not associated with vaginal 
dysbiosis, the ge- nus Shuttleworthia was positively correlated with 
Candida load and increased time between treatments and is often 
observed in high levels in vaginal microbiome studies (39). 
Regardless of disease status, Lactobacillus was negatively correlated 
with the pres- ence of Candida as well as increased numbers of 
episodes and time between treatments, 
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FIG 8 Gene networks of gene ontology (GO) terms and upregulated genes in dual-species biofilms. Constructed gene networks of GO terms in 24-h biofilms 
with L. crispatus (a). Important biological, cellular, and molecular functions in dual-species biofilms with L. crispatus (b). Log2 fold change of key gene expression 
in C. albicans from single- to dual-species biofilms with L. crispatus (c). Nodes are colored by significance. All GO terms have an adjusted P value  of  ,0.05.  
Networks  were  created  using  ClueGO. 
 
indicating the potential protection from Candida overgrowth 
provided by vaginal lacto- bacilli. These findings may be important 
for future studies investigating RVVC. It is hypothesized that changes 
within Candida allow it to switch from asymptomatic com- mensal 
to pathogenic yeast. It may now be more important to study RVVC 
with a specific focus on the microbes present during RVVC, 
specifically Lactobacillus, and interkingdom interactions which may 
influence this pathogenic switch in Candida. 
Influence of Candida biofilm formation in RVVC. Consistent with epidemiological 
reports, we observed C. albicans to be the most common isolate identified, followed by 
C. glabrata. Though C. albicans has been shown to form biofilms on 
vaginal mucosa and Candida clinical isolates have been shown to 
form biofilms in vitro, the presence of bio- films during RVVC 
infection is still disputed (37). Despite evidence to the contrary, our 
study has shown heterogeneous biofilm formation in C. albicans 
RVVC isolates and shows clear visualization of C. albicans hyphae and 
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aggregates in lavage fluid from a patient with RVVC. Moreover, 
transcripts from genes associated with biofilm formation were 
readily detected from vaginal lavage fluid. Therefore, Candida 
biofilm formation within the vagina should not be discounted as a 
potential cause of failed clinical treatment and subsequent 
recurrence of disease. We also show the capacity of various 
Lactobacillus spe- cies to inhibit C. albicans biofilm formation when 
cocultured. L. rhamnosus has been stud- ied extensively for its 
potential as a probiotic and has been shown to prevent adhesion of 
C. albicans to mucosal surfaces (39). Here, we show the ability of L. 
rhamnosus to down- regulate C. albicans biofilm-related gene 
expression. In contrast, L. iners results in upregu- lation of both ALS3 
and ECE1. This is consistent with previous findings suggesting that L. 
iners may be indicative of a dysbiotic vaginal environment and 
should not be considered as a probiotic intervention for C. albicans 
infections (40). 
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FIG 9 Twice-daily addition of L. crispatus reduces C. albicans load within a complex biofilm model in vitro. The potential 
probiotic properties of L. crispatus against C. albicans were assessed in a 11-species biofilm model treated twice daily 
with L. crispatus. Live/dead qPCR allowed quantification of percentage composition of total 
(a) and live (b) C. albicans DNA within the biofilm. Average fold change in the C. albicans percentage composition 
from the untreated 11-species biofilm is also shown (c). Data are means and SD. Statistical analysis was performed 
using paired t tests comparing raw CFE values (*, P , 0.05). 
 
Antagonism of Lactobacillus and C. albicans. In our 
transcriptomic analyses we aimed to examine mechanisms of 
reported antagonism between C. albicans and L. crispatus. It has 
previously been shown in Lactobacillus clinical isolates that secreted 
metabolites can remain at low levels from 72 or 120 h of incubation, 
which may account for the delay in interaction (41). The in  vivo  
vaginal pH is thought to be ,4.5; however, in this dual-species 
model, the pH was sustained between 6 and 7. It is possi- ble that in 
the in vivo setting, the lower environmental pH could affect C. 
albicans gene expression. Nonetheless, the stability of the neutral 
pH throughout this experiment dictates that any transcriptomic 
changes observed are not due to acidification of the medium and 
are a result of interactions between C. albicans and L. crispatus. 
Transaminase activity is primarily associated with a-amino acid 
breakdown and bio- synthesis. It has been shown in a model of 
Saccharomyces cerevisiae, L. lactis, and L. plantarum that in 
nitrogen-rich environments, yeasts secrete an array of metabolites, 
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primarily amino acids, thereby facilitating the growth of lactobacilli 
(42, 43). The upreg- ulation of various amino acid biosynthesis 
processes in our study may be attributed to this nutrient cross-
feeding. As opposed to a convenient coincidence, this may be a 
deliberate process by which L. crispatus is able to drive synthesis of 
amino acids in C. albicans, as well as suppressing arginine 
breakdown, to facilitate its own metabolism and growth. The 
upregulation of the amino acid starvation indicators bat21 and ilv1 
in dual-species biofilms shows that despite the upregulation of 
various amino acid bio- synthesis processes, C. albicans is unable to 
utilize them. This may be a contributing factor in the process by 
which L. crispatus is able to outcompete Candida during VVC and 
potentially re-establish a healthy microbiome. Furthermore, the 
pry1 gene, encod- ing a secreted glycoprotein associated with 
virulence and sterol binding in the 
 
July/August 2021    Volume 6    Issue 4    e00622-21 msystems.asm.org    13 
Interactions of Candida and Lactobacillus in RVVC 
 
233 
 
 
presence of lactate, was found to be downregulated in dual-species biofilms (44). Thus, 
L. crispatus may possess a mechanism by which it can suppress 
lactate-associated viru- lence in C. albicans. Species-specific 
differential transcriptomic profiles in vaginal candi- diasis have been 
demonstrated, and therefore, interactions between Lactobacillus 
and other prevalent Candida species should be considered (44). 
These data collectively show a potentially probiotic effect of L. 
crispatus against C. albicans in nonacidic envi- ronments. This 
antagonism is governed by the overproduction of amino acids from 
C. albicans, which may facilitate restoration of a healthy microbiome 
through lactobacil- lus proliferation. 
Finally, we investigated the potential probiotic effect of L. crispatus against C. albicans 
within a complex biofilm model. Although studies have assessed the 
inhibitory effect of 
L. crispatus against C. albicans monospecies biofilms (33, 45, 46), to our knowledge, this is 
the first report of L. crispatus reducing C. albicans composition within a polymicrobial bio- 
film model in vitro. Our data support other studies confirming the probiotic potential of L. 
crispatus against C. albicans biofilm infections. 
This study assessed the vaginal microbiome only of women in the 
United Kingdom; results may differ based on geographical prevalence 
of different Candida and Lactobacillus species. Additionally, a larger 
sample set may allow for statistically significant differences in the 
microbiome of women with VVC and healthy controls. It may be 
useful for future studies to observe transcriptional changes of C. 
albicans with other health-associated vagi- nal Lactobacillus species, 
such as L. jensenii and L. gasseri. 
In conclusion, Candida burden is increased in women with RVVC 
compared to asymp- tomatic controls and continues to increase 
following antifungal intervention due to re- sistant communities. 
The reduction of protective H2O2-producing Lactobacillus species 
during RVVC is exacerbated in women who have RVVC for longer than 
6 months, those who have culturable Candida, those who use no 
contraception or a contraceptive device, and those who are treated 
less frequently. Additionally, demonstration of biofilm-form- ing 
capabilities and imaging of C. albicans aggregates in patient lavage 
fluid, as well as the expression of C. albicans biofilm-related genes, 
suggest that there is a high probabil- ity of Candida biofilm formation 
in the vagina during RVVC. The subsequent increased antifungal 
tolerance of these biofilms may allow Candida to persist within the 
vagina and cause recurrence of VVC. Our study suggests that it may 
be important to view RVVC as a result of fluctuation in antagonistic 
interkingdom interactions between Candida and Lactobacillus, 
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potentially as a result of Candida biofilm formation. Additionally, we 
show for the first time the potential of L. crispatus to re-establish a 
healthy vaginal environment through altered gene expression in C. 
albicans and the ability to reduce fungal composi- tion in a complex 
biofilm model. Lactobacilli are key protective organisms in the 
healthy vaginal microbiome, and their antagonistic effect on Candida 
is of clinical significance. As demonstrated within our clinical study, 
there was a decrease in levels of protective Lactobacillus species in 
RVVC patients. The decrease of levels of these species also inver- 
sely correlated with an increase in fungal load. Further 
understanding of this antagonism offers potential avenues for 
improving women’s health through probiotic/prebiotic regi- mens. 
This interaction could prove impactful in the development of novel 
mechanisms for antifungal treatments, and therefore, further 
studies of this interaction are required. 
 
MATERIALS AND METHODS 
Patient recruitment and collection of clinical samples. One hundred women aged 18 and over 
attending Glasgow Sandyford Sexual Health Clinic were enrolled in the study. Patient recruitment and 
obtaining of written informed consent were carried out at the clinic from prospective participants after they 
had read the patient information sheet. If the patient chose to participate, a questionnaire was completed 
and given to the clinician in charge of the study (R.M.). Patients with current, confirmed symptomatic RVVC 
(n = 40) were recruited as well as asymptomatic women attending the clinic for con- traceptive intrauterine 
device (IUD) implantation, acting as a healthy cohort (n = 60). This study was granted ethical approval by 
the Sheffield Research Ethics Committee (16/YH/0310). Patients were excluded from the study if they had 
prior or active bacterial vaginosis, were pregnant, immunosup- pressed, menstruating, or menopausal, or 
had taken antibiotics/antifungals within 7 days prior to sam- pling. From each patient, one high vaginal swab 
(HVS) and one cervicovaginal lavage fluid sample (CVL) were collected. A graphical representation of sample 
collection and processing can be found in Fig. S1. 
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Detection of inflammatory biomarkers in CVL fluid. CVL fluid supernatants were recovered by cen- 
trifugation. Levels of IL-8 were measured by enzyme-linked immunosorbent assay (ELISA) (Invitrogen, Paisley, 
UK), following the manufacturer’s instructions. CVL fluid was diluted 1:2, and absorbances were measured 
using a spectrophotometer at 450 nm and 570 nm. 
Quantification of microbial load by quantitative PCR. HVS samples were used to extract DNA for 
quantitative PCR (qPCR) analysis of Candida/bacterial burden. DNA was extracted using the QIAamp DNA 
minikit, per the manufacturer’s instructions (Qiagen, Crawley, UK), and qPCR was used to quantify fungal and 
bacterial load in each sample. Primers specific to the conserved Candida internal transcribed spacer (ITS) 
rRNA gene (47) were used to determine Candida load. For bacterial load, primers and probe specific to the 
16S rRNA gene were used (48, 49). Primer sequences can be found at https://www 
.glasgowbiofilms.co.uk/. The total qPCR volume was 20 ml, with 1 ml of extracted DNA, 500 mM forward/ 
reverse primers, and UV-treated RNase-free H2O. For 16S, 250 mM probe and 2 TaqMan universal PCR master 
mix (Thermo Scientific, Loughborough, UK) was used; 2 Fast SYBR green PCR master mix (Thermo Scientific, 
Loughborough, UK) was used for ITS primers. qPCR was carried out using a Step-One Plus real-time PCR 
machine (Life Technologies, Paisley, UK) with the following thermal conditions: an activation step of 50°C for 
2 min and 95°C for 10 min followed by 40 cycles of 95°C for 10 s to denature and annealing at 60°C for 30 
s. Standard curves constructed from serially diluted DNA of C. albicans SC5314 and Escherichia coli K-12 were 
used to extrapolate Candida and bacterial colony-forming equiva- lents (CFE) per milliliter, respectively, as 
described previously (50). 
Preparation of 16S amplicon libraries for Illumina sequencing. To observe bacterial populations in 
the samples, 16S rRNA sequencing was performed. Briefly, previously extracted HVS DNA was used to 
sequence the 16S rRNA V4 region using the Illumina MiSeq sequencing platform (Edinburgh Genomics) using 
2 x 250-bp paired-end reads. Amplification of the V4 region was achieved using fusion Golay adaptors 
barcoded on the reverse strand as described previously (51) using the univer- sal primer 515F (59-
TATGGTAATTGTGTGCCAGCMGCCGCGGTAA-39) and reverse primer 806R (59- 
AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-39). Quality control (QC) of reads was performed within the 
R package DADA2 (v1.14.1). Reads were filtered and trimmed using standard error rates before reads were 
denoised and merged and chimeric sequences removed. Amplicon sequence variants (ASV) were 
annotated by the Silva 132 16S rRNA database with an exact match to the ASV. ASV and taxonomic 
assignments were utilized for downstream data analysis. 
Identification and biofilm screening of Candida species from cervicovaginal lavage fluid. Lavage 
fluid samples were screened for presence and identification of Candida species using Colorex Candida 
chromogenic agar (E&O Laboratories Ltd., Bonnybridge, UK) and matrix-assisted laser desorp- tion 
ionization–time of flight (MALDI-TOF) mass spectrometry. For culture identification, 20 ml of CVL samples 
was spread across the surface of a chromogenic agar plate before 48 h of incubation at 30°C. The color 
of the colonies cultured was used to determine Candida species, colony numbers were used to calculate 
the number of CFU per milliliter. Clinical isolates were then stored on beads in glycerol in Microbank vials 
(Pro-Lab Diagnostics, Cheshire, UK) at 280°C. Each isolate was then subsequently identi- fied by MALDI-TOF 
analysis using a Bruker Microflex system, comparing recorded spectra to the Bruker database to confirm 
identify to the species level. 
Candida clinical isolates were assessed for biofilm-forming capabilities by crystal violet assay. Candida 
isolates (n = 33) were cultured on Sabouraud’s (SAB) agar for 48 h at 30°C. For biofilm formation, overnight 
cultures were grown in yeast extract peptone dextrose (YPD) at 30°C. Cultures were washed twice with 
phosphate-buffered saline (PBS) and standardized in RPMI 1640 medium to a final cell density of 1 106 
CFU/ml. Eight biofilms of each isolate were grown in 96-well, flat-bottomed polystyrene microtiter plates for 
24 h at 37°C before biomass measured by the crystal violet assay (52). For visualization of Candida aggre- gates, 
30 ml of CVL was stained with calcofluor white (CFW) to a final concentration of 0.06 mg/ml for 1 h at 37°C, before 
being imaged using the EVOS live cell imaging system (Thermo Scientific, Loughborough, UK). 
Antagonism of C. albicans and Lactobacillus in coculture. The ability of the following 7 Lactobacillus 
strains to inhibit C. albicans SC5314 biofilm formation was assessed: L. casei ATCC 393, L. fermentum ATCC 
14931, L. crispatus ATCC 33820, L. iners DSMZ 13335, L. salivarius ATCC 11741, L. jensenii ATCC 25258 and 
L. rhamnosus ATCC 7469. Overnight cultures of C. albicans and Lactobacillus were grown in YPD and de Man, 
Rogosa, and Sharpe (MRS; Merck UK) medium, respectively, under appropriate culture conditions. For these 
experiments, we used an optimized medium of Todd-Hewitt broth (THB; Merck UK) supplemented with 
10 mM menadione and 10 mg/ml hemin (Thermo Fisher) and mixed 1:1 with RPMI (referred to here as 1:1 
broth), as described previously for coculture experiments (53). For biofilm 
formation, overnight cultures were standardized to 1 x 106 CFU/ml for C. albicans and 1 x 107 CFU/ml 
for Lactobacillus species in 1:1 medium. Eight bio lms of each C. albicans-Lactobacillus pair were incu- bated 
in 5% CO2 for 24 h. In addition, C. albicans biofilms were grown for 4 h prior to Lactobacillus being added for 
20 h, with biomass quantified using the crystal violet assay. 
C. albicans biofilm-related gene expression analysis. To assess C. albicans biofilm-related gene expres- 
sion, RNA was extracted from dual-species biofilms using the PureLink RNA minikit (Thermo Scientific, 
Loughborough, UK), following manufacturer’s instructions. In brief, 2 mg of RNA was converted to cDNA using a 
high-capacity cDNA reverse transcription kit (Thermo Scientific, Loughborough, UK) and 1 ml was used in a 
20-ml qPCR with 10 ml 2x Fast SYBR green PCR master mix, 1 ml forward/reverse primer, and UV-treated 
H2O. Primer sequences can be found at https://www.glasgowbiofilms.co.uk/ (54–56). 
Gene expression was analyzed in duplicate on three separate occasions; no-reverse-transcription (NRT) 
controls and no-template controls (NTC) were included throughout. Gene expression was nor- malized to the 
ACT1 housekeeping gene and calculated using the DDCT method (57). 
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In vitro transcriptomic analysis of C. albicans interactions with L. crispatus. C. albicans and L. 
crispatus type strains SC5314 and ATCC 33820, respectively, were used for transcriptional analysis in this 
component of the study. Biofilms were formed as described above. Cultures were washed twice with PBS 
and standardized in 1:1 broth to 1 x 106 CFU/ml for C. albicans and 1 x 107 CFU/ml for L. crispatus. Initially, 
C. albicans biofilms were grown in T-75 cell culture flasks (Corning, USA) for 4 h in 5% CO2. Following 
incubation, medium was removed, and biofilms washed before L. crispatus was added for an additional 2, 4, 
or 20 h. At each time point, the medium was removed and biofilms were washed with 
PBS before being scraped into 1 ml of RNAlater (Thermo Scientific, Loughborough, UK). Spent medium from 
biofilms was retained, and pH was monitored throughout the experiment. RNA was extracted from microbial 
biofilms using the RiboPure RNA purification kit for yeast (Thermo Scientific, Loughborough, UK), following 
manufacturer’s instructions. Integrity of RNA was assessed using a Bioanalyzer system, and genome-wide 
Candida transcripts were sequenced using the Illumina NOVASeq6000 sequencing platform (Edinburgh 
Genomics). FastQC was used to assign quality scores to the produced reads, and Illumina adaptors and poor-
quality reads were trimmed using Trimmomatic (V0.38). Hisat2 (v2.1.0) was then used to align the resulting 
reads to a reference C. albicans genome (http://www.candidagenome.org/) before the number of sequences 
that were aligned to each gene was counted using HTSeq-count (v0.11.0). The counted genes were 
subsequently imported into RStudio, and the DESeq2 package was used to analyze the differentially 
expressed genes. A summarized illustration of the experimental and bioinformatics pipe- lines can be found 
in Fig. S1b and c. 
Investigating the probiotic potential of L. crispatus in a complex biofilm model. Complex 11-spe- 
cies biofilms were formed as described previously by our group with slight modifications (58). Overnight 
broths of each organism were standardized in 1:1 medium prior to addition to the biofilm on 13-mm 
discs. For probiotic treatment, each biofilm was treated twice daily (12 h intervals) with 5     107 CFU/ml of 
L. crispatus for 5 min before treatment was removed, biofilms washed 3 times in PBS and fresh media 
replaced. On day 3, after 4 probiotic treatments, 48-h biofilms were analyzed for compositional analysis. On 
day 5, following 8 probiotic treatments, 96-h biofilms were removed for compositional analysis. At each time 
point, biofilms were washed 3 times and sonicated in 1 ml of PBS at 35 kHz for 10 min to remove biomass. 
Sonicates were split in two, with one sample having 5 ml of 10 mM propidium monoa- zide (PMA) added to 
it for the quantification of live C. albicans DNA. PMA is a DNA-intercalating dye used to bind DNA from 
dead cells or those with a compromised membrane following exposure to a hal- ogen light (59, 60). The other 
sample, lacking PMA, allowed quantification of total C. albicans DNA per biofilm. All samples were incubated 
in the dark for 10 min, then placed on ice, and exposed to a 650-W halogen light for 5 min. DNA was then 
extracted using the QIAamp DNA minikit, per the manufacturer’s instructions (Qiagen, Crawley, UK). To a 20-
ml qPCR mixture, 1 ml of biofilm DNA was added; the mixture contained 10 ml Fast SYBR green master mix, 1 
ml of 10 mM C. albicans forward and reverse primers, and UV-treated nuclease-free water. Primer sequences 
can be found at https://www.glasgowbiofilms.co.uk/. The following thermal profile was used: 95°C for 2 min 
and 40 cycles of 95°C for 3 s followed by 55°C for 30 s. Samples were assessed in duplicate from 2 separate 
experiments. Fungal CFE/ml were then calcu- lated as described above. 
Statistical analysis. Microbiome figures were created using MicrobiomeAnalyst (61). Bacterial diver- 
sity and abundance plots were made using alpha diversity and stacked-bar charts, respectively. Random 
forest plots were used to predict important species present under each condition. Transcriptome pipe- line 
figures were constructed using BioRender and differential gene expression plots using the DESeq2 package 
in RStudio. Gene ontology networks were constructed using ClueGO software, available through Cytoscape 
(62). All other figures and analyses were performed in GraphPad Prism (version 8; GraphPad, La Jolla, CA, 
USA). 
Data availability. Microbiome data are deposited under the accession number PRJNA719953 in the 
SRA database. 
 
SUPPLEMENTAL MATERIAL 
Supplemental material is available online only. 
FIG S1, TIF file, 0.2 
MB. 
FIG S2, TIF file, 0.1 
MB. 
FIG S3, TIF file, 0.1 
MB. 
FIG S4, TIF file, 0.2 
MB. 
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